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Abstract 
 
Bioorganometallic chemistry is a growing field of research in which organometallic chemistry 
is combined with biology to achieve novel molecules with novel properties at the biological 
level. In this area, the tagging of DNA with bioorganometallic molecules such as ferrocene 
has been the object of much attention over the past few decades. In recent years, a novel 
approach has been developed consisting of replacing parts of nucleic acids with organic 
groups including metal-binding ligands. Considering this approach, it was decided to 
investigate the replacement of DNA dinucleotides with a tetra-substituted ferrocenyl 
monomer containing nucleobases, leading to the formation of a novel nucleic acid analogue 
called ferrocene nucleic acid (FcNA). The synthesis of several monomers containing adenine 
and uracil has been the subject of this thesis. Coupling nucleobases to form bis-substituted 
ferrocenes was first investigated as a model for the subsequent synthesis of tetra-
substituted ferrocenyl monomers with high chiral purity. The compounds were characterised 
using a range of spectroscopic and analytical techniques, including X-ray crystallography.  
The influence of the nucleobases and the nature of the linker to the ferrocenyl group have 
also been investigated using electrochemistry. The work has also led to investigations to 
develop ferrocene compounds as potential organometallic drugs. 
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1
1 CHAPTER 1: INTRODUCTION 
 
Sixty years ago in 1953, Edmund Hillary & Tensing Norkay reached summit of Everest for the 
first time, the Pulitzer prize was awarded to Ernest Hemingway for his book The Old Man 
and The Sea and in the same year, a famous paper in the scientific journal Nature written by 
Watson and Crick,1 elucidated for the first time the structure of DNA. In this paper, they 
wrote: “We wish to suggest a structure for the salt of deoxyribonucleic acid. This structure 
has novel features which are of considerable biological interest”. This discovery started a 
revolution in molecular biology that reached its culmination point with the sequencing of 
the entire human genome and just recently, the synthesis of a genome by artificial means 
and its incorporation in a cell.2 These breakthroughs have enhanced genomics, chemical 
biology, and have even inspired recent development in the field of artificial nucleic acid. 
 
1.1 DNA 
DNA is a macromolecule that is essential for all forms of life. Using the four canonical 
nucleobases: adenine (A), thymine (T), cytosine (C) and guanine (G), the nucleic acid 
assembly encodes the genetic information and blueprint of living organisms. Nucleobases, 
the central building blocks of this giant molecule, are connected to a deoxyribose sugar via 
the N-1 atom for pyrimidines (T and C) and the N-9 atom for purines (A and G) to form 
nucleosides. Nucleosides are linked together via phosphodiester bridges to form 
nucleotides. Most DNAs are double stranded duplexes in nature, where two complementary 
single strands pair together in an anti-parallel orientation. Each single strand of DNA is 
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defined by a specific sequence of these nucleotides. The double stranded helical shape of 
DNA comes from the ability of nucleotides to selectively form hydrogen bonds between their 
respective nucleobases, which play a determinant role in the stability and the specificity of 
duplex formation. Adenine creates two hydrogen bonds with thymine and guanine three 
with cytosine (Figure 1-1). The duplex is also stabilised by base stacking interactions. Those 
two types of interaction are the building blocks of the secondary structure of DNA. 
 
 
 
Figure 1-1: a) The four canonical bases forming A-T and C-G H-bonding base pairs, b) Three 
conformational shapes of DNA duplex (http://x3dna.org/articles/seeing-is-understanding-as-well-as-
believing) 
Chapter 1: Introduction 
 
3
The tertiary structure of DNA corresponds to the 3 dimensional shape of the double 
stranded helix. Three different structural conformations of DNA have been reported: A, B 
and Z (Figure 1-1).3 A-DNA structure is a short and thick helix that contains a deep and 
narrow major groove and a superficial minor groove. This conformation is usually favoured 
at low water concentration. B-DNA conformation is thinner and longer than A-DNA. It 
presents a wide major groove that facilitates protein anchorage and a narrow minor groove. 
This is the most common structure of DNA found in vivo and is favoured at high water 
concentrations. Z-DNA is thinner and more elongated than B-DNA with a deeper minor 
groove and a shallower major groove. This conformation can be formed in high salt 
concentration conditions but it is not encountered in vivo. 
 
The base pairing and base stacking are disrupted during DNA replication and its transcription 
into ribonucleic acids (RNA). RNA also consists of a chain of nucleotides but is usually much 
shorter than DNA and often found as a single strand in vivo. RNA contains ribose sugars and 
uracil replaces thymine as the complementary base to adenine. 
 
1.2 Oligomer synthesis 
Directly after the structural elucidation of DNA in the early 1950’s and the publication of 
amino acid sequence of insulin by Sanger in 1955, studying genes and their influence on cell 
behaviour became a major goal for molecular biologists. DNA has quickly become a 
significant tool and target in many domains such as nanotechnology4, disease diagnostics5 
and gene therapy.6 From here, chemists have started to develop ways to mimic and modify 
its supramolecular structure. However before gene sequences could be studied and 
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eventually manipulated, it was important to develop a convenient way of synthesising DNA 
through chemical means. The development of automated DNA synthesis using 
phosphoramidite chemistry played a significant role in addressing this challenge.  
 
Automated oligonucleotide synthesis7 is based on a succession of cycles involving four major 
steps. The synthesis starts from the solid support where the first protected nucleoside (n) is 
attached; it then continues over each cycle with the incorporation of each new nucleoside as 
a phosphoramadite (n+1) and finally ends up with the release of the desired oligonucleotide. 
(Figure 1-2) 
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Figure 1-2: Oligonucleotide synthesis cycle 
 
The first step of the cycle is a detritylation of the first nucleoside (n). Cleavage of 
dimethoxytrityl (DMT) group is usually obtained by acid treatment with trichloroacetic acid 
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(TCA) or dichloroacetic acid (DCA) in order to obtain the free 5’-OH. The second step consists 
of coupling the activated nucleoside (n) and the new phosphoramidite (n+1). This reacts with 
the 5’-OH of n in the presence of tetrazole. In practice, the reaction is never completely 
quantitative; consequently the third step called capping is important since it allows 
unreacted deprotected nucleosides n to be removed before the next cycle. Acetic acid is 
used to acetylate the free hydroxyl, avoiding side reactions and truncated sequences. The 
phosphite triester synthesized in the coupling step is relatively unstable. Oxidation of the 
phosphite to the corresponding phosphate diester stabilizes the oligonucleotide before 
coupling with the next nucleoside.  
 
The development of efficient chemical synthesis of DNA has enabled the widescale 
availability of primers, linkers and probes, for example for sensing applications. In the 
context of nucleic acid modifications for biological purposes, novel strategies have emerged. 
One of them consists of replacing parts of a nucleic acid with other organic groups that has 
led to the development of various DNA mimics and analogues. The first test of a DNA 
analogue is its ability to form complexes with DNA/RNA or with itself in the same way that 
natural duplexes are formed. Moreover these analogues should ideally enhance pre-existent 
natural DNA/RNA properties or confer new properties, leading to a new range of 
applications. Consequently, many different types of DNA modification have been 
investigated over the past decades varying from simple tagging to more drastic changes such 
as nucleobase and backbone replacement. Some examples are presented in the following 
section. 
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1.3 DNA functionalisation and DNA analogues 
1.3.1 Fluorophore functionalization 
One popular way to functionalise a nucleic acid is to attach a fluorophore as a label for 
sensing applications. Fluorophores are fluorescent species that can re-emit light after light 
excitation, which may be detected at very low concentrations. They can be used as dyes for 
staining certain structures or tissues and as markers when attached to macromolecules. 
Different types of fluorophores have been incorporated into nucleic acids. Fluorescein and 
rhodamine, which are two of the most commonly used fluorophores, have been 
incorporated into oligonucleotides as phosphoramidites via automated synthesis8. (Figure 1-
3) 
 
Figure 1-3: Rhodamine and Fluorescein structures 
 
Fluorescein and rhodamine have been used in the widely utilised Taqman® assay.9 This assay 
detects polymerase chain reaction (PCR) products by hybridisation and cleavage of a double-
labelled probe called a Taqman probe. The latter contains fluorescein as fluorescent dye and 
rhodamine as quencher dye respectively attached to the 5’ and 3’-end of the oligonucleotide 
sequence.10 If both dyes are close enough to each other, rhodamine quenches fluorescence 
emission of fluorescein by fluorescence resonance energy transfer (FRET). During the PCR, 
the Taq polymerase replicates the targeted sequence by recognition of unmodified primers 
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until it reaches the hybridised Taqman probe. The nuclease activity of the polymerase 
degrades the Taqman probe releasing the fluorescein, which is no longer quenched. The 
increase of fluorescence intensity reveals formation of the PCR product (Figure 1-4).11 This 
technique has been used in numerous applications, for example in the diagnostic of base 
variation in DNA.  
 
Figure 1-4: Taqman® assay principle 
 
In another example of luminescent dyes inserted into DNA sequence, Mesmaeker et al.12 
described how they incorporated a ruthenium complex into the middle of a strand sequence. 
As soon as the probe hybridised with the target sequence, the luminescent signal produced 
by the complex was quenched through photo-induced electron transfer (PET) from the 
guanine nucleobases of the target strand. In the same way, pyrene is known for its 
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sensitivity towards quenchers13, 14 and has also been used as a DNA tag.15,16 For example, in 
2001, Yamana et al. attached a pyrene to the 2’ position of the sugar of a nucleotide that 
showed an enhancement of fluorescence when pairing with the complementary RNA 
target.17  
 
Figure 1-5: Pyrene attached to nucleotide sugar by Yamana15 
 
1.3.2 Fluorescent base analogues  
As described above, fluorescent tags can be connected to DNA via a linker, but this approach 
often places the fluorophore relatively far away from the duplex. Furthermore, the freedom 
given by the flexibility of the linker enables the dye to move around, which affects the ability 
to accurately predict the orientation of the fluorophore. However the use of a fluorescent 
base analogue avoids this problem since the analogue is tightly located inside the duplex. 
Fluorescent base analogues have the ability to be fluorescent and to form hydrogen bonds 
with complementary bases. As an example, 2-aminopurine (2-AP), which is one of the most 
frequently used fluorescent base analogues, is highly fluorescent and its UV band is at a 
longer wavelength than normal bases. This means it is possible to selectively excite it even in 
presence of a large excess of natural bases. As an adenine analogue 2-AP can pair with 
thymine and uracil but also with cytosine18, as shown in Figure 1-6. 
Chapter 1: Introduction 
 
9
 
Figure 1-6: 2-Aminopurine pairing with thymine and cytosine via hydrogen bonding 
 
However, the utilisation of 2-AP has its limitations such as having less specific and less 
efficient base pairing than natural adenine, which perturbs the native structure of DNA. Its 
fluorescence depends on its proximate environment and it is considerably quenched when 
incorporated into a duplex19 but this sensitivity to its microenvironment has been used in 
many investigations including nucleic acid structure analysis and DNA-protein interactions.20, 
21, 22 
 
1.3.3 Metal-mediated base pairing and base pair analogue 
A couple of decades ago, interest in the substitution of natural DNA base-pairs with metal 
complexes started to develop. In this context, the development of ligand-like nucleobases 
containing metals led to the creation of “metal base-pair” systems. In these systems, Watson 
and Crick hydrogen bonds are replaced by interactions between a metal acting as a guest 
species and nucleobases, or their derivatives or mimics, acting as ligands. As described later, 
metal introduction can result in increased stability of the duplex and in certain cases, 
magnetic or conducting properties.  
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In 1963, Katz described insertion of one atom of Hg2+ between two natural thymines of a 
DNA duplex.23 He hypothesised a slippage process as shown on Figure 1-7, that would bring 
the thymines together to form a Hg2+ base pair. 
 
 
Figure 1-7: a) The base pair structure proposed by Katz23. b) Formation of the base pair by a slippage 
process 
 
This concept was verified and supported by many subsequent studies, and most recently, by 
Ono et al., 24  who through melting-curve studies and ESI mass spectrometry data, 
demonstrated the formation of stacking interactions between three consecutive T-Hg-T 
base-pairs, as shown in Figure 1-8.  
 
Figure 1-8: Incorporation of three consecutive T-Hg-T base pairs in a DNA duplex.24 
 
Chapter 1: Introduction 
 
11
Numerous examples demonstrated that modified nucleobases could also take part in metal 
base pairing. Meggers, Romesberg and Schultz described the first example of metal-base 
pairing with synthetic ligands in 2000.25 They synthesised a planar pyridine dicarboxylate 
(Dipic) as a tridentate ligand and a pyridine nucleobase as the complementary donor ligand. 
The Dipic:Py pair was incorporated into the middle of a 15-oligonucleotide and Cu2+ was 
added. Formation of a copper bridge between the couple tridentate ligand-pyridine (“copper 
base-pair” formation) stabilized the modified DNA duplex almost as well as a dA:dT natural 
base pair at the same site. The tight binding to copper comes from the tridentate character 
of the Dipic ligand. Several other types of metals such as Ni2+, Pd2+ or Pt2+ were studied but 
none of them stabilized the duplex formation as well as copper. Compared to Ni2+ or Zn2+, 
Cu2+ has the highest complex formation constant. On the other hand, Pd2+ and Pt2+ are 
bigger and do not fit into the binding site of the tridentate ligand, which explains why copper 
has a higher affinity than these softer transition metals.26 
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Figure 1-9: Schultz's "Dipic:Py pair"and its crystalline structure25 
 
Schultz’s group also inserted two Dipic-Py metal base pairs into a dodecamer and 
successfully obtained the first crystal structure of a metal-base pair in a DNA duplex.27 
Another copper base pair derivative (B in Figure 1-9) containing a pyridine 2,6 
dicarboxamide ligand (Dipam) was also incorporated into an oligonucleotide and revealed an 
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improvement in duplex stabilisation of 3˚C and 4˚C compared to normal base pairs dG:dC 
and dA:dT respectively. 
 
In 2002, Shionoya and Tanaka28 prepared a “silver base-pair” complex with a pyridine mono-
ligand that allowed formation of duplexes and triplexes. They also designed a 
dihydroxypyridone complex binding Cu2+ inside a DNA duplex (Figure 1-10). 
 
Figure 1-10: Shionoya’s metal base-pair complexes. a) Silver base pair. b) dihydroxypyridone base 
pair.28 
 
In 2003, they synthesised a short oligonucleotide made of five consecutive hydroxypyridone 
ligand complexes pairing with five Cu2+ ions and flanked with one natural base-pair on both 
5’ and 3’ sides, called d(5'-GH5C-3').
29  
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Figure 1-11: Complexation scheme of d(5'-GH5C-3') and 5 eq of Cu
2+ 29 
 
The chosen hydroxypyridone nucleobase was a bidentate ligand that formed a neutral 
complex in presence of the copper. The lack of charge decreased electrostatic repulsion 
between adjacent Cu2+ ions and consequently increased the thermal stability of the duplex. 
UV studies clearly showed that no duplexes were formed without presence of copper but 
the absorption at 280 nm and 307 nm changed significantly and simultaneously with 
addition of Cu2+ to the modified oligonucleotide. (Figure 1-12A)  
 
Figure 1-12: UV spectrum of d(5'-GH5C-3') in presence of an increasing amount of Cu
2+ 
 
The possibility of secondary structures like hairpin or loop was excluded by electrospray 
ionisation mass spectrometry. Further results showed that Cu2+ ions were coupled 
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ferromagnetically with one another through unpaired d electrons to form magnetic chains. 
The authors hypothesised that these results could lead to the development of metal-base 
molecular devices like molecular wires. Meggers et al.30 described in 2005 the synthesis of a 
copper base pair using hydroxyquinolines (HQ) as ligands and a deoxyribose phosphate or a 
propylene glycol as backbone. (Figure 1-13) 
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Figure 1-13: Meggers’s hydroxyquinoline base pair with a deoxyribose phosphate or a propanediol 
phosphate backbone.30 
 
 
Melting temperature (Tm) measurements on a HQ:HQ duplex pairs showed that even 
without metals, the complex could form stable base pairs due to the high hydrophobicity of 
HQ. However, from a value of 36˚C without copper, the Tm could reach a temperature of 
65˚C in presence of one equivalent of Cu2+, that is 20˚C more than natural dA-dT or dG-dC 
base pairing. 
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Figure 1-14: Thermal studies of HQ:HQ duplex stability with or without Cu2+ ions30 
As a result of the exceptional high stabilization of the duplex, HQ:HQ base pairing was 
selected to be a starting point for the investigation of a complete backbone modification. As 
a way of reducing the complexity of the backbone, the natural deoxyribose sugar was 
exchanged with an artificial derivative of glycidol and led to the synthesis of a new 
monomer: C3HQ. To synthesise a C3HQ unit, a tritylated epoxide S-(-)-glycidol A was first 
selectively opened via a magnesium derivative of B. The TBS protecting group was then 
exchanged for a pivaloyl group followed by phosphitylation to afford D.  
 
Scheme 1-1: Synthesis of the propylene glycol unit developed by Meggers et al.30 
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An investigation of the stability of the homopair C3HQ:C3HQ incorporated into a DNA duplex 
revealed that without Cu2+ no duplex was formed. However with one equivalent of Cu2+, UV 
melting studies indicated a Tm of 70.5 ˚C. The increased stability of C3HQ:C3HQ compared to 
HQ:HQ (∆Tm + 5.5 °C) was explained by a less hindered acyclic backbone that would give 
more conformational flexibility and help duplex formation (Scheme 1-1). The structural 
backbone change leading to the design of C3HQ was inspired by Eschenmoser’s l-α-
threofuranosyl oligonucleosides studies.31 His studies were done in the context of defining a 
“chemical etiology of nucleic acid structure” where Eschenmoser tried to find the answer to 
the question “Was RNA the first genetic material or was it preceded by a simpler genetic 
material?”.32 The results of his investigations led to the development of new carbohydrate 
phosphodiester-based DNA analogues such as GNAs or TNAs as described below. 
 
1.3.4 Backbone analogues  
1.3.4.1 TNA 
In his quest to understand the different criteria selected by Nature to choose ribo- and 
deoxyribonucleic acids as genetic supports, Eschenmoser emphasised that fully hydroxylated 
hexopyranosyl oligonucleotides gave weaker base pairing than RNA for steric reasons.33 
These findings orientated his research towards less bulkier pentopyranosyl oligonucleotides, 
which gave much stronger Watson and Crick base pairing than RNA.34  He therefore 
emphasised the possibility of using other types of sugar than those in DNA/RNA to support 
Watson-Crick base pairing. In 2000, the synthesis of the first Threose Nucleic Acid (TNA) was 
described. 35  TNAs are composed of repeated units of threoses linked together by 
phosphodiester bonds and have proven to be able to pair with DNA, RNA and with 
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themselves (Figure 1-15). Ichida et al. polymerized more than 50 nucleotides of TNA from a 
DNA template via a mutant polymerase called therminator DNA polymerase.36 
 
Figure 1-15: DNA and its analogue TNA 
 
1.3.4.2 GNA  
Another nucleic acid analogue emerged in 2005 when Meggers et al. described the synthesis 
of a glycol nucleic acid (GNA), where the sugar of natural DNA/RNA nucleotides was replaced 
by an acyclic three-carbon propylene glycol.37 
 
Figure 1-16: The phosphodiester DNA analogues, GNA 
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Thermal stability studies of GNA duplex formation gave Tm values that were 20.5 ˚C and 22.5 
˚C greater than the corresponding DNA (Tm = 40.5 ˚C) and RNA (Tm = 42.5 ˚C) duplexes 
respectively. To prove that the duplex consisted of a proper Watson and Crick base pairing, 
they studied the stability of a duplex where one strand included a T:T mismatch. They 
noticed an important decrease in stability with a Tm = 55 ˚C, showing that hybridisation 
mainly depends on nucleobase pairing interactions.  
 
1.3.4.3 α-TNA and SNA 
In a direct continuation of Meggers’s work, Asanuma et al. published in 2010 a novel acyclic 
nucleic acid from D-threoninol. 38  Their α-Threoninol Nucleic Acid (α-TNA) presented 
interesting features compared to DNA and GNA: duplex formation via complementary base 
pairing occurred in an antiparallel manner and α-TNA duplex stability was higher than DNA 
and GNA duplexes. Furthermore, due to the flexibility of the acyclic backbone, the single-
strand of α-TNA did not need to adopt the characteristic pre-organised conformation to 
form the duplex. It had previously been demonstrated that oligomers had to present a 
conformational “pre-organisation” to allow duplex formation. 39, 40, 41 However, the nucleic 
acid backbone was not flexible enough to allow cross-pairing with DNA or RNA. 
Consequently, one year later they published a new example of a nucleic acid analogue that 
overcame this problem.  
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Figure 1-17: SNA and α-TNA 
 
They synthesised a Serinol Nucleic Acid (SNA)42, based on an achiral amino-propanediol 
(serinol) scaffold, which is more flexible than threoninol. Duplex formation occurred in an 
antiparallel fashion and presented significantly higher stability compared to DNA and RNA. 
SNA was able to cross-hybridise with DNA and RNA in contrary to GNA and α-TNA and can 
therefore be used as antigene/antisense agents.  
 
1.3.4.4 LNA  
The sugar moiety in DNA and RNA can adopt two representative favoured conformations: 
C2-endo and C3-endo, also called the B-form and A-form respectively. Nucleosides exist as an 
equilibrium mixture of these two conformations but the B-form conformation is dominant in 
DNA and the A-form is dominant in RNA (Figure 1-18). The reduction of flexibility through 
synthetic modifications of the sugar could help to improve binding affinities between a new 
type of nucleic acid and DNA/RNA.  
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Figure 1-18: Two favoured representative conformations of a nucleoside. 
 
In 1997, Imanishi et al.43, described the synthesis of two “locked” nucleosides A and B, which 
they called Locked Nucleic Acid (LNA) in reference to the conformational restriction brought 
by the introduction of an ether group between the 2’-O and the 4’-C to the sugar moiety 
(Figure 1-19). The bridge “locks” the ribose in a specific conformation (A-form in this case) 
that enhances base stacking and backbone pre-organisation.  
 
Figure 1-19: Locked Nucleic Acid 
 
A couple of months later, Wengel et al.44, described the synthesis of the same monomer that 
they incorporated into a 9-mer, giving a stabilizing effect on duplex formation compared to 
DNA and RNA.  
 
1.3.4.5 PNA 
A more radical approach to DNA analogues would be to introduce a completely new 
backbone linking nucleobases via amide bonds rather than via phosphodiester bonds. In 
1991, Nielsen and co-workers described a design of a new type of oligomer called Peptide 
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Nucleic Acid (PNA) that could form duplexes/triplexes with natural DNA/RNA or with itself. 45 
(Figure 1-20) The first homo-thymine PNA they synthesised could mimic an oligonucleotide 
and selectively form a triplex with a double-stranded DNA, via Hoogsteen base pairing. The 
nucleic acid analogue consisted of repeating aminoethylglycine units linked by amide bonds 
and attached to nucleobases through methylene carbonyl linkages. (Figure 1-20) 
 
Figure 1-20: PNA linked to Adenine (A), Guanine (G) and Thymine (T) 
PNAs are acyclic, achiral and neutral and consequently, they can bind complementary 
nucleic acids in both antiparallel and parallel orientations. PNA can form PNA/DNA and 
PNA/RNA duplexes that are more stable than DNA/DNA and DNA/RNA but still not as stable 
as 2PNA/DNA triplexes. 
 
They are now many types of nucleic acid analogues known as XNAs, they are currently being 
investigated for their ability to mimic DNA function for example by acting as templates for 
enzymatic nucleic acid synthesis.46 
1.4 Bioorganometallic chemistry and Ferrocene 
The field of bioorganometallic chemistry concerns the synthesis and the study of 
organometallic species in biological structures and biological systems. Following the 
discovery of ferrocene and its “sandwich structure”, active research grew around the 
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understanding of metal-carbon bonds (σ, π and δ) such as metallocene, carbonyls and 
carbenes. Ferrocene was first reported by Pauson in 195147,48 as a compound containing one 
atom of iron linked to each cyclopentadienyl rings by a single atom of carbon as presented in 
Scheme 1-2. Ferrocene was synthesised via reaction of the Grignard reagent 
cyclopentadienyl magnesium bromide with iron chloride in diethyl ether. 
 
 
Scheme 1-2: First reported synthesis of ferrocene  
 
The right structure of the metallocene was determined by Wilkinson and Woodward a year 
later.49 They demonstrated via early proton NMR characterisation that the five protons of 
each Cp rings were equivalent, leading to the correct structural representation of ferrocene. 
(Figure 1-21) 
 
Figure 1-21: Wilkinson representation of Ferrocene 
 
Ferrocene has proven to possess high chemical stability and electrochemical properties that 
made it a very popular molecule for biological applications, asymmetric catalysis 50 , 
biomaterials, 51  DNA analysis 52  and DNA sensing. The stability of ferrocene enables 
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functionalization of one or both rings leading to the synthesis of large range of derivatives 
and their conjugation with biomolecules such as proteins or nucleic acids.   
 
The first work on ferrocene linked to nucleosides was published by Gautheron et al.53 twenty 
years ago. They reported the synthesis of several “metallocenonucleosides” in which 
ferrocene was attached to adenosine, deoxyuridine or uridine via a two carbon linker. This 
was made possible by the condensation of a 5-halogeno nucleosides with zirconylated 
derivatives of ferrocene using (C6H5CN)2-PdCl2 as a catalyst. 
 
Scheme 1-3:  Ferrocenonucleosides developed by Gautheron 
 
It was also possible to couple ethynylferrocene to 5-iodouracil, iodouridine, 2-
desoxyiodouridine and bromoadenosine via a Sonogashira coupling in presence of 
(Ph3P)PdCl2 to give the corresponding 5-ethynylferrocenyl nucleobases. Interestingly, It was 
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described that 5-ethynylferrocenyluracil derivatives could be cyclised in presence of 
triethylamine with heat. (Scheme 1-4) 
 
Scheme 1-4: Ferrocenonucleosides via Sonogashira coupling 
 
This side reaction is due to a stabilisation of a positive charge on the first carbon of the 
ethynyl linker by the ferrocenyl group,54 inducing an oxygen-attack of the uracil on the 
stabilised carbon. Houlton et al.55 reported that cyclisation could be avoided by running the 
Sonogashira coupling at room temperature.  
 
Another approach developed by Houlton et al.56 consisted of coupling different nucleobase 
derivatives with the trimethyl(ferrocenylmethyl)ammonium iodide salt. An example is 
presented in Scheme 1-5. 
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Scheme 1-5: Ferrocenonucleobase by Houlton 
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Ganesh et al.57 used a completely different way to couple ferrocene to nucleobases. 
Thymine and uracil were attached to mono and bis-ferrocene via 1 and 4 carbon linkers 
using the Mitsunobu reaction. The one-carbon systems were synthesised from the bis-
carboxaldehyde ferrocene, which was reduced to the corresponding bis-hydroxylmethyl 
ferrocene. The two nucleobases were attached to the bis-hydroxymethyl ferrocene via a 
Mitsunobu reaction in presence of DIAD, triphenylphosphine in THF, followed by a 
deprotection of the nucleobases using potassium carbonate. (Scheme 1-6) 
 
Scheme 1-6: Synthesis scheme of bis-methyl ferrocenyl thymine and uracil by Ganesh 
 
The synthesis of the ferrocenyl derivatives containing a butyl spacer was achieved by first 
reacting ferrocene was first reacted with succinic anhydride using Friedel-Crafts acylation. 
The carbonyl group and the ester moiety were then reduced to give the corresponding 
alcohol, which was then reacted with uracil or thymine under Mitsunobu conditions. The 
bases were then debenzoylated in presence of potassium carbonate to afford the target 
compounds. (Scheme 1-7) 
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Scheme 1-7: Ferrocenonucleoside with a butyl linker chain by Ganesh 
 
The tagging of ferrocene to nucleic acids has become a topical theme, mainly due to 
continued interest in the electrochemical sensing of various biomolecules and biological 
units.58 In 2001, Yu and coworkers59 described an early example where they synthesized two 
electrochemically different ferrocenyl monomers by introducing ferrocene derivatives on to 
the sugar of a nucleoside (Figure 1-22). The monomers were then incorporated into 
oligonucleotide probes using automated DNA synthesis.   
 
Figure 1-22: Two electrochemically different ferrocenyl complexes developed by Yu and coworkers59 
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The two investigated targets differed by a single-base mismatch at the same position. Each 
probe synthesized was sequence-specific for only one of these targets. Because the two 
ferrocenyl-complexes appeared as two different electrochemical peaks in alternative current 
voltammetry, it was possible to discriminate the two different targets and consequently the 
two different mismatches. The detection of these mismatches was performed on a chip-
array coupled to an electrochemical detector. As a result, a direct application of this study is 
the detection of SNPs. 
 
Another interesting example of a ferrocene tag was described by Ricci and coworkers60 in 
2007. Ferrocene was coupled to the end of an oligonucleotide to sense nucleotide 
hybridization. The technique was based on the disappearance of the electrochemical signal 
upon hybridization. (Figure 1-23) 
 
Figure 1-23: Detection of targeted oligonucleotides hybridisation by Ricci and al.60 
 
The probe was bound to a gold electrode as shown in Figure 1-23. When the sequence is 
target-free, the sensor gives a well-defined voltammetry peak. When the target complexes 
the probe, the current is largely reduced. This can be explained by a gain in rigidity of the 
double strands compared to the single strand, which leads to an increase in the distance 
between ferrocene and the electrode. 
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Another example of tagging is the gene sensing method for diagnosis developed in 2002 by 
Nakayama and Ihara61. This method is based on the formation of a ternary complex that 
gives an electrochemical response when the targeted sequence is present. The ternary 
complex is formed when the target hybridises to the single strand oligonucleotide, which is 
attached on the surface of a gold electrode, and to the sensing probe containing a ferrocene 
moiety. (Figure 1-24) 
 
Figure 1-24: Electrochemical gene sensing method by Ihara61 
 
If the target fully matches with the probe and the oligonucleotide attached to the electrode, 
the ternary complex is formed and the ferrocene stays close to the electrode. This creates a 
electrochemical signal and a high peak appears on a differential pulse voltammogram due to 
the oxidation of the metallocene (plain line in Figure 1-25). However if the target is a mutant 
(single-base mismatch), the ternary complex cannot efficiently be formed any more resulting 
in a drop of the electrochemical signal (dashed line), as shown in Figure 1-25.   
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Figure 1-25: DVP of the electrode by two different treatments61 
 
However this method has its limitations. Although longer sequences would result in a 
stronger signal, they would be less specific and would be more tolerant to mismatches. The 
distance between the ferrocene and the electrode could also affect the detection.  
 
Ferrocenyl monomers have also been attached to PNA by Metzler-Nolte and coworkers,62, 63 
who described in 1999 the first organometallic PNA monomer system, with ferrocene 
incorporated at the end of an oligomer. 
 
1.5 Incorporation of ferrocene into the backbone of DNA 
Another interesting way to use ferrocene in a nucleic acid is to incorporate it directly into an 
oligonucleotide backbone. Brisset and his team64 described such an example in 2004 by 
inserting a ferrocenyl-phosphoramidite into a DNA chain (Figure 1-26). 
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Figure 1-26: Ferrocenyl phosphoramidite developed by Brisset 
 
The monomer was synthesised via a Wittig-Horner reaction involving 1-1’-bis-
formylferrocene and a triethyl phosphonoacetate followed by hydrogenation of the 
corresponding double bonds and a reduction of the ester functions using LiAlH4. The 1-1’-
bis-propanolferrocene was tritylated and the final phosphoramidite was then obtained via 
phosphitylation. (Scheme 1-8) 
 
 
Scheme 1-8: Ferrocenyl derivative synthesis by Brisset 
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 The ferrocenyl monomer was then incorporated into specific oligonucleotides sequences 
using an automated synthesizer at various positions along the sequence. The study revealed 
that all the oligonucleotides were detectable by electrochemistry and the detection could be 
optimized by the introduction of several ferrocenyl derivatives into the sequence.  
Other related work was reported by Ihara and co-workers65 in 2009, who also described the 
direct incorporation of ferrocenyl monomers into the DNA-backbone. The influence of the 
DNA-structure on the redox potential of different ferrocene conjugates was investigated. 
Inspired by Brisset’s work, they synthesised similar bis-substituted ferrocenyl derivatives A, 
C, and D as shown in Scheme 1-9. The synthesis of monomer A was done following Brisset’s 
procedure, although they used NaBH4 in presence of CuCl instead Pd/C catalysis in presence 
of H2 for the hydrogenation step. Extension of hydroxyl linker chain of C and E was 
performed via Williamson ether synthesis involving the protected bromide B and the 15-
crown-5-ether. DMTr protection and phosphitylation were achieved as previously described 
in Brisset’s work. 
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Scheme 1-9: Fc-based Amidites with different linker chains 
 
Thermal analysis of duplex and hairpin DNA structures via UV melting experiments revealed 
a destabilisation of the duplex structure, which was probably due to the flexibility of the Fc 
unit inserted, since the continuity of the sequence was broken. This tendency increased with 
the length of the linker chain. Contrary to the duplex, insertion of ferrocene into the loop of 
the hairpins seemed to have a stabilization effect on the structure. Electrochemical studies 
revealed that the potential of ferrocene in the two different structures shifted in opposite 
directions: to negative potentials for the duplex and to positive potentials for the hairpin 
structure. This could be due to the differences in hydrophilicity between the two structures.  
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In the light of these inspiring works on nucleic acid analogues and ferrocenyl conjugates, our 
group decided to investigate a way to develop a novel type of nucleic acid combining 
Brisset’s and Ganesh’s independent works. It consisted of linking ferrocene with nucleobases 
to obtain a ferrocenyl monomer, which could be incorporated into an oligonucleotide 
sequence or oligomerised. The rationale for this novel Ferrocene Nucleic Acid is detailed in 
the following section. 
 
1.6 Aims 
Inspired by the previously described work on metal-containing nucleic acids, the thesis 
describes the design and synthesis of novel ferrocenyl monomers that make up the 
component of a bioorganometallic nucleic acid analogue, called Ferrocene Nucleic Acid 
(FcNA). The idea is based on the incorporation of a ferrocenyl monomer into the backbone 
of a nucleic acid, replacing an entire dinucleotide sugar-phosphate-sugar (SPS) unit by the 
Cp-M-Cp motif of the monomer (Figure 1-27). One justification for this approach comes from 
the similar distance between the two cyclopentadienyl rings (3.3 Å)66 of the ferrocene and 
the distance between two stacked nucleobases in natural B-DNA (3.4 Å).67 In this context, 
the two rings would replace two sugars and the iron atom would replace one linking 
phosphodiester unit. Another interesting property of ferrocene is that the Cp rings have the 
ability to rotate independently around the iron axis, giving to the monomer more 
conformational freedom. It is assumed that this would limit the disruption to the hydrogen 
bonding and stacking interactions during duplex formation. Additional preliminary 
computational studies processed by Tiffany Walsh in Warwick and Mark Rodger in 
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Birmingham, indicated that one ferrocenyl monomer would fit if designed with a two 
carbons linker between each nucleobase and the ferrocene unit.  
 
Figure 1-27: Scheme of incorporation of tetra-substituted ferrocene into DNA 
 
In order to obtain the target oligomer, tetra-substituted ferrocene monomers would first 
have to be made. The synthetic design was framed by the fact that both Cp rings would form 
a part of the backbone. As shown in Figure 1-27, each ring would then be di-substituted, 
with one linker to the phosphodiester part of DNA and one linker to the nucleobase. The 
“DNA-linker” was designed to contain three carbons following previous literature results.68 
Acting as a cornerstone of the monomer synthesis, chirality also would have to be carefully 
controlled.  
 
The thesis is organised in the following way: In Chapter 2, an investigation into the coupling 
of one or two adenine, uracil and cytosine units to ferrocene is described. The 
electrochemical properties of these derivatives have also been studied via cyclic 
voltammetry. In Chapter 3, the synthesis of a tetra-substituted ferrocenes coupled to 
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adenine, uracil and cytosine will be described, that are monomeric precursors to FcNA 
oligomers. The final results chapter, Chapter 4, describes the development of 
bioorganometallic nucleoside drug mimetics via the synthesis of various ferrocene 
monomers. 
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2 CHAPTER 2: MONO AND BIS-SUBSTITUTED FERROCENES 
 
2.1 Introduction 
To investigate the best way to attach nucleobases to ferrocene, it was decided to investigate 
various model compounds consisting of mono and bis-substituted ferrocenes obtained 
through various coupling routes. According to the literature, there are a number of examples 
of ferrocene being linked to nucleobases. As briefly described in the previous chapter, 
Ganesh and coworkers1 synthesised ferrocene-linked nucleobases conjugates from mono 
and bis-(hydroxybutyl)-ferrocene via a Mitsunobu reaction. (Figure 2-1) 
 
Figure 2-1: Bis-uracil and bis-thymine ferrocene with 1 and 4 carbons space linkers by Ganesh1,2 
 
Crystallographic structure analysis of bis-thymine and bis-uracil ferrocene conjugates 
revealed self-assembled motifs consisting of Watson-Crick base pairing. In 2010,2 Ganesh 
and coworkers compared these results with new supramolecular assemblies they obtained 
using a methylene linker instead of a butylene. They concluded that nature of the spacer 
induced a specific orientation of Cp rings with both contributing to the formation of these 
specific assemblies. (Figure 2-2)  
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Figure 2-2: Different crystalline structures of bis thymine ferrocenyl compounds depending on the 
nature of the spacer (Methyl spacer in red and blue and Butyl space linker in green and yellow)2 
 
In earlier work, Houlton3 developed another method to couple ferrocene to nucleobases. 
Mono-substituted ferrocenes linked to thymine, uracil, cytosine and purine derivatives were 
synthesised by refluxing an aqueous solution of trimethylammonio-methylferrocene iodide 
with a nucleobase. Adenine-containing ferrocene derivatives are less common than their 
thymine and uracil analogues. However, Houlton coupled a mono functionalised ferrocene 
to adenine through a methylene linker using the same method.4 In addition, Kumar reported 
that an assembly of four adenine ferrocenylpropanones formed an elegant quartet structure 
(Figure 2-3). 5, 6 
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Figure 2-3: Adenine-ferrocene derivatives forming a quartet via hydrogen bonding5,6 
 
Enlightened by these studies, different coupling methods were investigated to generate the 
targets in Figure 2-4 including the Horner-Wittig reaction, the Mitsunobu reaction and a 
bromide substitution. Adenine, uracil and cytosine also had to be suitably protected to 
enable their use as appropriate reagents in these coupling. 
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Figure 2-4: Targets: ferrocene-containing adenine, uracil and cytosine 
 
 
2.2 Coupling: Horner-Wittig approach 
2.2.1 Literature background 
Amongst others, the Horner-Wittig reaction, which is a variant of the Wittig reaction, has 
been used to couple nucleobases to different types of compounds. For example, Dahl and 
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coworkers7 prepared a series of alkenyl adenine and thymine derivatives via this reaction. To 
begin with, they synthesised phosphonates and phosphine oxide derivatives of the 
nucleobases. Alkylated bases were then protected with a benzoyl group or a 
dibutylformamidine group to avoid side reactions during the following step. The bases were 
then coupled with various carbonyls such as benzaldehyde, leading to the desired alkenes. 
Replacing benzaldehyde with ferrocene was a new approach that the Tucker group decided 
to investigate in order to synthesise the target compounds.  
 
First reported in 1953 by Wittig and Geissler,8 the Wittig reaction and its derivatives are 
characterised by treatment of a ketone with a phosphonium ylid to give an alkene. Ylids are 
neutral compounds containing opposite charges on two adjacent atoms. The positive charge 
is located on the phosphorus and the negative on the carbon (Scheme 2-1). Ylids are usually 
produced via deprotonation of phosphonium salts with a strong base such as butyllithium, 
tert-butoxide or sodium hydride.  
 
 
Scheme 2-1: Formation of an ylid by deprotonation of a phosphonium salt 
 
The mechanism of the Wittig reaction is based on the intramolecular formation of an 
intermediate called oxaphosphetane (Scheme 2-2). First, the nucleophilic carbanion of the 
ylid attacks the carbonyl. The lone pair on the oxygen attacks the phosphonium forming a 
four-membered ring. The unstable oxaphosphetane undergoes elimination to give an alkene 
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and a phosphine oxide as a side-product. The phosphorus-oxygen double bond is very strong 
and drives the reaction forward. 
 
Scheme 2-2: Wittig reaction mechanism 
 
The Wittig reaction is regioselective and stereoselective. Indeed, when a substituted ylid 
reacts with an aldehyde, both Z and E alkene isomers are formed. The stereoselectivity 
essentially depends on the type of the ylid involved in the reaction and consequently on the 
nature of its substituents. Ylids can be divided into two categories: ylids with anion-
stabilizing substituents and ylids without. In the first category, the negative charge on the 
carbon is stabilized not only by the phosphorus but also by adjacent conjugating 
substituents. They are called stabilized ylids and give mainly E-isomers. The others are called 
unstabilized ylids and give mainly Z-isomers. 
 
It is important to consider the relationship between the nature of the ylid and the 
stereoselectivity of Wittig reaction. Addition of the ylid to the carbonyl produces two 
diastereoisomers of the oxaphosphetane: A and B (Scheme 2-3). In the case of stabilised 
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ylids, the stereoselectivity of the reaction is thermodynamically controlled. The formation of 
A and B is reversible because of the high stability of the ylid. Consequently, the 
oxaphosphetane diastereoisomers can interconvert and the equilibrium of the reaction 
turns towards formation of the more stable intermediate A. It is reasonable to assume that 
the trans is the more stable isomer for steric reasons. The two largest groups are on 
opposite sides of the ring, reducing steric hindrance. Stereospecific elimination of the 
intermediate gives mainly the E-alkene isomer. 
 
Scheme 2-3: Wittig mechanism with stabilised ylid 
 
In the case of unstabilized ylids, the formation of the oxaphosphetane intermediate is 
irreversible because of the unstable nature of the ylid. The stereoselectivity of this step is 
kinetically controlled and the cis-diastereoisomer is formed preferentially. As shown in 
scheme 2-4, the ylid and the aldehyde approach each other perpendicularly and form a 
“puckered” oxaphosphetane ring. The transition state is formed in a way that steric 
hindrance is reduced, leading to the cis-oxaphosphetane A. This isomer is probably less 
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stable, but is formed quicker than the trans. Stereospecific elimination of the intermediary 
leads to the formation of Z-alkene. 
 
Scheme 2-4: Wittig mechanism with unstabilized ylid via a puckered transition state 
 
Variants of the Wittig reaction have been developed to optimise stereoselectivity. Amongst 
others, the Horner-Wittig reaction is one that is characterised by the use of 
diphenylphosphine oxide ylids. Horner was the first to use those ylids in order to produce an 
alkene. Isomeric Z and E-alkenes were formed directly, but using lithium bases enabled 
isolation of intermediates C and D (Figure 2-5). The separated intermediaries could then be 
treated separately with a base to obtain the corresponding pure isomer of the alkene. The 
Horner-Wittig reaction can also be carried out without isolation of the intermediates.  In this 
case, the nature of the ylid plays again a significant role in the Z:E ratio. When the ylid is 
unstabilized, the stereoselectivity of the reaction is not really well controlled but tends to go 
towards the Z-alkene if R1 and R2 are bulky. 
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Figure 2-5: stabilised intermediates via lithium salt formation 
 
The following section will discuss the utilisation of the Horner-Wittig reaction as a way to 
couple ferrocene with adenine and cytosine. The N-9 position of adenine was alkylated 
following the usual procedure but with the N-6 position first protected to avoid side-
reactions. In the same way, cytosine was alkylated at the N-1 position and protected at the 
N-4 position. 
 
2.2.2 Synthesis results 
2.2.2.1 Adenine/cytosine alkylation 
In the procedure reported by Dahl and coworkers,7 adenine is alkylated and coupled with 
benzaldehyde via the Horner-Wittig reaction. To begin with, the alkylated adenine is 
synthesised. The deprotonation at the N-9 position with NaH in DMF is followed by addition 
of the (4-nitrophenylsulfonyloxymethyl) diphenyl phosphine oxide. After stirring for four 
days, N,N-dibutylformamide dimethyl acetal is added and reacted for three more days to 
protect the alkylated base. (Scheme 2-5) 
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Scheme 2-5: Alkylation and protection of adenine by Dahl7 
 
Following this method, alkylation and protection of adenine was investigated. 
Diphenylphosphine chloride 1 was treated with hydrochloric acid and formaldehyde at 50˚C 
overnight to give the (hydroxymethyl)diphenyl phosphine oxide 2 in 84% yield as reported 
by Marmor and Seyferth.9 Adenine is a poor nucleophile and nucleophilic substitution on the 
α carbon of a phosphine oxide is difficult. To overcome this problem, 4-nitrophenylsulfonyl 
was used as a good leaving group and linked to the (hydroxymethyl)diphenyl phosphine 
oxide to aid the alkylation of adenine. Substitution of 2 with the 4-nitrophenylsulfonyl 
chloride 3 was catalysed by DMAP acting as an activator of 3 with triethylamine 
deprotonating the alcohol. The alcohol attacked the sulfonyl to form the desired (4-
nitrophenylsulfonyloxymethyl) diphenyl phosphine oxide 4 in 55% yield. (Scheme 2-6) 
 
Scheme 2-6: Alkylation precursor synthesis scheme 
Chapter 2: Mono and bis-substituted ferrocenes 
 
48
The following step consisted of alkylation of adenine with the previously synthesised 
diphenylphosphine oxide 4. NaH was used as a strong base to deprotonate the N-9 hydrogen 
of adenine. The nucleobase attacked 4 releasing the nitrobenzensulfonate. The desired 
compound 5 was obtained with a 58% yield. The reaction was performed in DMF to allow 
the purine to dissolve and to favour the SN2-type mechanism. Adenine was mainly alkylated 
at the N-9 position and the minor N-7 isomer was removed by column chromatography after 
N-6 benzoyl protection. A comparison of the 13C NMR values of 5 with literature values10 
confirmed that N-9 alkylation was obtained (Table 2-1), with position 4 being particularly 
diagnostic. 
Table 2-1: Comparison of 13C NMR values of 5 to literature values  
 
 
 
 
 
 
 
 
 
 
 N-7 Literature example10 N-9 Literature example10 5 
C2 152.3 152.5 152.8 
C4 159.8 149.9 149.9 
C5 111.7 118.7 129.1 
C6 151.9 155.9 155.3 
C8 145.9 141.4 140.8 
 
To avoid side reactions during the coupling reaction with ferrocene, the primary amine of 
adenine had to be protected. Benzoyl chloride was chosen instead of the 
dibutylaminomethylene used by Dahl. Indeed, benzamide protecting groups are commonly 
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used in DNA synthesis to protect nucleosides; thus we investigated this way of protection 
bearing in mind the later tetra-substituted ferrocene synthesis. Following to the procedure 
reported by White,11 benzoylation was performed in the presence of pyridine with benzoyl 
chloride overnight to give 6 in 77% yield after a basic work-up and purification on silica gel 
using 30% hexane in EtOAc.  
 
Scheme 2-7: Alkylation and protection of adenine 
 
Given the reasonably good yields obtained with adenine compared to the results obtained 
by Dahl and coworkers7, the same series of reactions were performed to alkylate and 
protect cytosine. Alkylation of cytosine was obtained in 61% yield and mono-protected with 
benzoyl in 72% yield. Interestingly in this case di-benzoylation was not observed according to 
the analysis of the proton and carbon NMR spectrums. 
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Scheme 2-8: Cytosine alkylation and protection 
 
2.2.2.2 Horner-Wittig coupling 
The other starting material needed for the coupling reaction was 1-1’-dicarboxaldehyde 
ferrocene 9. It was synthesised following the procedure described by Balavoine et al. in 
1991. 12  The first step involves metalation of ferrocene with n-butyllithium and 
tetramethylethylenediamine (TMEDA). Dimethyl formaldehyde then reacts as an 
electrophile with the dilithio-ferrocene-TMEDA complex to give the target compound 9 in 
78% yield after an aqueous work-up and purification via flash column chromatography using 
70% EtOAc in hexane. (Scheme 2-9) 
 
Scheme 2-9: Synthesis of 1,1'-bis-dicarboxaldehyde ferrocene 
 
Ferrocene 9 was then reacted with adenine phosphine oxide 6 under Horner-Wittig 
conditions.  
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Scheme 2-10: Horner-Wittig coupling with ferrocene carboxaldehyde and alkylated adenine. 
 
The reaction was quenched with a 1:1 mixture of EtOAc/Water and purified via flash 
chromatography with a 60% EtOAc/hexane mixture to give 1,1’-Bis-N-6-
(dibenzoyladenine)ethenyl ferrocene 10 in 52% yield. Analysis of 1H NMR shows two singlets 
at 8.75 and 8.09 integrating for the cyclic protons of the two adenines and two doublets at 
6.84 and 6.39 ppm integrating for the four protons of double bonds. The vicinal CH=CH 
coupling constant value determined from the 1H NMR spectrum were JHH = 8.7 Hz, which is 
consistent with the formation of Z-isomer of the alkene13 and agrees with the results 
obtained by Dahl. In their case, the reaction of N-6-(Dibutylaminomethylene)-9-
(diphenylphosphorylmethyl) adenine and benzaldehyde gave a 2:7 mixture of E:Z isomers of 
the resulting alkene in 65% overall yield. Their results and our results are consistent with the 
previously developed theory on the Horner-Wittig mechanism involving unstabilized ylids 
with diphenylphosphine oxide. 
 
Reduction of the double bonds and the deprotection of the protecting groups were 
investigated next as described below. (Scheme 2-11) 
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Scheme 2-11: Hydrogenation of the unsaturated product of the Horner-Wittig reaction and 
debenzoylation of adenine. 
 
Hydrogenation of the unsaturated bonds of 10 was achieved in 72% yield with Pearlman’s 
catalyst Pd(OH)2/C (20%) using H2 gas as source of hydrogen at normal atmospheric pressure 
(1 atm). The disappearance of the vicinal proton peaks in the proton NMR spectrum 
indicated that an overnight reaction was sufficient to obtain 11. No undesired deprotection 
of adenine was observed. The overall yield of the coupling and the hydrogenation was 37%. 
Removal of the benzoyl protecting group was achieved with a methylamine solution giving 
12 in 66% yield and 13 in 77% yield from compounds 11 and 10 respectively.  
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The same Horner-Wittig coupling reaction was then tried with alkylated cytosine 8 but 
unfortunately no reaction was observed. After stirring overnight, both starting materials 
were recovered but with a slight degradation of the phosphine oxide cytosine, probably due 
to oxidation (Scheme 2-12). The reaction was performed again in drier conditions but 
without success.  The coupling reaction was then tried under Mitsunobu conditions and via a 
bromide substitution. This will be discussed in the next sections.  
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Scheme 2-12: Horner-Wittig coupling with ferrocene carboxaldehyde and alkylated cytosine 
 
Compound 12 was recrystallized by slow evaporation from a DCM/MeOH solvent mixture to 
afford crystals suitable for X-Ray diffraction. 
 
Figure 2-6: Crystal structure of 12 with ellipsoids drawn at the 50 % probability level. The iron atom is 
located on an inversion centre such that only half of the molecule is crystallographically independent. 
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The structure (Figure 2-6) reveals interesting features as well as providing proof of the 
success of the synthesis, confirming for example alkylation of adenine at the N-9 position 
and not at the N-7 position. This is of importance for the later coupling of adenine with the 
tetra-substituted ferrocenyl monomer. Indeed N-7 substitution would affect the ability of 
the monomer to form hydrogen bonds, which would disfavour any duplex formation. The 
iron atom of 12 is placed on an inversion centre of the molecule, which means that only half 
of the molecule is crystallographically unique and the two cyclopentadienyl rings are 
identical. The C6-C7 bond lengths confirmed the saturated nature of the linker with a 
characteristic length of 1.54 (Å). (Table 2-2)  
 
Table 2-2: Selected bond lengths (Å) and angles (°) for 12 
Bond lengths and angles 
(and their standard deviation) 
12 
C6–C7 1.536 ± 0.009 
N2–C8 1.31 ± 0.001 
N2–C9 1.415 ± 0.009 
N5–C12 1.321 ± 0.009 
C1–C6–C7 115.1 ± 0.6 
C6–C7–N1 110.3 ± 0.6 
C8–N2–C9 103.6 ± 0.6 
N4–C12–N5 117.9 ± 0.7 
C9–C12–N5 126.0 ± 0.7 
 
The crystal structure also shows a Cp twist angle of 36°, and an axial positioning of the 
ferrocene substituents, giving a torsion angle of 180° between them (C6-C1-C1-C6). This 
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particular arrangement is due to the formation of intermolecular hydrogen bonds between 
the bases. This feature has already been described by Ganesh in the case of thymine and 
uracil.1,2 The packing organisation is represented in Figure 2-7. 
 
Figure 2-7: Molecular packing diagram showing the H-bonded sheet formed by A:A base pairs of 
crystallographically independent molecules of 12. 
 
Compound 12 forms a sheet of hydrogen-bonded ribbons, with each adenine interacting 
with one another via two H-bonds coming from protons on the exo-amine acting as donors 
and two H-bonds coming from the nitrogens on the purine ring acting as acceptors. 
Hydrogen bonds lengths and angles are reported in Table 2-3. Only two are presented 
because of the symmetry of the molecule. 
 
Table 2-3: Detail of hydrogen bonding (Å) and (°) in crystalline structure of 12. 
Donor−H∙∙∙Acceptor d(D−H) d(H∙∙∙A) d(D∙∙∙A) ∠(DHA) 
12: N5−H5A...N2 0.88 2.28 3.159 ± 0.008 175.3 
12: N5−H5B...N4 0.88 2.02 2.850 ± 0.008 156.8 
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Even though the Horner-Wittig was a successful way to synthesise a new adenine-containing 
ferrocene,14 the yield of the coupling reaction to form 10 was quite low and the overall 
number of steps was quite large. Furthermore no product was observed in the 
corresponding reaction with cytosine, therefore other routes were also explored. As 
mentioned earlier, the Mitsunobu reaction has been used to couple ferrocene to thymine 
and uracil via a 1- and 4-carbon linker1 and was therefore considered to be an interesting 
alternative for improving the coupling reaction. The results of these studies are outlined 
below. 
 
2.3 Coupling: Mitsunobu approach 
The reaction of an alcohol and a nucleophile in the presence of diethyl azodicarboxylate 
(DEAD) or diisopropyl azodicarboxylate (DIAD) and triphenylphosphine is called the 
Mitsunobu reaction or sometimes DEADCAT reaction (DiEthyl AzoDiCarboxylate with Acid 
and Triphenylphosphine). The general mechanism can be explained in five steps, as shown in 
scheme 2-13. In the first step, triphenylphosphine attacks the N=N azodicarboxylate bond to 
form the corresponding nitrogen anion, which is stabilised by one of the ester groups. In the 
second step the lone pair on the carboxylate is delocalised onto the nitrogen, which is basic 
enough to deprotonate the alcohol. The third step is driven by the strong affinity of the 
oxygen towards the phosphorus. Indeed, the alkoxide immediately attacks the phosphorus 
leading to the formation of a second nitrogen anion and a phosphoryl derivative. The 
negative charge on the nitrogen is delocalised in the same way as the first. In the fourth 
step, the negatively charged nitrogen deprotonates the nucleophile, which attacks the 
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phosphorus derivative in the final fifth step. The result of this last step is the production of a 
reduced azodiester, a triphenylphosphine oxide, and the desired compound.  
Scheme 2-13: Mitsunobu reaction mechanism 
 
In the process of linking nucleobases to ferrocene via the Mitsunobu reaction, a ferrocenyl 
derivative acts as an electrophile and the nucleobase as the nucleophile. To play these roles, 
ferrocene was functionalised with an alcohol moiety and the nucleobases were protected as 
described in the following section.  
 
2.3.1 Synthesis 
2.3.1.1 Bis/Mono hydroxyl-Ferrocenyl precursor 
Ferrocenyl alcohols have been the subjects of many synthetic investigations.15 For example, 
in 2009, Swarts and coworkers reported the synthesis of a series of primary ferrocenyl 
alcohols with different carbon linker lengths by reduction of the corresponding 
ferrocenylcarboxylic acids A.16 They also used the γ-ketoacid ferrocenylpropanoic acid B that 
was reduced with AlCl3/LiAlH4, the ester methyl 4-ferrocenylbutanoate C that was reduced 
with LiAlH4 and the ferrocenylcarboxaldehyde D that was reduced with NaBH4 (Scheme 2-14). 
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Scheme 2-14: Synthetic routes to the different ferrocenyl alcohols by Swarts 
 
Another interesting approach was proposed by Barry and Nataro17, who described a simple 
way to synthesise 1,1’-bis-(hydroxyethyl) ferrocene from the 1,1’-bis-vinyl ferrocene in 44% 
yield. The vinyl intermediate was obtained in 63% yield from 1,1’-dicarboxaldehyde 
ferrocene. (Scheme 2-15) 
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Scheme 2-15: Synthetic route to the hydroxyethyl ferrocene by Nataro 
 
This pathway was followed to achieve the synthesis of 1,1’-bis-(2-hydroxyethyl) ferrocene 
and mono-(2-hydroxyethyl) ferrocene (Scheme 2-16). The first step after the formylation of 
ferrocene is a Wittig reaction. 1,1’-Dicarboxyaldehyde ferrocene was treated with 
triphenylmethylphosphonium bromide in the presence of potassium tert-butoxide in dry THF 
and reacted overnight. The reaction was catalysed by dibenzo-18-crown-6-ether, which 
possesses a strong binding affinity for potassium. 1,1’-Bis-vinyl ferrocene was obtained in 
70% yield and vinyl ferrocene in 78% yield.  
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Scheme 2-16: Formation of mono and bis-vinyl ferrocene via Wittig reaction 
 
The following step is the hydroboration-oxidation of 1,1-bis-vinyl ferrocene 15 that consisted 
of a two-step reaction that converted the alkene moiety of 15 and 15a into the alcohol 16 
and 16a. (Scheme 2-17) 
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Scheme 2-17: Hydroboration of bis-divinyl ferrocene 
 
The hydroboration step is an “anti-Markovnikov” type addition where the hydride attacks 
the more substituted carbon of the alkene or the more stable carbocation of the transition 
state. This regioselectivity is also due to the polarity of the B-H bond where the partial 
negative charge is located on the hydrogen. The hydroboration is syn-selective and proceeds 
via the formation of a four-membered ring transition state. The monoalkyl borane can 
undergo two more alkylations depending on its steric hindrance.  
 
The oxidation part of the hydration of the vinyl derivative involves hydrogen peroxide that 
replaces the carbon-boron bond with a carbon-oxygen bond to give the alcohol. The 
peroxide anion reacts with the boron atom and the alkyl chain moves from the boron to the 
oxygen of the peroxide, releasing a hydroxide anion. The reaction usually occurs via the 
formation of a trialkyl borate. The final alcohol is then released from the alkylborate after 
reaction with hydroxide.  
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1,1’-Bis-(hydroxyethyl) ferrocene 16 and mono-(hydroxyethyl) ferrocene 16a were 
accordingly synthesised in 69% yield and 65% yield respectively after extraction with DCM 
and purification via flash chromatography with a 3:7 EtOAc/hexane mixture. Analysis of both 
hydroxyethyl ferrocene 1H NMRs showed the desapearance of the vinyl peaks at 5.0, 5.3 and 
6.4 ppm and revealed the presence of peaks at 2.6 and 3.7 ppm corresponding to the CH2. 
The obtention of the compounds were also confirmed by 13C NMR and high resolution mass 
spectrometry. 
 
2.3.1.2 Adenine, uracil and cytosine protection 
To be reliable reagents in the Mitsunobu coupling reaction, adenine and uracil had to be 
selectively protected. Protection of the N-6 primary amine of adenine, the N-3 of uracil and 
the N-4 of cytosine avoids potential side-reactions during the coupling. Benzoyl chloride was 
chosen as it had been previously investigated for the diphenylphosphine adenine 6. 
Furthermore, in the Mitsunobu reaction, the nucleobases act as nucleophiles. To be able to 
play that role, the N-9 position in adenine and the N-1 in uracil and cytosine have to remain 
unprotected. Indeed, the reaction mechanism imposes a deprotonation of those nitrogens 
to enable nucleophilic attack of the alcohol. 
 
To fulfil these conditions, a protection strategy for adenine was devised to avoid 
simultaneous protection of the N-6 and N-9 positions. To begin with, N-9 had to be 
protected via tritylation, followed by protection of the N-6 primary amine with benzoyl 
chloride. The trityl was then deprotected while the benzoyl remained. This strategy is based 
on the different acid-base sensitivity of trityl and benzoyl groups. Trityl is acid labile, 
whereas benzoyl is base labile. 
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Scheme 2-18: Synthesis strategy to selectively protect adenine 
 
The first step of the adenine protection was performed using trityl chloride in DMF/Py at 
room temperature overnight, as described by Hakimelahi et al.18 Adenine is poorly soluble in 
the solvent mixture but its tritylation increases the solubility of the product. After overnight 
stirring, the solution was clear and the reaction was quenched with water. A quick extraction 
with ethyl acetate and a filtration was sufficient to obtain a very pure solid product that 
corresponded to the desired 9-trityladenine 17 in 86% yield. The 13C NMR chemical shifts of 
17 were consistent with a similar example found in the literature10 to indicate alkylation of 
N-9 instead of N-7, as shown in Table 2-4. 
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Table 2-4: Comparison of 13C NMR values of 17 to literature values  
 
 
 
 
 
 
 
 
 N-7 Literature example10 N-9 Literature example10 17 
C2 152.3 152.5 152.3 
C4 159.8 149.9 151.4 
C5 111.7 118.7 121.5 
C6 151.9 155.9 155.8 
C8 145.9 141.4 141.9 
 
 
The second step consisted of benzoylation of the primary amine using benzoyl chloride as 
described previously. The fully protected adenine was synthesised in 77% yield. The last step 
consisted of deprotection of the trityl with a strong acid. As described by Fletcher19 a classic 
and efficient way to deprotect the acid-labile trityl is to use trifluoroacetic acid (TFA) in DCM 
for 3 h. The compound was successfully synthesised in 68% yield.   
 
With the idea of selectively protecting the N-3 and not the N-1 position, uracil was protected 
following the procedure described by Reese20 who reacted it with a large excess of benzoyl 
chloride in acetonitrile/pyridine for 16 h. The crude was then filtered off and washed with 
acetonitrile. Reese obtained the N-1,N-3-dibenzoyluracil in 65% yield and then treated it 
with potassium carbonate in dioxane/water to remove the N-1 group and afford the N-3-
benzoyluracil, also in 65% yield. However in our case, the crude was directly purified by 
column chromatography to directly access the mono-N-3 compound 20. However 20 was 
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obtained in 25% yield instead of the 43% overall yield obtained by Reese.20 The 1H NMR 
signal for the NH at 11.6 ppm and the 13C NMR signal of C5 at 100.1 ppm reported by 
Reese,20 agree with the values found for 20 and confirmed that the right compound had 
been synthesised. 
 
Figure 2-8: N-3-benzoyluracil 
 
Mono-protection of cytosine was achieved using benzoyl chloride via the procedure 
described by Acevedo et al.21 using 5 eq of benzoyl chloride followed by basic treatment 
with NaOH for 1 h. After an acid treatment with HCl, the compound was recrystallised from 
ethanol for 1 h. A white powder was collected after filtration in a 53% yield. Attempts to 
synthesise N,N-4-dibenzoylcytosine by adding 1 eq or 2.5 eq of benzoyl chloride to N-4-
benzoylcytosine led to the protection of the N-1 position instead. Therefore it was decided 
to try the coupling with mono-benzoyl cytosine. 
 
Figure 2-9: N-4-benzoylcytosine 
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2.3.1.3 Adenine/Uracil coupled with Bis/Mono hydroxyl ferrocenyl precursor 
The investigation of the Mitsunobu coupling consisted of reacting both mono and bis-
(hydroxyethyl) ferrocene 16a and 16 with adenine 19, uracil 20 and cytosine 21. DEAD and 
DIAD were tried independently to get an idea of the best reagent to use. In each reaction, 
triphenylphosphine attacks azodicarboxylate, which deprotonates the ferrocene ethanol. 
The ferrocenyl ethoxide then attacks triphenylphosphine to form a triphenylphosphonate 
ferrocene. Finally, azodicarboxylate deprotonates the N-9 of adenine or the N-1 of uracil and 
cytosine, which attacks the ferrocene to form the final coupled compound. (Scheme 2-19) 
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Scheme 2-19: Mitsunobu mechanism of mono-substituted ferrocene uracil 24 
 
The reaction was first tried on mono-(hydroxyethyl) ferrocene 16a. Two equivalents of each 
reagent (azodicarboxylate, Ph3P and the nucleobase) were used for one equivalent of mono-
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(hydroxyethyl) ferrocene. Adenine mono substituted ferrocene 22a was obtained in 33% 
yield in presence of DEAD and the corresponding uracil derivative 24a was obtained in 83% 
yield (Scheme 2-20). A better yield was obtained with uracil due to the use of DIAD instead 
of DEAD, which is less reactive. However adenine solubility in THF was not good, which could 
also explain the big difference of yield. The reaction was also tried with the cytosine 
derivative in the same conditions but only the mono substituted cytosine was obtained in 
very small amount, probably due to the lack of the nucleobase solubility in THF. The reaction 
was then tried in acetonitrile at 85˚C, but these changes did not improve the results. 
 
Scheme 2-20: Coupling adenine, uracil and cytosine to mono-ethanol ferrocene under Mitsunobu 
conditions 
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The deprotection of 22a and 24a was also investigated and performed in methylamine, 
giving 100% yield for the uracil derivative 25a and 58% for the adenine derivative 23a. 
Methylamine acts as a nucleophile towards the carbonyl function of the benzoyl, releasing 
the deprotected amine and N-methylbenzamide. 
Coupling adenine 19, uracil 20 and cytosine 21 to bis-(hydroxyethyl) ferrocene 16 was 
performed in the same way (Scheme 2-21) but in these cases, 3 eq of triphenylphosphine 
and DIAD and 2.6 eq of adenine or uracil were used for one equivalent of bis-(hydroxyethyl) 
ferrocene. The bis-coupled adenine ferrocene 22 was obtained in a 46% yield and the bis-
coupled uracil ferrocene 24 in a 53% yield. Cytosine coupling was also tried but once again 
no reaction occurred for solubility reasons. 
 
Scheme 2-21: Coupling adenine and uracil to bis-ethanol ferrocene via Mitsunobu 
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Only deprotection of 24 was tried because this reaction had already been investigated 
earlier with adenine. Compound 25 was recovered quantitatively as a yellow powder that 
could not be dissolved in the usual NMR solvents (CH2Cl2, MeOD, D2O, DMSO or THF). 
However, the compound was characterised by mass spectrometry. An exact mass of 
485.0888 m/z was found which correlated well with the calculated mass of 485.0872 (for M 
+ Na+). Furthermore IR spectroscopy showed peaks corresponding to the carbonyl of the 
urea moiety (stretching: 1744 cm-1), the carbonyl (stretching: 1699 cm-1) and the NH of the 
amide group (bending: 1550 cm-1). 
 
2.4 Cytosine coupling: Bromide substitution approach 
The case of cytosine is interesting because of the low solubility of its derivatives in almost all 
types of solvent used in the laboratory. As previously seen, mono-protected cytosine was 
not soluble enough in THF to couple with ferrocene but a quick investigation revealed that 
DMF and DMSO could dissolve it. Therefore, to achieve the coupling of cytosine with 
ferrocene, a reaction using DMF or DMSO as main solvent had to be considered. In 1997, 
Howarth and Wakelin22 reported the synthesis of a new type of PNA called α-PNA made of a 
backbone containing a series of homoserine derivatives linked together with glycine. The 
four canonical bases including cytosine had been attached to the backbone. The monomer 
was synthesised in three steps from the N-Boc-homoserine (Scheme 2-22). The carboxylic 
acid moiety was first esterified with methyl iodide to allow the conversion of the alcohol 
function to the corresponding bromide. This bromination involving NBS and triphenyl 
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phosphine will be described in more detail in the following section. Alkylation of the Cbz-
cytosine to the PNA monomer was performed in DMF in a 61% yield.  
 
Scheme 2-22: Cytosine coupling approach by Howard and Wakelin 
 
This coupling method was followed to link cytosine to a ferrocene bromide, as described 
below. 
 
2.4.1 Synthesis 
2.4.1.1 Mono/Bis-Bromo-ferrocenyl precursor  
As mentioned above, synthesis of 1,1’-(bromoethyl) ferrocene was essential to study 
cytosine coupling. The bromination procedure used by Howarth and Wakelin22 was also used 
by Tius and Fauq23 in the total synthesis of the (+)-Desepoxyasperdiol, which is a synthetic 
precursor to the antitumor natural product Asperdiol. (Figure 2-10) 
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Figure 2-10: (+)-Desepoxyasperdiol precursor of Asperdiol 
 
This procedure was tested on both mono and bis-(hydroxyethyl) ferrocene leading 
successfully to the corresponding bromides 27a and 27 in yields of 91% and 97% yield 
respectively.  
 
Scheme 2-23: Bromination of mono and bis-ethanol ferrocene 
 
The mechanism is based on the activation of N-bromosuccinimide by triphenylphosphine 
releasing bromide ions.24 In presence of pyridine, the bromide ion would replace the 
triphenylphosphonium formed with the alcohol, releasing 27a, triphenylphosphine oxide 
and the succinimide. (Scheme 2-24) 
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Scheme 2-24: Mechanism of bromide ions production suggested by Trippett24 and bromination 
mechanism of hydroxethyl ferrocene 
 
2.4.1.2 Bromide substitution coupling 
The coupling reaction is based on a nucleophilic substitution of the bromide by a cytosine. It 
is reasonable to think that the substitution is of type 2 (SN2) for the following reasons. First 
of all, the substrate is unhindered. Indeed, the reaction occurs in one step and the 
nucleophile needs space to replace the leaving group by breaking the bromide-carbon bond. 
Furthermore, bromide is a good leaving group. Cytosine is deprotonated by NaH to form the 
corresponding anion. The pyrimidine is then able to act attack the ferrocene bromide. DMF 
is polar and aprotic so favours the nucleophilic substitution towards SN2.  
 
According to Howarth and Wakelin,22 the reaction was performed at room temperature. 
Unfortunately, repeating the same conditions with 27 only produced mono substituted 
cytosine in poor yield even after a reaction overnight. Therefore, to improve the efficiency of 
the reaction and to obtain the bis-coupled cytosine ferrocene 28, the reaction was heated 
up to 50˚C. 
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Scheme 2-25: Coupling cytosine to mono and bis-bromoferrocene 
 
After an aqueous work-up and purification, 28a and 28 were obtained in yields of 68% and 
25% respectively. The debenzoylation of 24a with methylamine in ethanol gave 29a in 61% 
yield. The solubility of 28 was not good in CDCl3 and two carbon peaks (C2 and C4) on its 
13C 
NMR spectrum were not observable. To overcome this problem, a few drops of MeOD were 
added to the NMR sample. As shown in Figure 2-11, the two carbons appear at 167 and 156 
ppm.  
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Figure 2-11: 
13C NMR spectrum of 28 using Uniform Driven Equilibrium Fourier Transform (UDEFT) 
 
 
2.5 Electrochemistry  
In order to obtain a better understanding of the electrochemical behaviour of substituted 
ferrocenes with adenine, uracil and cytosine, as well as the influence of the linker on the 
electrochemical response, cyclic voltammetry studies were performed on the following 
compounds. (Figure 2-12)  
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Figure 2-12:  Ferrocenyl compounds coupled with adenine, uracil and cytosine subjected to 
electrochemical studies 
 
Cyclic voltammetry is one of the most widely used electroanalytical methods to study 
electroactive species.25 It brings qualitative information about redox mechanisms and offers 
a quick determination of electrode potentials. This is made possible via analysis of the 
voltammograms that are obtained by cyclically sweeping the potential between two defined 
values at a fixed rate. The potential is measured at the working electrode and the resulting 
current flows through a counter electrode. The electrode potential is measured relative to a 
reference electrode and the voltammogram is displayed as a function of current against 
potential. (Figure 2-13) 
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Figure 2-13: Cyclic Voltammogram  
 
The redox properties of these compounds were investigated using a Pt working electrode, a 
Pt counter electrode and an Ag/AgCl reference electrode. Tetrabutylammonium 
hexafluorophosphate (0.1 M) was used as the supporting electrolyte in DCM and 
decamethylferrocene was used as an internal reference to be able to compare different 
ferrocenyl derivatives.  
 
As shown in Figure 2-13, the anodic current (blue) increases due to oxidation of the redox-
active species until all the starting material diffusing near the electrode surface have been 
oxidised. When the scan is reversed, the current switches to negative values and the 
cathodic current (red) corresponds to the reduction of the previously oxidised species at the 
electrode surface. Chemical irreversibility (i.e. reaction or decomposition) is characterised by 
a smaller or no return peak after oxidation or reduction. Furthermore, electrochemical 
reversibility is characterised in a number of ways: 
Anodic Peak 
Cathodic Peak 
Formal potential E0’ 
Chapter 2: Mono and bis-substituted ferrocenes 
 
77
- The ratio between current peaks is equal to one. 
- The potential of oxidation and reduction peaks does not change with the scan rate. 
- The potential difference between the anodic and cathodic peaks is 59 mV. 
- A linear relationship between the peak current and the square root of the scan rate.  
 
In the following, three factors are investigated via analysis of cyclic voltammograms: (1) The 
electrode potentials and their electrochemical reversibility; (2) the type and number of 
linker groups and (3) the type of nucleobase. 
 
2.5.1 Influence of linker nature 
The influence of the linker group was studied by comparing the effect of the saturated and 
unsaturated bonds on the electrode potentials of ferrocene of 12 and 13. Cyclic 
voltammograms and electrode potentials of both compounds are presented in Figure 2-14 
and Table 2-5. 
 
Figure 2-14: Cyclic voltammograms of 12 (dotted line) and 13 (plain line) in DCM (scan rate = 500 
mv.s-1). 
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Table 2-5: Electrochemical potentials vs decamethylferrocene of 12 and 13 in DCM. 
 
 
 
 
 
 
 
  
N
N
N
N
H2N
Fe
N
N
N
N
H2N  
 12 13 
E0′ (mV) 552  770  
 
The nature of the linker between the base and the ferrocene has a significant effect on the 
electrode potential values. As can be seen on the graph, oxidation of 13, which contains an 
unsaturated linker, is more difficult than 12. In each case, the more electron-rich saturated 
linker lowers the ferrocene-centred redox couple. This results in the value for 13 being 
higher than 12 by 218 mV. Similar effects have been observed previously in related 
systems,26 including adenine-based ferrocene derivatives27 containing either a triple bond or 
a saturated linker. Both compounds 12 and 13 give linear current versus ν1/2 relationship 
with an intersection at zero as shown in Figure 2-15.  
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Figure 2-15: Electrochemical reversibility of compounds 12 (dotted line) and 13 (plain line). 
 
2.5.2 Effect of the number of substituents on ferrocene  
As described above, the nature of the linker (saturated or unsaturated) plays a significant 
role in the electrochemical behaviour of ferrocene. It is reasonable to assume that the 
electrochemical properties of ferrocene could also be affected by the way it is substituted in 
terms of number of substituents. Therefore, bis and mono substituted ferrocenes were 
compared. Three couples of compounds were studied: 11 and 22a for adenine derivatives, 
24 and 24a for uracil derivatives, and 28 and 28a for cytosine derivatives. Their cyclic 
voltammograms are shown in Figure 2-16. 
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Figure 2-16: Cyclic voltammogram of 11, 22a, 24, 24a, 28 and 28a (scan rate = 100 mv.s-1)  
vs. decamethyl ferrocene. 
 
The graphs show oxidation and reduction peaks for adenine derivatives (Green), uracil 
derivatives (red) and cytosine derivatives (blue) at a scan rate of 100 mv.s-1. Bis-
ethylferrocenyl-adenine 11 shows a positive shift of 41 mV compared to its mono 
counterpart 22a, 24 gave an electrode potential 23 mV higher than 24a and 28 was 10 mV 
higher than 28a. Therefore, these results indicated that bis-substituted ferrocenes 11, 24 
and 28 are more difficult to oxidise than their mono-substituted analogues 22a, 24a and 
28a. (Table 2-6) 
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Table 2-6: Electrochemical potentials of mono and bis-ferrocene linked to adenine, uracil and 
cytosine. Electrode potentials, E0′, where E0′= (Epa + Epc)/2, are referenced to decamethylferrocene 
(ca. 1 mM), which was used as an internal reference. The conﬁdence limit is ± 5 mV. 
 
Compounds E0′  (mV) 
 
11  624 
N
N
N N
N
Fe
Bz
Bz
 
22a  583 
Fe
N
N
NBz
NBz
O
O
O
O
 
24  597 
 
24a  574 
 
28  573 
 
28a  563 
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As reported by Houlton and coworkers3 in his publication about the synthesis and the redox 
properties of several ferrocenylmethyl nucleobases, nucleobases are playing a determinant 
role in the electrochemical behaviour of the ferrocenyl moiety. For example, he compared 
the electrode potentials of 9-ferrocenyl-methyladenine A with ferrocene using cyclic 
voltammetry. He noticed a potential increase of 90mV for the ferrocenyl-methyladenine A 
compared to ferrocene. He justified this result by the electron withdrawing effect of the 
nitrogen, which as a part of an aromatic system of adenine, is making oxidation of the 
ferrocenyl moiety more difficult to achieve. Furthermore, he demonstrated that additional 
withdrawing groups (chloride group) on the adenine could increase the redox potential by 
100 mV for compounds such as 2-amino-6-chloro-9-ferrocenylmethylpurine B compared to 
ferrocene. Houlton also measured the electrochemical response of the 6-chloro-2-
ferrocenylmethylaminopurine C, where the ferrocenyl moiety is link to a nitrogen atom that 
is not incorporated into the purine rings. This resulted in a negative shift of the formal 
electrode potential of 8 mV indicating that the ferrocenyl moiety is unaffected by the base. 
(Figure 2-17) 
 
Figure 2-17: Formal electrode potentials (vs. ferrocenium–ferrocene) for the ferrocenyl-
methyladenine A and related derivatives B and C obtained from cyclic voltammetry (scan rate 500 
mv.s-1) 
 
In view of these elements, it can be postulated that bis-substituted ferrocenyl derivative 11, 
24 and 28 are more difficult to oxidise than their mono counterparts 22a, 24a and 28a 
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because they contain twice as much nucleobases and thus ferrocenyl moiety oxidation is 
made more difficult by the electron withdrawing effect of the two nucleobases. 
 
Electrochemical reversibility of the six compounds was also determined. Their reversible 
linear profiles are presented in Figure 2-18. 
 
 
Figure 2-18: Electrochemical reversibility plots of 11, 22a, 24, 24a, 28 and 28a 
 
2.5.3 Effect of the nucleobases 
The influence of the type of nucleobase linked to ferrocene and their influence on the 
electrode potential was then investigated. As can be seen in Table 2-7, adenine ferrocenyl 
derivatives are the most difficult to oxidize, followed by uracil ferrocenyl derivative and 
finally cytosine ferrocenyl derivatives. 
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Table 2-7: Effect of the type of nucleobase on the electrode potential of the ferrocenyl moiety. 
Electrode potentials, E0′, where E0′= (Epa + Epc)/2, are referenced to decamethylferrocene (ca. 1 mM), 
which was used as an internal reference. The conﬁdence limit is ± 5 mV. 
 
 Adenine Uracil Cytosine 
 
 
Fe
N
N
NBz
NBz
O
O
O
O
 
 
 11 24 28 
E
0′ 
(mV) 624 597 573 
 
  
 
 22a 24a 28a 
E
0′ 
(mV) 583 574 563 
 
Houlton compared the electron-withdrawing environment of adenine derivative A with the 
N-1 of cytosine derivative D and the N-3 of uracil derivative E.3 In the cytosine derivative, the 
N-1 is adjacent to one carbonyl group (C2) and one alkene moiety (C6), and the formal 
potential of the compound was +74 mV compared to ferrocene. In the case of E where uracil 
is substituted at the N-3 position, the two carbonyls (C2 and C4) increase the electron 
withdrawing effect, resulting in a higher formal potential compared to ferrocene (+135 mV). 
(Figure 2-19)  
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Figure 2-19: Electron withdrawing effect of uracil, cytosine and adenine and their corresponding 
formal electrode potentials. 
 
The nucleobases in compound A and D are substituted at the same position as compounds 
22a and 28a and give a very similar trend, with the adenine derivative having a slightly 
higher electrode potential. However the uracil derivatives E and 24a are substituted 
differently, which explains the different trend for these compounds. Our studies show that 
when ferrocene is placed at the position where normally the sugar would be connected, 
adenine has a more powerful influence on the oxidation of the ferrocenyl moiety than 
pyrimidines due to the stronger electron-withdrawing environment of the N-9 nitrogen. 
 
To conclude, our results are consistent with Houlton’s conclusions on the importance of the 
electron-withdrawing effect of the nucleobases on the electrode potential of the ferrocenyl 
compounds. They also confirm the importance of the nature as well as the number of 
nucleobases on the electrochemical behaviour of these ferrocenyl derivatives. 
 
2.6 Conclusion 
In this chapter it has been demonstrated that it was possible to successfully attach ferrocene 
to adenine, uracil and cytosine via different coupling methods, including Horner-Wittig, 
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Mitsunobu and a bromide substitution. In the case of the bis-adeninyl ferrocene, the 
Mitsunobu coupling gave a better yield compared to the Horner-Wittig reaction. Cytosine 
was successfully coupled to ferrocene despite its poor solubility in most usual solvents. 
However, it would be interesting perform further investigations on this reaction to improve 
the coupling yield. Crystal structure analysis revealed interesting features such as the 
formation of elegant assemblies via hydrogen bonding for adenine-containing ferrocenes. 
Electrochemistry studies exhibit good electrochemical reversibility for the different 
ferrocene derivatives and demonstrate the importance of the nature of the linker as well as 
the nature and number of nucleobases on the redox properties. 
 
These results aided our investigations on the synthesis of more complex tetra-substituted 
ferrocene monomers, with the aim of designing and creating novel types of nucleic acid 
analogues. 
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3 CHAPTER 3: TETRA-SUBSTITUTED FERROCENE MONOMERS 
 
3.1 Introduction 
In the light of significant work on nucleic acid analogues developed over the past few 
decades, the Tucker group devised the notion of an organometallic version called ferrocene 
nucleic acid (FcNA), which is based on ferrocenes linked together via phosphodiester 
linkages. In order to make a version of FcNA shown in Figure 3-1, the synthesis of 
appropriate monomer units first had to be successfully achieved.  
 
Figure 3-1: DNA and FcNA oligomer (B = Base) 
 
Several factors were taken in account in the synthetic design of the monomer. First of all, a 
phosphoramidite version of the monomer was required so that the oligomer could be 
synthesised via automated nucleic acid synthesis. Consequently, each cyclopentadienyl ring 
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had to be substituted with a “phosphodiester-linker” containing one alcohol moiety. The Cp 
rings were also to be substituted with an alkyl spacer group linked to nucleobases to allow 
duplex formation via base pairing. Finally, the tetra-substituted ferrocene monomers would 
have to be chirally pure, with the monomer units shown in Figure 3-1 each containing four 
stereogenic elements. 
 
The synthesis of the monomers can be divided into three sections. The goal of the first part 
was to develop a tetra-substituted ferrocenyl precursor. In this step, central and planar 
chirality were to be introduced, with C2 symmetry retained to minimise potential side 
reactions. The second part was to deal with construction of the three-carbon 
“phosphodiester-linker” groups, consistent with the spacing previously seen in the 
literature.1 The third part was to be concerned with coupling ferrocene to nucleobases 
adenine and uracil followed by deprotection. 
OH
OH
Fe
Base
OH
OH
Fe
I
Fe
NMe2
NMe2
I
Fe
X = I, Br
II
Base
Base = Adenine, Uracil
 
Scheme 3-1: Retro-synthetic scheme of the synthesis of adenine and uracil tetra-substituted 
ferrocenyl monomers 
 
Two tetra-substituted ferrocenyl monomers were eventually synthesised to afford the 
targeted diols. These diols were then to be primed for oligomerisation via phosphitylation 
and tritylation. The first monomer is a tetra-substituted ferrocene coupled to adenine. Due 
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to synthetic difficulties encountered using the Horner-Wittig approach that had previously 
been successfully used to give the thymine target, developed in parallel in the group, a new 
route had to be investigated using Mitsunobu coupling. The second monomer is a tetra-
substituted ferrocene coupled to uracil. This was also synthesised via the same Mitsunobu 
approach. This route builds on the successful attempts to make bis-functionalised ferrocenes 
as described in Chapter 2. 
 
3.2 Part 1: Monomer precursor 
The main goal of this part was to synthesize a common basic unit for the two tetra-
substituted ferrocene monomers. Starting from ferrocene, the first key-step corresponded 
to the introduction of two specific chiral centres on the α-positions of the ferrocene. The 
second key-step involved the introduction of planar chirality via a halogen substitution on 
each Cp ring. (Scheme 3-2) 
 
Scheme 3-2: The two first key-steps for the synthesis of the precursor of the tetra-substituted 
ferrocenyl monomers 
 
This halogenation is actually based on a directed ortho-metallation involving a chiral 
dimethylamine ferrocene and a lithium base. The mechanism of this induced-halogenation is 
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based on interaction between lithium and the dimethyl amine group, as shown in Figure 3-2. 
The mono-substituted monomer instead of the bis-substituted monomer is shown for clarity 
purposes. 
 
Figure 3-2: Ortho-lithiation of Ugi’s amine  
 
Ugi 2  explained that stereoselectivity of the ortho-metallation can be induced by a 
stereogenic chiral centre situated on the α-position of the ferrocene. In the case of a chiral 
R-α-N,N-dimethylaminoethyl ferrocene treated with n-BuLi, he showed that proton H2 and 
H5 were replaced by lithium with a 96:4 selectivity ratio. This ratio can be explained by the 
position of the methyl, which is slightly above the Cp ring when butyllithium is interacting 
with nitrogen. Indeed, this conformation is energetically lower than when the methyl is 
closer to the iron. Considering R configuration of the chiral centre, H2 is more likely to be 
replaced by lithium than H5, as shown in Scheme 3-3.  
 
 
Scheme 3-3: Ugi's abstraction2 of ortho-H on a mono substituted ferrocene 
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Butler3 and Knochel4 supported this theory via 2D-NMR and NOE (Nuclear Overhauser 
Effect) experiments. To conclude, the diastereoselectivity of this ortho-metallation is highly 
influenced by the configuration of the chiral centre and leads to a highly selective 
substitution.  
 
As explained above, depending on the configuration of the stereogenic carbon centre, two 
ortho-positions could be considered for the introduction of the halogen: a and b giving 
respectively compounds A (R,R,Sp,Sp)  and B (S,S,Rp,Rp). (Scheme 3-4) 
 
Scheme 3-4: Introduction of the base linkers on the ortho-position 
 
A modelling study within the group indicated that either enantiomer (C or D) could be placed 
within a B-DNA duplex structure but enantiomer C gave the more stable duplex according to 
modelisation, consequently it was decided to start with the synthesis of C. 
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The monomer precursor was synthesised in five steps as summarised in Scheme 4. 
Ferrocene was first acylated and then reduced in order to obtain α-chiral diol 31. Acetylation 
was followed by a nucleophilic substitution leading to the dimethylamine 33. The 
dimethylamine ferrocene was then substituted at its ortho position to give 34. Some of the 
mechanisms are discussed in the following sections. 
 
 
Scheme 3-5: First part synthesis scheme 
 
3.2.1 Friedel-Crafts Acylation 
Acylation was one of the first reactions performed on ferrocene after its discovery.5 In the 
presence of aluminium chloride and acetyl chloride, ferrocene can be acylated in DCM to 
give 1,1'-diacetylferrocene. The mechanism is based on the Friedel-Crafts reaction, which 
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attaches electrophiles to aromatic rings. An acylium ion is formerly produced by the reaction 
of acetyl chloride with aluminium chloride, which acts as a Lewis acid. Ferrocene attacks the 
acylium producing the bis-ketone ferrocene and releasing HCl. Slightly more than one 
equivalent of the catalyst (aluminium chloride) is used per mole of reagent because the first 
mole of catalyst forms a complex with the carbonyl of the reagent. (Scheme 3-6) 
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Scheme 3-6: Friedel-Crafts acylation 
 
1,1'-Diacylferrocene 30 was obtained via this method in a yield of 85%. 13C NMR shows a 
peak at 177 ppm characteristic of the ketone carbonyl.  
 
1.1.1 Enantioselective reduction of ketone 
Reduction of ketones consists of addition of two hydrogens to the carbon-oxygen bond of 
the carbonyl, leading to the formation of an alcohol. This is usually done via a strong 
reducing agent such as lithium aluminium hydride or sodium borohydride. Non-symmetrical 
ketones are prochiral and depending on which face of the carbonyl is attacked, two 
enantiomers can be obtained (R or S). In the case of reduction with LiAlH4 or NaBH4, there is 
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no distinction between the two faces for the attack of the hydrogen, which leads to a 
racemic product. Interest in enantioselective reduction of ketones led to the development of 
chiral reducing agents that could direct the reduction towards a specific enantiomer. In the 
1980’s, Itsuno and his group6,7 reported the enantioselective reduction of achiral ketones 
using a chiral amino-alcohol (S-Valinol) in presence of BH3.THF (Scheme 3-7). Further 
developments with this approach improved the enantioselectivity of the reduction. It was 
only with the work of Corey, Bakshi and Shibata8,9 that the mechanism of this reaction was 
clarified. It goes through the formation of a chiral oxazaborolidine by reaction of the tertiary 
amino alcohol (valinol derivative) with BH3. 
 
Scheme 3-7: Enantioselective reduction of ketone via oxazaborolidine 
 
Corey et al. found out that the Corey-Bakshi-Shibata catalyst, inspired by Itsuno’s 
oxazaborolidine, gave much better results towards the enantioselective reduction of 
ketones. (Scheme 3-8) 
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Scheme 3-8: CBS enantioselective reducing agent developed by Corey et al. 
 
To further understand the stereochemistry of the reaction, Corey et al. developed a 
mechanistic model represented in Scheme 3-9. 10 
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Scheme 3-9: Mechanistic model proposed by Corey for the enantioselective reduction of ketone by 
CBS catalyst 
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The first step of the reaction is the coordination of BH3 to the nitrogen of the 
oxazaborolidine A to form complex B. This activates BH3 as a hydride donor and activates the 
Lewis acidity of the heterocyclic boron atom. Both activated sites enhance binding to the 
ketone. To minimise steric interactions, the ketone binds complex B by the less hindered 
electron pair of the oxygen (a) in syn-configuration towards BH3 with the phenyl group being 
in pseudo equatorial position, forming a six-member ring transition state. The reduction 
occurs via hydrogen transfer, forming a chair or a boat transition state. The catalyst is then 
regenerated by cyclo-elimination.  
 
The CBS catalyst has demonstrated its efficiency through numerous applications over the 
last decades and was consequently chosen for the reduction of 1,1’-diacylferrocene 30 
following the procedure developed by Schwink and Knochel4 . The (S)-isomer of the catalyst 
was used in the presence of borane dimethylsulfide (BMS) to give the desired (R,R) 
diastereoisomer 31,  in 93% yield. (Scheme 3-10) 
 
Fe
O
O
Fe
OH
OH
(S)-CBS cat,
BH3.SMe2, THF
93%
30 31  
Scheme 3-10: Ketone reduction using (S)-CBS catalyst 
 
The 1H NMR of 31 gives a quadruplet at 4.68 ppm that integrates for 2H, corresponding to 
the two protons of the chiral carbons of 31. The singlet at 4.34 ppm also integrates for 2H 
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and corresponds to the two alcohol protons. Its 13C NMR spectrum confirmed the 
disappearance of the carbonyl peak. 
 
1.1.2 Acetylation 
Since Ugi’s work in 1970,2,11 it has become well established that the α-chiral primary alcohol 
on ferrocenes can be substituted with various nucleophiles with retention of configuration. 
Schwink and Knochel4 described interesting acetylation examples involving bis-α-chiral 
hydroxyferrocenyl systems as well as their ruthenocene analogues. Using Knochel’s 
procedure, acetic anhydride was added to a solution of 31 in DCM followed by DMAP and 
triethylamine. The acetic anhydride is activated by DMAP releasing acetic acid. Then 31 
attacks the activated carbonyl to give the protonated form of the final acetyl derivative 
(R,R)-1,1'-bis(α-acetoxyethyl)ferrocene 32. The acetic acid deprotonate it and react finally 
with Et3N to form the corresponding salt. (Scheme 3-11) 
 
Scheme 3-11: Acetylation step 
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An attempt at purification of the crude product on silica or alumina led to partial 
degradation of 32. To overcome this problem, 1% of TEA was added to the eluent to 
neutralise the silica and improve purification. The 1H NMR spectrum of 32 shows a 
characteristic singlet at 2.05 ppm integrating for 6H and corresponding to the methyl of the 
acetyl group of 32. Analysis of the proton decoupled 13C NMR spectrum shows a carbonyl 
peak at 170.44 ppm. 
 
1.1.3 Dimethylamine substitution 
The reaction involved in this step is a SN1-type substitution involving an α-ferrocenyl 
carbenium intermediate as described by Ugi9. Ferrocene can in fact stabilise a positive 
charge in the vicinal position of a side chain. This has been justified by iron participation12 or 
iron hyperconjugation13 involving an HOMO-LUMO interaction between d orbitals of the iron 
and the p orbital of the carbocation. The mechanism of the reaction is based on the 
departure of the leaving group to give the carbocation. The positive charged is then 
stabilised, possibly by electronic participation of the iron,12 as shown in Scheme 3-12. The 
nucleophilic substitution occurs with retention of configuration via attack on the carbenium 
on the exo-side. 
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Scheme 3-12: Carbenium intermediate and nucleophilic attack with retention of configuration  
 
Schwink and Knochel4 reported this reaction in methanol/water and obtained the (R,R)-1,1'-
bis(α-N,N-dimethylaminoethyl)ferrocene 33 with a yield of 91% and 98% retention of 
configuration. (Scheme 3-13) 
 
 
Scheme 3-13: Dimethylamine substitution 
 
Following the same procedure, (R,R)-33 was obtained in 76% yield. Its 1H NMR spectrum 
showed a singlet at 1.98 ppm integrating for 12H and corresponding to the four methyl 
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groups on the two amines. Analysis of the proton decoupled 13C NMR spectrum revealed the 
disappearance of the carbonyl peak. 
 
1.1.4 Directed ortho-halogenation 
The main challenge of this reaction was to attach a halogen at the right position to obtain 
the desired nucleobase linkers. One of the most efficient ways14 to prepare enantiopure 
planar chiral ferrocenes involves a directed ortho-metallation described by Ugi, as previously 
mentioned (introduction of Part 1). The ortho-halogenation involves ortho-lithiation in 
position 1 of the ferrocene using n-BuLi followed by lithium-halogen exchange that leads to 
the 1,1’-(dimethylaminoethyl)-2,2’-dihalogeno ferrocene 34. (Scheme 3-14) 
 
 
Scheme 3-14: Ortho-halogenation via lithium-halogen exchange in position 1 
 
As described in Scheme 3-15, three mechanisms have been put forward to explain the 
lithium-halogen exchange:15 a) “Four-centred transition state model”; b) radical transfer 
between lithium and halogen leading to an exchange of substituents; c) formation of an 
“ate” complex intermediate, leading to the nucleophilic substitution of the lithium by the 
halogen. 
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Scheme 3-15: Three possible lithium-halogen exchange mechanisms 
 
Kang et al.16 reported bromide substitution on a dimethylaminopropyl ferrocene with 1,2-
dibromotetrachloroethane as a halogen source. They obtained a single diastereoisomer of 
the dibromoferrocene with retention of configuration in 84% yield. Based on this procedure, 
only lithium-bromide and lithium-iodide exchange were investigated. Indeed, organic 
fluoride and organic chloride are known to not undergo metal-halogen exchange as shown 
by Gilman.17 
 
Scheme 3-16: Ortho-metallation of (R,R)-1,1’-bis-(α-dimethylaminoethyl)ferrocene. 
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Halogenation with iodine was achieved in 80% yield (34) compared to 55% with C2Br2Cl4 
(34a). As shown by Gilman18, the halide exchange rate is faster with iodide, which could 
explain the difference in yields. Iodine was therefore chosen as t he suitable halogen for 
future reactions. 1H NMR analysis revealed the ferrocene protons integrating for 6H instead 
of 8H, proving disubstitution on each Cp ring. Analysis of the proton decoupled 13C NMR 
spectrum gave a peak at 88.22 ppm corresponding to the ipso carbon bonded to bromide 
and 90.8 ppm for the ipso carbon attached to iodine, confirming halogenation in each case.  
 
Figure 3-3: Proton decoupled Pendant 13C NMR spectrum of 34 in CDCl3  
 
With the introduction of planar chirality, the configuration of compounds 34 and 34a were 
assigned (R,R,Sp,Sp) as presented in Figure 3-4. 
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Figure 3-4: Chirality determination of 34 and 34a 
 
To check the enantiopurity at this stage of the synthesis, the specific optical rotation of 34 
and its corresponding isomer was measured in DCM with a polarimeter: [α]D (c = 0.0053 
g/mL) = +178.8 and the opposite enantiomer synthesised by Dr. Nguyen, postdoc in the 
Tucker group, gave [α]D (c = 0.0054 g/mL) = -192.5. Considering the 0.5% instrumental error 
of the polarimeter on the optical rotation displayed, the two absolute values are similar, 
suggesting a good enantiomeric ratio in favour of 34. Chiral analysis using chiral high-
performance liquid chromatography (HPLC) was then performed to prove enantiopurity. It 
revealed a single peak at 4.6 min using 10% IPA in hexane as eluent mixture. Using peak 
areas for the two enantiomers, the enantiomeric excess ratio was calculated as >99.9% for 
the (R,R,Sp,Sp) enantiomer. The chiral HPLC graphs are shown in the appendix. (Figure 7-5, 7-
6 and 7-7) 
To conclude, compound 34, the precursor to linker elongation and nucleobase coupling, was 
successfully synthesised. HPLC demonstrated that 34 was synthesised in high chiral purity. 
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3.3 Part 2: Linker extension 
The second part of the synthesis was focused on the extension of the three-carbon 
“phosphodiester-linker” of the tetra-substituted ferrocenyl precursor.  A six-step route was 
investigated, going through acetylation and reduction, methoxylation, formation of an ester 
using silyl enol ether, ester reduction and finally protection of the alcohol via benzylation. A 
summary of the synthesis is shown in Scheme 3-17. 
 
Scheme 3-17: Linker extension synthesis  
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3.3.1 Acetylation and reduction 
In the context of studying the influence of a ferrocenyl diphosphine on the palladium-
catalysed asymmetric alkylation of diphenylpropenyl acetate, Kang and coworkers 19 
reported acetylation of dibromo-dimethylamine ferrocene using acid anhydride at 70˚C for 
10 h in 85% yield, followed by reduction using KOH, leading to the corresponding alcohol 
with complete retention of configuration in 99% yield. Following Kang’s procedure, the 
acetylation was performed on 34 at 50 °C for 2 h instead of 10 h at 70˚C to avoid 
degradation. The desired iodine derivative (R,R,Sp,Sp)-35 was obtained in 77% yield. Analysis 
of the proton NMR spectrum of the acetate gave a singlet at 2.04 ppm, which integrated for 
6H corresponding to the methyls groups of the acetate. However 35 was not stable, so its 
hydrolysis was done straight away after purification. The reduction was then performed in 
ethanol by heating at 85 °C for 15 min. After quenching the reaction with water and 
extraction with DCM, the crude product was checked by 1H NMR spectroscopy and the 
resulting spectrum was very clean. The crude was purified on silica gel column to eliminate 
all eventual traces of salts formed during the reaction. The methyls signal had disappeared 
and a new broad singlet at 2.5 ppm integrating for 2H was assigned to the hydroxyl protons. 
The reduction gave (R,R,Sp,Sp)-36 in 99% yield. (Scheme 3-18) 
 
 
Scheme 3-18: Acetylation and reduction from the diaminoferrocene 
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Both reactions occur via the previously described SN1-type mechanism involving the 
ferrocene carbenium intermediate stabilised by electronic interaction with the iron. Optical 
rotation was determined and gave [α]D (c = 0.0061 g/mL, DCM) = +95.0 for 36 and [α]D (c = 
0.0060/mL g, DCM)= -92.0 for the opposite enantiomer also synthesised by Dr. Nguyen. 
Chiral HPLC was performed on the acetate 35 and the alcohol 36 to confirm the 
enantiopurity over these two steps. Both compounds were eluted with 10% IPA in hexane. 
35 gave a peak at 18.4 min, giving an enantiomeric excess ratio of 99% and 36 at 28.8 min, 
giving an enantiomeric excess ratio of >99.9%. The chiral HPLC graphs are shown in the 
appendix. (Figure 7-8, 7-9 and 7-10) 
 
3.3.2 Methanolysis and esterification 
Locke et al.20 synthesised a C2 symmetric ferrocenophane via Friedel-Crafts cyclisation 
(Figure 3-9) via methoxylation and esterification of a bis-benzyloxy ferrocene. 
 
Figure 3-5: Ferrocenophane 
Methoxylation gave a relatively low yield of 42% in the presence of a 9:1 methanol/acetic 
acid mixture stirred overnight. The following esterification was performed using a silyl enol 
ether and BF3.OEt2 and gave a 98% yield with 92% ee for the diester. (Scheme 3-19) 
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Scheme 3-19: Methoxylation and esterification by Lock, Richards and coworkers20 
 
The same synthesis scheme was therefore followed for the synthesis of 39. Methoxylation of 
(R,R,Sp,Sp)-36 was performed keeping the 9:1 methanol/acetic acid conditions but running 
the reaction for three days, leading to a two-fold improvement in the yield of product 
(R,R,Sp,Sp)-37 (81%). The optical rotation of the compound was measured, giving [α]D (c = 
0.0054 g/mL, DCM) = +149.6 for 37 and [α]D (c = 0.0054 g/mL, DCM) = -155.6 for the  
corresponding enantiomer synthesised by Dr. Nguyen. For the esterification of 37, it was 
necessary to synthesize one essential reagent: silyl enol ether 38. Silyl enol ether is usually 
prepared from ketones using a strong base and trimethylsilyl chloride (TMSCl). Fukuzumi and 
co-workers21 described its synthesis from ethyl acetate using diisopropylamine, n-BuLi and 
trimethylsilyl chloride for the enolate protection, as shown in Scheme 3-20. 
 
 
Scheme 3-20: Silyl enol ether synthesis 
 
The same procedure was followed and the crude was purified on a Kugelrohr at 50 °C under 
vacuum. Analysis of the 1H NMR spectrum revealed the presence of ethyl acetate and 
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hexane. The boiling points of the silyl enol ether and these solvents are quite close, making 
the distillation step difficult. 
 
The formation of the ester was attempted anyway following the method used by Richards 
and coworkers in 1994.22 Richards et al. investigated the reaction with different types of silyl 
enol ethers and stabilised or unstabilised α-carbenium ferrocenes. They prepared carbenium 
ions via addition of HBF4 on a mono (α-hydroxyethyl)-ferrocene that they reacted with a 
series of silyl enol ethers in the presence of BF3.OEt2, leading to the corresponding esters 
(Scheme 3-21). They showed that the success of the reaction did not depend on the relative 
stability of the carbenium and proceeded with retention of configuration. 
 
 
Scheme 3-21: Extension of a three carbons chain by esterification 
 
Esterification of 37 adds two more carbons to the linker chain via nucleophilic attack of the 
enol ether on the ferrocenyl carbenium. It is worth pointing out that the absolute 
configuration of the two centrally chiral carbons during this step as shown in Figure 3-6. 
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Figure 3-6: Chirality assignment of 37 and 39 
 
The reaction was done with a considerable excess of silyl enol ether (> 4 fold) to take into 
account the ethyl acetate impurity. However, the product (S,S,Sp,Sp)-39 was obtained in the 
high yield of 92%. The optical rotation of the compound was measured giving [α]D (c = 
0.0066 g/mL, DCM) = +123.0 and [α]D (c = 0.006 g/mL, DCM) = -112.6 for the opposite 
enantiomer. The absolute optical values of the two enantiomers are slightly different but 
chiral HPLC clearly showed an enantiomeric excess >99.9%, with one single peak obtained at 
22.7 min with 5% IPA in hexane (Figure 7-11, 7-12 and 7-13). A lower percentage of IPA was 
used compared to previous compounds due to the higher hydrophilicity brought by the ester 
groups and the use of an OD column instead of an AD column. The chiral HPLC graphs are 
shown in the appendix. (Figure 7-11, 7-12 and 7-13) 
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The (S,S,Sp,Sp) configuration of the chiral centre of 39 was proven by X-ray analysis of crystals 
grown from the slow evaporation of DCM. (Figure 3-7) 
 
Figure 3-7: Crystal structure of 39 with ellipsoids drawn at the 50% probability level. 
 
The structure gave two crystallographically independent molecules but only one is shown for 
clarity. Furthermore the methyl group C(16) (73%) /C(16’) (27%) of the ester group of the 
second molecule is disordered over two positions and the minor positions have been 
omitted, again for clarity (Figure 6-2). Of interest is the presence of two intramolecular and 
one intermolecular halogen bonds shown in table 3-1. 
 
Table 3-1: Halogen bonds for 39 in (Å) 
Donnor…Acceptor d(D...A) 
I(101)…O(101) 3.08 ± 0.01 
I(101)…O(01’) 3.04 ± 0.02 
I(102)…O(1) 3.263 ± 0.06 
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3.3.3 Ester reduction 
Among many other examples of ester reduction, Brisset65 used LiAlH4 to reduce 1,1’-bis-[(2-
ethyloxycarbonyl)ethyl]-ferrocene in diethyl ether under reflux for 1 h. The corresponding 
alcohol was obtained in 75% yield. (Scheme 3-22) 
 
Scheme 3-22: Brisset’s ester reduction 
 
Under similar reaction conditions, reduction of 39 gave 40 in 70% yield after an overnight 
reaction, followed by a laborious Fieser work-up for larger scales. Fieser work-up consists in 
adding successively n mL of water, n mL of NaOH (15%) and 3n mL of water for every n g of 
LiAlH4 used. Although the reaction was successful and gave a decent yield, 39 was also 
treated with DIBAL-H as a trial. (Scheme 3-23) 
 
Scheme 3-23: Ester reduction using DIBAL-H 
 
DIBAL-H is a weak reducing agent and is usually known to reduce esters to the 
corresponding aldehydes at low temperature with 1 equivalent of DIBAL per ester. It was 
decided to perform the reaction in diethyl ether for 1 h at room temperature using an excess 
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of DIBAL-H (3 equivalent per ester groups). The reaction was quenched with ethyl acetate 
and sodium potassium tartrate (Rochelle’s salt), extracted with diethyl ether and washed 
with brine. Rochelle’s salt is an excellent the aluminium ligand that breaks up the aluminium 
emulsion after quenching. The final compound (S,S,Sp,Sp)-40 was obtained in 89% yield after 
purification. Chiral HPLC was conducted and as shown in Figure 3-14, 40 showed a single 
peak at 48.9 min in a 10% IPA in hexane eluent mixture. Indicating the formation of the pure 
enantiomer (S,S,Sp,Sp) (ca. 99.9% ee) and full retention of configuration for this step. The 
chiral HPLC graphs are shown in the appendix. (Figure 7-14, 7-15 and 7-16) 
 
3.3.4 Benzylation 
To avoid side-reactions during the nucleobase coupling reaction, the hydroxyl groups of the 
phosphodiester linkers had to be protected. The Horner-Wittig coupling reaction leads to 
the formation of a double bond that can be reduced via hydrogenation on Pd(OH)2/C. 
Interestingly, benzyl groups are sensitive to hydrogenation. Therefore, using benzyl as a 
protecting group gave an opportunity to reduce the unsaturated bond and deprotect the 
alcohol moiety at the same time in the last step of the synthesis. 
 
NaH was used to deprotonate 40 in DMF and benzyl chloride was added to enable 
nucleophilic substitution by the alkoxide. The bis-protected alcohol (S,S,Sp,Sp)-41 was 
obtained in 80% yield. However, even after an overnight reflux, the reaction was not 
complete and some starting material and mono-substituted alcohol remained. 
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Scheme 3-24: Benzylation 
 
To conclude this part of the synthesis, the extension of the phosphodiester-linkers was 
successfully achieved in six steps showing relatively good yields in a stereospecific manner as 
demonstrated by HPLC. The next part presents the different coupling methods used to 
attach adenine and uracil to the tetra-substituted ferrocene. 
 
3.4 Part 3: Nucleobase coupling 
3.4.1 Horner-Wittig approach 
3.4.1.1 Formylation 
Based on previous studies carried out on mono and bis-substituted ferrocenes, the Horner-
Wittig coupling of tetra-substituted ferrocenes with adenine was investigated. To be able to 
perform the coupling, first formylation of the tetra-substituted diiodo ferrocene 41 had to 
be achieved. The formylation of ferrocene is a two-step reaction. The first step is a halogen-
lithium exchange, as described earlier in the directed ortho-metallation step. The second 
part of the reaction is a lithium-formaldehyde exchange leading to the formation of the 
aldehyde.  
Chapter 3: Tetra-substituted ferrocene monomers 
 
115
Fe
I
I
O
41 42
1) n-BuLi, Ether,
2) DMF
90%
O
Fe
CHO
CHO
O
O
 
Scheme 3-25: Formylation of 41 to give aldehyde 42 
 
The lithium-iodide exchange was performed in diethyl ether in presence of n-BuLi at -78˚C 
(Scheme 3-25). When the dilithio-ferrocene was formed, DMF was added to form a dark-red 
solution of the corresponding aldehyde. After purification to remove a small amount of 
mono-aldehyde, (S,S,Sp,Sp)-42 was obtained in 90% yield. The aldehyde protons appeared on 
the 1H NMR spectrum as a singlet at 10.04 ppm, integrating for 2H. Analysis of the proton 
decoupled 13C NMR spectrum confirmed the success of the reaction, with a characteristic 
peak for the carbon of the aldehyde at 193.1 ppm and a shift downfield of the ipso carbon 
linked to the aldehyde from 46.7 (C-I) to 77.7 ppm (C-CHO). 
 
3.4.1.2 Horner-Wittig coupling with adenine 
Horner-Wittig coupling was performed following the procedure previously described 
(Chapter 2). The diphenylphosphine oxide of dibenzoylated adenine 6 was reacted with NaH 
to form the ylid to attack the bis-aldehyde ferrocene 42. (Scheme 3-26) 
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Scheme 3-26: Horner-Wittig coupling of tetra-substituted ferrocene aldehyde 42 with adenine 6 
 
After purification, three fractions were collected. The first and major fraction corresponded 
to the Z isomer of (S,S,Rp,Rp)-43 and was obtained in 43% yield. Analysis of the 
1H NMR 
spectrum gave the vicinal CH=CH coupling constant value JHH = 8.8 Hz, which corresponds to 
cis-isomer of the alkene (Figure 3-8). The second fraction yielded the mono-substituted gave 
a singlet at ca 9 ppm integrating for 1H corresponding to an aldehyde proton and two other 
singlets at ca 8.6 ppm and 8.7 ppm. Each of these integrated for 1H and corresponded to the 
vicinal protons of the solitary adenine attached to the ferrocene. The last fraction 
corresponded to the starting material. 
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Figure 3-8: 
1H NMR spectrum of 43 in CDCl3 
 
3.4.1.3 Hydrogenation  
Hydrogenation consists of the addition of H2 to a compound containing a multiple bond in 
presence of a catalyst. The catalysts used can be divided in two classes: heterogeneous and 
homogeneous. Heterogeneous catalysts such as palladium on charcoal (Pd/C) or Raney 
Nickel are insoluble in the reaction solvent. Homogenous catalysts are soluble in the reaction 
medium. In this step, only heterogeneous catalysts were used since they are easily separable 
from reaction mixtures.  
 
Most catalytic reductions of unsaturated bonds involve a syn addition of hydrogen to the 
less-hindered face of the bond. The mechanism is not completely understood but the 
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generally accepted mechanism is a two-step process (Scheme 3-27). Firstly, the compound is 
adsorbed on the surface of the catalyst on the less-hindered face of the bond. Hydrogen 
atoms are then successively transferred to the compound to give the final reduced 
compound. In the specific case of hydrogenolysis of O-benzyls, which corresponds to the 
hydrogenation of a C-O bond, affinity of oxygen for the metal promotes the rupture of the 
bond. Numerous methods of hydrogenolysis have been reported affording debenzylation23 
in very good yields.  
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Scheme 3-27: Hydrogenation via Heterogeneous catalysis 
 
In the case of the tetra-substituted ferrocene 43, hydrogenation was meant to reduce the 
double bond formed after Horner-Wittig coupling and to deprotect benzyl groups at the 
same time. Based on Brisset’s procedure64 described in chapter 1, the reaction was set up in 
ethyl acetate, in presence of Pearlman’s catalyst and a balloon of hydrogen. Unfortunately 
the reaction did not proceed well in either the reduction of the double bond or the full 
deprotection of the alcohol groups. The hydrogen source, pressure of hydrogen gas, solvent, 
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temperature and reaction time were all then varied in an attempt to obtain the desired 
compound as shown in Table 3-2, however none were successful.  
 
Table 3-2: Different hydrogenation conditions towards reduction and deprotection of 43 
 
Catalyst (2eq) H2 source 
Pressure (1 atm 
unless specified) 
Solvent T (°C) t (days) Results 
Pd(OH)2/C H2 gas Balloon EtOAc RT 2 
Mono deprotection 
Partial deprotection of Bz 
Pd(OH)2/C H2 gas Balloon 
EtOH 
MeOH 
35 2 
Mono deprotection 
Partial deprotection of Bz 
Pd(OH)2/C H2 gas Balloon MeOH 
35 
50 
3 
Mono deprotection 
Partial deprotection of Bz 
Pd(OH)2/C H2 gas Balloon EtOH 75 3 Degradation 
Pd(OH)2/C Cyclohexene Balloon EtOAc RT 3 
Mono deprotection 
Partial deprotection of Bz 
Pd(OH)2/C H2 gas 
Pressure Reactor 
(1 to 4 atm) 
EtOH 
EtOAc 
RT 
37 
70 
3 
Mono deprotection 
Deprotection of Bz 
 
The double bond environment is quite bulky and it is known that hydrogenation is sensitive 
to steric hindrance. This could explain why the reduction of the double bond did not occur. 
However, this assumption cannot readily explain why hydrogenolysis of benzyls also did not 
occur. It is possible that this was caused by an interaction between the catalyst and the first 
deprotected alcohol. To get a better understanding and to improve the reaction, stepwise 
reduction and deprotection was investigated independently, first on the double bond alone 
and then on the benzyl using the dibenzyl-diiodo-ferrocene 41. To selectively reduce the 
double bond without removing the benzyl groups, sodium borohydride in the presence of 
acid acetic and Pd catalyst were used in isopropanol, according to Tran’s procedure.24 
Several other solvents such as THF and acetonitrile were also tried in order to improve the 
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solubility of 43. However in all cases, only a partial deprotection of the alcohol was observed 
instead of the double bond reduction. To investigate hydrogenolysis the benzyl groups in 
compound 41, three methods were tried as presented in Table 3-3. Once again the results 
were not satisfactory with no or low yields of the desired product. Interestingly the 
analogous reaction with the less hindered thymine substituent was found to proceed 
cleanly.25  
Table 3-3: Deprotection conditions via hydrogenation of 41 
Catalyst 
(2eq) 
H2 source Solvent T (°C) t (days) Results 
Pd(OH)2/C H2 
EtOAc 
(+ Acetic acid)26 
RT O/N No deprotection 
Pd(OH)2/C Cyclohexene Ethanol 75 O/N No deprotection 
Ni Raney
27
 H2 Ethanol RT 2 days 
Fully debenzylation (minor fraction) 15% 
Partial deprotection (minor fraction) 28% 
No deprotection (major fraction) 57% 
 
These investigations of hydrogenation and hydrogenolysis are not comprehensive enough to 
give a clear explanation as to why both reactions did not work. However, it is possible that 
steric hindrance was a likely cause of the failure of hydrogenation of the double bond. 
Therefore, another synthetic route was investigated to avoid formation of a double bond. 
The new route involved a change of protecting group, with Mitsunobu coupling leading 
directly to the formation of a saturated bond, as described below.  
3.4.2 Mitsunobu approach 
The first part of the new synthetic route consisted of developing a suitable tetra-substituted 
ferrocene precursor for the Mitsunobu coupling, which was previously investigated on bis-
substituted systems, as described in Chapter 2. This precursor had to contain two protected 
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alcohols that would go on to provide the phosphodiester linkers and two hydroxyethyl 
linkers that would react with the nucleobases during the coupling. 
 
3.4.2.1 Protection of alcohols 
As previously described, benzyls were difficult to cleave on hindered ferrocenes via 
hydrogenation. Consequently, an investigation of alternative protecting groups was carried 
out. Silyl ethers are frequently used as protecting groups for alcohols. Indeed, their reactivity 
can be adjusted by modifying the substituents linked to the silicon atom. Among the 
numerous different silyl groups, reactivity towards acid treatment increases with 
substitution as follows: TMS (1) < TES (64) < TBDMS (20,000) < TIPS (700,000) < TBDPS 
(5,000,000), as it does with basic treatment as follows: TMS (1) < TES (10-100) < TBDMS - 
TBDPS (20,000) < TIPS (100,000). TMS is too sensitive to acidic and basic conditions and 
would be susceptible to cleavage during Mitsunobu coupling. It is likely that TBDMS would 
be cleaved in the presence of lithium during the formylation reaction or even later during 
the borohydration-oxidation. TBDPS is a very stable group under acidic and basic conditions 
and can be readily removed with TBAF.28 For these reasons, the TBDPS protecting group 
seemed to be the most promising and was consequently chosen for the protection. 
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Scheme 3-28: Hydroxyl protection with TBDPS 
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Following the procedure reported by Hanessian and Lavalee28 in 1975, diol 40 was treated 
with TEA, TBDPSCl and DMAP in DCM overnight to give (S,S,Sp,Sp)-44 in 95% yield (Scheme 3-
28). The presence of silyl groups was highlighted by 1H NMR analysis, showing three 
characteristic peaks. Two multiplets at 7.67 and 7.4 ppm, integrating respectively for 8H and 
12H, corresponded to the phenyl substituents and the tert-butyl substituent was 
characterised by a singlet at 1.05 ppm, integrating for 18H (Figure 3-9). Analysis of the 
proton decoupled 13C NMR spectrum and high-resolution mass spectrometry confirmed that 
the protection had been successful. 
 
 
Figure 3-9: 
1H NMR spectrum of 44 in CDCl3 
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3.4.2.2 Synthesis of hydroxyethyl linkers 
The synthesis of suitable linkers for the coupling reaction with adenine and uracil followed 
the same route as that described for the bis-susbtituted systems (Chapter 2). To begin with, 
formylation of 44 was performed using the same conditions previously developed for the 
dibenzyl diiodo ferrocene 41. The dialdehyde (S,S,Sp,Sp)-45 was obtained in 78% yield and 
was then subjected to a Wittig reaction in presence of triphenylmethyl phosphonium 
bromide and tert-butoxide in THF to give (S,S,Rp,Rp)-46 in 98% yield. During this step, the 
planar configuration changed due to the lower priority order of the vinyl chain compared to 
the phosphodiester-linker chain as shown in Figure 3-10. The configuration is now (S,S,Rp,Rp).  
 
 
Figure 3-10: Stereochemistry of 45, 46 and 47 
 
Hydroboration of the bis-divinyl ferrocene in presence of a borane tetrahydrofurane solution 
and hydrogen peroxide led to the synthesis of the bis-dihydroxyethyl ferrocene 47 in 78% 
yield as shown in Scheme 3-29.  
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Scheme 3-29: New route synthesis to Mitsunobu coupling 
 
 
Each compound was characterised by 1H NMR, 13C NMR, mass spectrometry, IR and melting 
point. To check for retention of configuration over these three steps, chiral HPLC was 
conducted on compound 47. As shown in the figure below, 47 gave only one single peak at 
53.1 min corresponding to the single enantiomer (S,S,Rp,Rp). A less polar eluent mixture 
(2.5% IPA in hexane) was used to obtain a good separation peak although the resolution of 
the peak was not optimal. Increasing the elution rate improved the resolution but reduced 
the separation between the peaks. Changing the column from AD to OD did not bring any 
improvements. The chiral HPLC graphs are shown in the appendix. (Figure 7-17, 7-18 and 7-
19) 
 
Crystals of 47 grown from the slow evaporation of an EtOAc/Hexane mixture were subjected 
to X-ray analysis. (Figure 3-11) 
Chapter 3: Tetra-substituted ferrocene monomers 
 
125
 
Figure 3-11: Crystalline structure of one of the two crystallographically independent molecules of 47 
with absolute stereochemistry (S,S,pR,pR) and with ellipsoids drawn at the 50 % probability level. 
 
 
The structure contains two crystallographically independent molecules, with matching 
stereochemistry and molecular geometry being the same within experimental error. Only 
one is shown for clarity. The structure confirmed the expected stereochemistry of the four 
stereogenic centres (S,S,Rp,Rp) and also revealed the presence of four hydrogen bonds 
between the two molecules as shown in Table 3-4. 
 
Table 3-4: Hydrogen bonds for 47 (Å and °) 
Donnor-H...Acceptor d(D-H) d(H...A) d(D...A) <(DHA) 
O(2)-H(2A)...O(102) 0.84 1.95 2.774 ± 0.004 168.1 
O(4)-H(4A)...O(2) 0.84 1.98 2.821 ± 0.004 177.8 
O(102)-H(12G)...O(104) 0.84 1.96 2.786 ± 0.004 166.0 
O(104)-H(14E)...O(4) 0.84 1.90 2.728 ± 0.004 170.0 
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3.4.2.3 Mitsunobu coupling with adenine and uracil 
The Mitsunobu reaction was used to couple adenine 19 and uracil 20 to the tetra-
substituted bis-dihydroxyethyl ferrocene 47. The conditions developed for the bis-
disubstituted ferrocene were followed for both couplings. The targets (S,S,Rp,Rp)-48 and 
(S,S,Rp,Rp)-49 were obtained in 52% and 75% yield respectively. However, instead of the 
expected dibenzoylated adenine compound, 1H NMR of 48 revealed a mono deprotection of 
adenine, which partially explained the lower yield for this compound. Furthermore, the 
reaction did not go to completion and some starting material remained. Longer reaction 
times gave full debenzoylation of adenine that could cause side-reactions during the 
coupling steps in the automated oligomer synthesis; this is why the reaction was stirred for 
only two hours. 
 
Notwithstanding the issues discussed above, uracil coupling is still more efficient than 
adenine coupling. As a purine, adenine is bigger than uracil and contains two benzoyl 
protecting groups as opposed to one for uracil. Consequently, adenine could have more 
difficulty accessing the ferrocene, causing a further drop in yield. (Scheme 3-30) 
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Scheme 3-30: Synthesis of 48 and 49 via a Mitsunobu coupling with adenine and uracil 
 
Chiral HPLC on the ferrocene nucleobases 48 and 49 was tried using both AD and OD 
columns and each column was used with different eluent mixtures but no resolved peaks 
were ever observed, although the other enantiomer has not been synthesised yet. The 
optical rotation of the two compounds were measured [α]D (c = 0.0066 g/mL, DCM) = -25.1 
for 48 and [α]D (c = 0.0066 g/mL, DCM) = +9.5 for 49. Although the stereoselectivity should 
not be affected by this step, further investigations on determination of enantiopurity should 
be conducted in the future. 
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3.4.2.4 Silyl deprotection 
The last step of the synthesis consisted of the deprotection of the TBDPS groups. Fluorides 
are normally used to achieve the deprotection since the Si-F bond is much stronger than Si-O 
bond. Following the procedure described by Hanessian and Lavallee28, a solution of TBAF in 
THF was used to deprotect 49 to give (S,S,Rp,Rp)-51 in quite a low yield of 34%. The poor 
yield of the reaction was mainly due to purification difficulties encountered. Indeed, TBAF 
impurities remained even after water work-up and column. The long butyl chains help to 
solubilise the salt in organic solvents such as DCM and MeOH that were used as purification 
eluents. TBAF impurities were finally removed via many NH4Cl washes followed by 
extractions with ethyl acetate. 48 was deprotected using a crystalline form of TBAF instead 
of a solution of TBAF leading to (S,S,Rp,Rp)-50 in 92% yield. (Scheme 3-31) 
 
 
Scheme 3-31: TBAF deprotection of tetra-substituted ferrocene adenine and uracil 48 and 49 
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Crystals structure of (S,S,Rp,Rp)-51 grown by the slow evaporation of a DCM solution were 
found to be suitable for X-ray analysis. (Figure 3-22) 
 
Figure 3-12: Crystalline structure of 51 with ellipsoids drawn at the 50 % probability level. A 
molecule of deuterated chloroform has been omitted for clarity. 
 
The structure confirms the configuration of the compound with the expected absolute 
stereochemistry of the four stereogenic centres (S,S,Rp,Rp) observed. In addition and reveal 
the presence of two intermolecular and intramolecular hydrogen bonds were observed, as 
reported Table 3-5. 
Table 3-5: Hydrogen bonds for 51 (Å and °) 
Donnor-H...Acceptor d(D-H) d(H...A) d(D...A) <(DHA) 
O(4)-H(4)...O(11) 0.84 2.03 2.848 ± 0.003 164.8 
O(3)-H(3A)...O(4) 0.84 1.98 2.814 ± 0.003 169.3 
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A comparison of the geometry of compounds 47 and 51 in the region of the added uracil is 
given in Table 3-6. 
Table 3-6: A comparison of bond lengths (Å), bond angles (°) and torsion angles (°) in compounds 47 
and 51. Ct(1)/Ct(101) is the centroid of the cyclopentadienyl ring C(1)-C(5)/C(101)-C(105) while 
Ct(2)/Ct(102) is the centroid of C(6)-C(10)/C(106)-C(110). 
 
 
47 
(Molecule 1 / Molecule 2) 
51 
C(1)-C(11) / C(101)-C(111) 1.505 ± 0.005 / 1.501 ± 0.004 1.504 ± 0.003 
C(11)-C(12) / C(111)-C(112) 1.512 ± 0.004 / 1.522 ± 0.004 1.519 ± 0.003 
C(12)-[O(1)/N(1)] / C(112)-O(101) 1.439 ± 0.004 / 1.432 ± 0.004 1.475 ± 0.003 
C(1)-C(11)-C(12) / C(101)-C(111)-C(112) 114.9 ± 0.003 / 109.2 ± 0.003 114.2 ± 0.002 
C(11)-C(12)-[O(1)/N(1)] / C(111)-C(112)-O(101) 110.6 ± 0.003 / 109.7 ± 0.003 109.5 ± 0.002 
C(1)-Ct(1)-Ct(2)-C(9) / C(101)-Ct(101)-Ct(102)-C(109) -64 / -64 -41 
C(1)-Ct(1)-Ct(2)-C(10) / C(101)-Ct(101)-Ct(102)-C(110) 8 / 8 31 
 
While the bond lengths and angles show no unexpected differences between the structures, 
it can be seen that the cyclopentadienyl rings of the ferrocene units are in an almost fully 
eclipsed confirmation in 47 (for eclipsed confirmation expected C(1)-Ct(1)-Ct(2)-C(9)/C(101)-
Ct(101)-Ct(102)-C(109) torsion is -72° and expected C(1)-Ct(1)-Ct(2)-C(10)/C(101)-Ct(101)-
Ct(102)-C(110) torsion is 0°) while in 51  the rings are in an almost fully staggered 
confirmation (for a staggered confirmation the expected C(1)-Ct(1)-Ct(2)-[C(9)/C(10)]/ 
C(101)-Ct(101)-Ct(102)-[C(109)/C(110] torsion is 36°). 
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3.4.2.5 Bromine substitution with Cytosine  
Preliminary work was carried on the coupling of cytosine with a tetra-substituted ferrocenyl 
bromide using the same method investigated in Chapter 2 with bis-substituted ferrocenyl 
derivatives. First, bromination of diol 47 was investigated. Compound 52 was obtained in 
97% yield in presence of 5.6 eq of triphenylphosphine, 6 equivalents of NBS and 2.4 eq of 
pyridine in DCM. (Scheme 3-32) 
 
Scheme 3-32: Bromination of tetra-substituted ferrocene 
 
Following the successful synthesis of 52, its coupling with N-6-benzoyl cytosine was then 
investigated following the procedure developed earlier in Chapter 2. Using three equivalents 
of cytosine and NaH, N-6-benzoyl cytosine was then successfully coupled to tetra-
substituted ferrocene 47 to give 53 as confirmed by 1H, 13C NMR and  high resolution mass 
spectrometry. As already mentioned in the case of the bis-(bromoethyl) ferrocene, the 
reaction was not complete. The reaction gave 53 in a low yield of 16%. The reaction should 
be reinvestigated to improve this yield, which could be a starting point for future work. 
(Scheme 3-33) 
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Scheme 3-33: Cytosine coupling via Bromide substitution 
 
3.5 Conclusion 
In this chapter, the synthesis of two tetra-substituted bis adenine/uracil/cytosine ferrocene 
derivatives have been investigated. To start with, the 1,1’-(α-dimethylaminoethyl)-2,2’-
diiodo ferrocene as common precursor of both monomers was synthesised via introduction 
of central chirality followed by planar chirality. The results confirmed that the chiral centre α 
to the ferrocene induced diastereoselectivity in the ortho-halogenation as described by Ugi. 
Then a series of nucleophilic substitutions have been carried out to achieve the synthesis of 
a three-carbon phosphodiester-linker chain. All these reactions were accomplished with 
configuration retention via formation of an iron-stabilised carbenium ferrocene 
intermediate. After a formylation, the tetra-substituted ferrocene was attached to adenine 
via Horner-Wittig coupling. Unfortunately, the later reduction/deprotection of the 
unsaturated benzoylated monomer could not be achieved for steric reasons.  
 
A new route was then investigated involving a new protecting group and a new coupling 
method. TBDPS was chosen as suitable protecting group before developing hydroxyl alkyl 
chains from iodine that were coupled to adenine and uracil via the Mitsunobu reaction. Both 
Chapter 3: Tetra-substituted ferrocene monomers 
 
133
compounds were deprotected via fluoride treatment leading to the synthesis of the two 
targeted adenine and uracil FcNA monomers. The tetra-substituted ferrocenyl monomer was 
also coupled to cytosine via a bromide substitution but in poor yields. Future work would 
consist of a reinvestigation of this coupling reaction to improve the efficiency of the 
reaction. An interesting alternative would be to attempt full protection of the exo-amine of 
cytosine leading to an improvement of its solubility in THF and then the coupling under 
Mitsunobu conditions. Further investigations on the preparation of the monomers for the 
automated oligonucleotide synthesis should also be conducted. The preparation of the 
monomers would consist of the tritylation and the phosphitylation of the two primary 
alcohols of the monomers as described in Scheme 3-34.  
 
 
Scheme 3-34: Tritylation and phosphitylation of the ferrocenyl monomers for their oligomerisation 
 
 
As previously described by Brisset64 and Ihara65 in chapter 1, DMTrCl was successfully used in 
presence of DMAP for the tritylation of one of the alcohol of a bis-hydroxyl-ferrocene. They 
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also reported the use of a chloro(diisopropylamine)(b-cyanoethoxy)phosphine in presence of 
DIPEA for the phosphitylation of the second hydroxyl.  
 
 
Scheme 3-35: Tritylation and phosphitylation of bis-hydroxy-ferrocene 
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4 CHAPTER 4: FERRONUCLEOBASES AS POTENTIAL DRUGS 
 
4.1 Introduction 
4.1.1  Drug discovery 
Medicinal chemistry has been practised for several thousand years. Mankind has always 
tried to treat and cure the diseases it has been affected by as a part of its survival.1 The 
beginning of drug discovery used to be based on plants and used to be empirical, which 
meant that people knew the beneficial or toxic effect of a substance without understanding 
the scientific reasons behind it. With the development of scientific and technological 
progress, scientists have been able to synthesise substances with predictable and 
controllable effects. Nowadays, drug discovery is the one of the most commun process by 
which a new drug is put on the market.  
 
The development of a drug goes through four major steps of research to finally end with the 
commercialisation of the drug.2  The first step corresponds to the synthesis of the drug 
candidate usually initiated by academic research, which is then tested in vitro via a sequence 
of defined experiments called drug screening. Following the evaluation of the drug activity 
on cells, the drug is tested on animal models and submitted to three phases of the clinical 
testing, which consist of evaluating the efficiency and the toxicity of the drug on humans. 
The last phase of the development is the commercialisation of the drug on the market and 
the monitoring of its side effects on the global population. (Figure 4-1) 
 
Chapter 4: Ferronucleobases as potential drugs 
 
137
 
Figure 4-1: The different stage of drug development 
 
In the first stages of drug discovery, the candidate is subjected to pharmacological tests to 
model the influence of the drug on the organism. Pharmacological studies consist of 
studying the substances interactions with living organisms through chemical processes by 
interaction with regulatory molecules (Proteins, DNA). The studies are based on 
pharmacokinetics and pharmacodynamics. As described by Benet3 “Pharmacokinetics may 
be simply defined as what the body does to the drug, as opposed to pharmacodynamics 
which may be defined as what the drug does to the body.” To model and simplify the many 
different processes happening between an organism and a drug, the ADME model4 is known 
to give a good approximation to these processes. ADME stands for absorption, distribution, 
metabolism and excretion. The absorption stage takes in account the different processes 
responsible for the penetration of the substance into blood circulation. The second stage 
corresponds to the distribution of the substance through the body, followed by the 
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metabolism stage corresponding to the bio-transformation of the substance in the body. The 
later process activates or inactivates the substance, which provokes biological effects and 
responses from the organism, both described by pharmacodynamics. The excretion stage 
consists of the elimination of the substance by the body. (Figure 4-2) 
 
 
Figure 4-2: The different stages of pharmacokinetics and pharmacodynamics. 
 
Prior to these pharmacological studies, the drug candidate is submitted to studies based on 
cell-based assays in order to evaluate its potency, which means the amount of compound 
needed to produce an effect with a defined intensity. A highly potent drug induces an 
intense response at low concentrations, whereas a drug with low potency produces a small 
response at high concentrations. The potency is usually expressed by the EC50 value. EC50 is 
the half maximal effective concentration and corresponds to the concentration at which the 
drug produces 50% of its maximal possible effect on a target or a biological process. The 
lower the EC50 is, the less the amount of the drug is needed to produce 50% effect on the 
target and higher is the potency. EC50 is obtained from a dose-response curve, which 
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represents the concentration of a drug as a function of the response of an organism (Cell). 
(Figure 4-3)  
 
Figure 4-3: Dose-response curve with EC50 and IC50 as the concentration of a drug that produces 
respectively 50% of activation and inhibition on biological response 
 
The dose-response relationship also gives the half maximal inhibitory concentration (IC50), 
which is comparable to EC50, in that it corresponds to the concentration of the drug required 
for 50% inhibition of a biological process in vitro. The two values allow an understanding of 
the activity and the efficiency of a drug on a target. Another important way to screen the 
activity of a substance is to study its cytotoxicity, which is by definition the ability of this 
compound to induce cell death. Cytotoxicity tests usually measure cell apoptosis and cell 
necrosis as a consequence of the activity of the substance and therefore give an idea of how 
efficient a drug is. The cytotoxicity is evaluated via the determination of CC50 and MCC, 
which are both related to IC50 but are more specific parameters. CC50 corresponds to the 
cytotoxic concentration required to reduce cell growth by 50%, which means that the 
number of cells is reduced by 50% compared to the control cells and the MCC corresponds 
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to the minimum cytotoxic concentration that causes a microscopically detectable alteration 
of cell morphology leading to a detachment of the cells from the support.  
 
Different assays have been developed, which are of importance for the determination of 
these indicators of the product biological activity. Some of them are presented in the 
following section. 
 
4.1.1.1 Assays 
The evaluation of drug activity is usually obtained via cell-based assays that probe 
mitochondrial function (MTT, MTS), the uptake of a dye by dead cells after failure of a cell 
permeability barrier (Trypan blue) and other parameters such as morphological 
modifications (CPE assay) or cell replication (BrdU assay). A brief description of these 
different assays is developed in the following.  
 
One of the most common assays to test cytotoxicity is the MTT assay,5,6 which is a 
colorimetric assay that measures the ability of the cell to survive, grow and multiply. Only in 
living cells, MTT is reduced by mitochondrial dehydrogenase into an insoluble dark purple 
product called MTT-formazan (Scheme 4-1). MTT-formazan is then solubilised with an 
organic solvent and measured via spectrophotometry. The amount of MTT-formazan dye is 
directly proportional to the number of living cells, and therefore the assay enables a direct 
measure of the viability of the cells after treatment with the drug. 
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Scheme 4-1: MTT reduction to formazan 
 
However, the assay has its limitations. For example, Johno et al.7 showed that pH could 
affect the outcome of the assay and the absorbance of the MTT-formazan decreases in a pH-
dependent manner but without affecting the cell viability.  
 
Other assays using an identical process of assessment of living cells have been developed, 
that use MMT derivatives such as XTT8 or MTS.9 These derivatives have reduced forms that 
are soluble in the culture media and are not toxic, so it is possible to reuse the cells for 
further investigations. The MTS assay also involves an electron-coupling reagent called 
phenazine methosulfate (PMS) (Scheme 4-2). After the protonation of PNS, it reduces MTS 
to MTS-formazan, which is directly detectable in the buffer, avoiding the intermittent step of 
solubilisation required in the MTT assay.  
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Scheme 4-2: Dehydrogenase reduction of MTS to MTSH (formazan) via PMS 
 
This assay allows a quantitative evaluation of the cytotoxicity of the compound and is usually 
combined with a cell morphology assay giving a more qualitative evaluation of the 
cytotoxicity. A common morphological assay is the cytopathic effect assay (CPE),10 which 
consists of evaluating the ability of the drug to prevent a virus from causing viral cytopathic 
effects in cells. Cytopathic effects, detected using inverted light microscopy, are 
morphological modifications of the cells caused by a viral infection. The antiviral activity of 
the drug consequently measures via the inhibitory concentration (IC50) that reduces the 
cytopathic effects caused by the virus by 50%.  
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Another colorimetric assay designed to measure cell viability is the Trypan blue exclusion 
assay11, which colours dead cells blue. Therefore, this assay also allows an evaluation of the 
cytotoxicity activity of the test drug. 
 
Figure 4-4: Trypan blue 
 
Viable cells are impermeable to trypan blue but when their membrane is damaged, the dye 
is taken up by dead cells so living cells appear clear and dead cells are stained in blue. 
However this method does not differentiate the apoptotic cells and the necrotic cells. 
 
Other types of cytotoxic assays have also been developed such as the genotoxicity BrdU 
assay, which measures cell proliferation. It involves the thymidine analogue BrdU (Figure 4-
5), which is incorporated at a specific stage of cell division (Phase S).  
 
Figure 4-5: BrdU as a thymidine analogue 
 
BrdU replaces thymidine during replication of DNA and fluorescent antibodies are used to 
recognise the bromide derivative of thymidine after denaturation of DNA. This assay is 
Chapter 4: Ferronucleobases as potential drugs 
 
144
therefore useful for giving information on the ability of the drug to reduce cell proliferation 
for example.  
 
4.1.2 Inorganic compounds as drugs 
In the 1960’s, a pivotal discovery propelled inorganic chemistry towards medicinal 
applications with the reports by Rosenberg on the antitumor properties of cisplatin (Figure 
4-6). 12,13 
 
Figure 4-6: Cisplatin 
In a cellular environment, one of the chloride ligands of cisplatin is replaced by a water 
ligand leading to the [PtCl(H2O)(NH3)2]
+, which readily binds to DNA nucleobases and 
preferably to adjacent guanines. Upon loss of a second chloride, which inhibits cell division, 
DNA repair mechanisms are not able to counter the effect of this adduct on DNA, which 
induces cell death as a result. Cisplatin has proven to be effective against many different 
types of cancer including testicular, ovarian or lymphomas.14 Consequently it has become a 
reference standard for tumour treatment and platinum complexes have been the objects of 
active research as potential antitumor drugs for the past 30 years. Nevertheless, only two 
other relative compounds have been authorised for clinical use: carboplatin and oxaliplatin. 
(Figure 4-7) 
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Figure 4-7: Carboplatin and Oxaliplatin structures 
 
However these platinum complexes show significant limitations. Severe toxic side effects 
such as nephrotoxicity, cell resistance and some limited activity against certain types of 
cancer have led to investigations to find new inorganic drugs, including those containing 
organometallic moieties as outlined below.  
 
4.1.3 Bioorganometallic compounds as drugs 
Organometallic complexes are attracting increasing academic interest in the field of 
medicinal chemistry.15 Ferrocene, which is the most common and popular representative of 
the metallocene family, is lipophilic, which helps penetration of cell membrane, and stable in 
biological environments and shows no toxic effects. 16  The ready functionalisation of 
ferrocene can further improve or change these properties and ferrocenyl derivatives are 
known to give interesting biological activities such as antitumor,17,18 or cytotoxic effects.19 In 
the 1970’s, Edwards et al. reported the synthesis of a series of β-lactamase inhibitors 
containing ferrocene such as ferrocenyl-penicillins and ferrocenyl-cephalosporins to 
overcome penicillin and cephalosporin resistances,20 which are antibiotics used against 
syphilis and other infectious diseases. 
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Figure 4-8: Ferrocenyl-penicillins and ferrocenyl-cephalosporins developed by Edwards 
 
No antibiotic effect was observed for compound I (Figure 8) but when ferrocene was 
separated from the β-lactamase ring via a methylene space linker (II) antibiotic activity was 
comparable to benzypenicillin. Edward’s work was the starting point for a large number of 
studies involving ferrocene in the design of potential organometallic drugs. For example, 
ferrocenyl derivatives such as ferrocenyl acetic acid have shown to be active against human 
andenocarcinoma, squamous cell carcinoma and large cell carcinoma of the lung, when it is 
used at high concentration (100 μg.mL-1) via a human tumor clonogenic assay.21 The 
clonogenic assay is used to evaluate the efficiency of a drug on survival and proliferation of 
cells. It consists of treating the cells, allowing them to grow and determining the percentage 
of cells that survived. Swarts et al. tested cytotoxicity of hydroxyl-ferrocenes on HeLa cells 
via a MTT assay and showed an interesting structure-activity relationship.22 (Table 4-1) 
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Table 4-1: EC50 values of hydroxyl-ferrocenes with different side chain length by Swarts 
 
Compounds IC50 (μM) 
 
>100 
 
35.0 
 
17.0 
 
5.7 
 
The data in Table 4-1 shows, the longer the side chain, the higher the cytotoxicity of the 
compounds. The ferrocenylbutanol (IC50 = 5.2 μM) was almost 20 times more effective than 
the ferrocenyl methanol (IC50 = 100 μM) for killing HeLa cells but not as active as cisplatin 
(IC50 = 1.3 μM) under the same conditions. It has been also been reported that the antitumor 
activity of ferrocenyl compounds is related to the oxidation state of the iron of their 
ferrocenyl moiety. According to Orsella et al.,23 the activity comes from the production of 
oxygen active radicals via enzymatic oxidation of Fe(II) to the ferrocenium form Fe(III). The 
ferrocenium ions interact with water and oxygen to form OH• radicals that break DNA 
molecules, leading to cell death.  
 
Based on the idea of “bio-isoterism”, which corresponds to the principle of exchanging a 
group by another with similar chemical or biological properties, Jaouen 24  developed 
Ferrocifen, which is active as an antitumor compound against breast cancer, and Biot 
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developed ferroquine25, which is an antimalarial compound. These two compounds are two 
recent examples of potential new organometallic drugs involving ferrocene. (Figure 4-9) 
  
Figure 4-9: Chemical structure of tamoxifen, hydroxytamoxifen, chloroquine and their corresponding 
ferrocenyl drugs ferrocifen, hydroxyferrocifen and ferroquine 
 
In 2010 in the UK, around 50,000 women were diagnosed with breast cancer. 26 
Unfortunately it is the most common cancer in UK and one of the most fatal of female 
cancers. Most breast tumour growths are linked to the presence of α-ERs (Estrogen 
Receptors) that are activated by the estrogen hormone. After many metabolic steps, 
interaction of estrogen with the receptors leads to cell proliferation. Tamoxifen is the 
standard treatment against hormone-dependent tumours (ER+) but it does not act directly 
on the receptors as it has a low affinity for the targeted receptor (ER). It has to be converted 
into the active antagonist hydroxytamoxifen by cytochrome P450 in the liver, whose anti-
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proliferative activity comes from its competitive binding to ER receptor, leading to a 
repression of DNA transcription in cancer cells.27 The limitations of this treatment are the 
low efficiency of the drug towards non-hormone-dependent tumours (ER-) and cell 
resistance against tamoxifen. (Figure 4-10) 
 
 
Figure 4-10: Estrogen receptor-positive and negative cancer mechanisms28  
 
To overcome these problems, Jaouen et al. developed hydroxyferrocifen by replacing the β-
phenyl group of hydroxytamoxifen by a ferrocenyl moiety. Indeed, this drug revealed 
significant antiproliferatives effects on both ER+ and ER- receptors. As previously explained, 
the ferrocenyl moiety is involved in the formation of radicals that play a significant role in 
the activity of the drug in parallel of its binding mode of action.29 This alternative activity of 
the ferrocenyl group was highlighted by related work on the ruthenium analogue of 
ferrocifen (Figure 4-11), which showed similar effects with ER+ cell lines but was inactive 
with ER- cell lines.  
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Figure 4-11: Ruthenocifen, the ruthenium analogue of ferrocifen 
 
Jaouen explained that ruthenocene and ferrocene are similar in size and shape, but differ by 
their electrochemical behaviour. Ruthenocene is harder to oxidise and more importantly the 
resulting electron transfer is not reversible, unlike its ferrocene analogue.30 This is a possible 
reason why ruthenocene does not allow formation of radicals and does not have any effects 
on ER- cells. 
 
Using the same kind of bio-isoteric approach but towards bacterial agents, Biot et al.23 
replaced a part of chloroquine, one of the principal treatments against malaria, with a 
ferrocenyl group. Malaria affects about 300 million of people per year, via the transmission 
of the parasite plasmodium falciparum by the bite of a mosquito. Chloroquine and quinine 
have been used widely against the disease but the parasite developed strong resistance 
against these treatments. Consequently, the development of new anti-malarial alternatives 
has been the subject of intense research over the past few decades.31 Unlike chloroquine, 
ferroquine does not seem to induce cell resistance and recently went through phase II of 
clinical trials as a potential efficient antimalarial drug.14 The ferrocenyl enhanced lipophilicity 
and redox activity was used to explain the improved results.  
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In the light of these inspiring works, our group decided to investigate analogues of the 
previously synthesised FcNA monomers as potential antitumor or antiviral drugs. 
 
4.2 Aim 
Intensive research over the past 30 years on the structural modification of nucleosides has 
promoted the development of nucleoside analogues as potential drugs. Modification of the 
nucleobase or the sugar itself has resulted in antiviral drugs such as Acyclovir,32 Brivudine33 
and Cidofovir32 and antitumor drugs such as Fluorouracil (5-FU).34  (Figure 4-12)  
 
Figure 4-12: Three nucleosides analogues 
 
Brivudine is an antiviral thymidine analogue used as a powerful inhibitor of Herpes Simplex 
Virus (HSV-1 and HSV-2) and the vesicular stomatitis virus (VZV). In fact it was first 
synthesised at the University of Birmingham in the 1980’s by A. S. Jones et al.35 Its 
mechanism of action is based on its incorporation into viral DNA and blocking DNA 
polymerase in DNA replication. The compound is activated after phosphorylation via the 
viral thymidine kinase (TK), which is a phosphotransferase enzyme that is also found in most 
living cells. The enzyme can be found in two forms, TK1 and TK2 and can be used as cell 
proliferation marker or as a way to identify a mechanism of action for drug candidates. As a 
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similar example of antiviral drug, Acyclovir is an acyclic analogue of guanosine, which is also 
used against Herpes Simplex virus and VZV. Its mechanism of action is comparable to 
Brivudine mechanism by its incorporation in viral DNA. Cidofovir, on the other hand is an 
analogue of cytosine as shown in Figure 4-13. It is used against CMV by preventing viral 
replication and transcription. It works similarly to Brivudine in that it inhibits DNA replication 
via its incorporation into DNA by viral DNA polymerase. However, unlike Brivudine or 
Acyclovir, it does not need to be activated via a viral kinase to be activated, but still needs to 
be phosphorylated. 
 
Figure 4-13: Cidofovir 
 
5-FU is an analogue of uracil used as an antitumor drug. Uracil is important for the synthesis 
of RNAs and is the principal source of thymidine triphosphate (TTP), which is incorporated 
into DNA after its synthesis by Thymidine synthase. 5-FU acts as a direct competitive 
inhibitor of the thymidine synthase and blocks the synthesis of TPP and DNA synthesis, 
leading to cell death.  It also intercalates into RNA leading to mistakes in transcription. 
 
 
Figure 4-14: 5-Fluorouracil 
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As explained by Romeo,36 nucleoside analogues showing antiviral or antitumor activities 
present three significant structural features (Scheme 4-3): a) the hydroxyl group (Red), to 
allow phosphorylation by kinases in biological environment, b) the nucleobase (Green) to 
allow its direct interaction with the target via hydrogen bonds, and c) the spacer (Blue) 
between the hydroxyl and the nucleobase for orientating both groups in the right position. 
The FcNA monomers previously described in Chapter 3 appeared to loosely fit the criteria 
(Scheme 4-3). Therefore the target FEN-T, containing just one base and one hydroxyl group, 
was designed and synthesised within the group following the same synthetic route 
developed for FcNA-Adenine, FcNA-Uracil and FcNA-Thymine. 
 
Scheme 4-3: Structural similarities between AZT and FcNA-T that led to the design of FEN-T 
 
The bio-activity of FEN-T was then tested in collaboration with the Laboratory of Virology 
and Chemotherapy in Leuven, Belgium, for preliminary pharmacological studies and was also 
studied in collaboration with researchers in LES (Biosciences) and MDS (Schools of Immunity 
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and Infection and Cancer Sciences) at the University of Birmingham. Encouraged by the 
promising results of FEN-T that are presented later on in this chapter, it was decided to 
extend the synthesis to analogues involving other nucleobases. The synthesis of the new 
ferronucleobases FEN-Adenine and FEN-Cytosine is detailed in the next section. (Figure 4-15) 
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Figure 4-15: Targets: Ferronucleobases containing adenine and cytosine  
 
4.3 Synthesis of ferronucleobases as potential drugs 
 
The synthesis of the ferronucleobases followed the previous synthetic route developed for 
FcNA monomers in Chapter 3 and goes through the same mechanisms but in this case only 
one Cp ring of the ferrocene was substituted. The synthesis was divided into three major 
steps. The first part consisted of the synthesis of disubstituted iodo-dimethylamine-
ferrocene, followed by the extension of the methyl-propanol arm via nucleophilic 
substitutions. In the final part of the synthesis, thymine was coupled to ferrocene via 
Mitsunobu coupling reaction after developing the two-carbon alkyl chain. 
 
4.3.1 Part 1: Precursor synthesis 
The Friedel-Craft acylation of ferrocene gave the mono-substituted ferrocene ketone in good 
yields, which was then subjected to enantioselective reduction using (S)-CBS catalyst to give 
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the chiral hydroxyl (R)-55 in 85% yield. Acetylation of the alcohol using acetic anhydride, TEA 
and DMAP in DCM gave mono-acetyl (R)-56 in 86% yield. In the next two steps leading to the 
disubstituted iodo-dimethylamine ferrocene (R,Sp)-58, two side-reactions were encountered, 
as shown in Scheme 4-4. 
 
Scheme 4-4: First part of the synthesis 
 
The nucleophile substitution of acetate 56 in presence of dimethylamine in MeOH/H2O gave 
dimethylamine (R)-57 in 76% yield. In parallel, a side-reaction formed the methoxy 
derivative 57a. This side-reaction has already been described by Schwink and Knochel37, who 
highlighted the strong influence of the solvent on the substitution reaction by comparison of 
two solvent systems: THF/H2O and MeOH/H2O. The targeted compound A was obtained 
quantitatively in THF/H2O but the same reaction in MeOH/H2O gave exclusively the methoxy 
derivative B (Scheme 4-5).37 
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Scheme 4-5: Influence of the medium on the substitution reaction by Knochel 
 
The result was explained by a combination of two factors. The first one is the parallel 
methanolysis reaction competing with the dimethylamine substitution. Methanol (solvent) is 
in excess compared to the dimethylamine reagent and therefore it displaces the reaction 
equilibrium towards formation of B via a thermodynamic process. The second factor is the 
ability of the electron-rich pentamethylferrocenyl moiety to stabilise the formation of the 
ferrocenyl carbenium ion.  
 
In the case of 56, the competing methanolysis reaction could be significantly reduced using a 
smaller volume of solvent and a larger excess of dimethylamine. The ability of the ferrocene 
to stabilise the carbenium is weaker than the pentamethylcylopentadienyl moiety and 
therefore the equilibrium towards the formation of 57 is favoured under these conditions. 
(Scheme 4-6) 
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Scheme 4-6: Side reaction process during dimethylamine substitution 
 
The following directed ortho-metallation of 57 with iodine gave (R,Sp)-58 in a yield of 55%, 
which is lower than the 80% yield obtained with the bis-dimethylamine ferrocene 33. 
(Scheme 4-7) 
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Scheme 4-7: Ortho-halogenation of bis and mono-substituted ferrocene 33 and 57 
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The low yield is due to a competing elimination reaction leading to the formation of vinyl 
(Sp)-58a as shown in Scheme 4-8. Several factors favoured elimination of dimethylamine: a) 
n-BuLi is a very strong base and is able to deprotonate the methyl at the β position of the 
dimethylamine; b) the carbenium formed is stabilised by the electron-rich ferrocenyl moiety 
and d) the reaction is performed in aprotic solvents (Et2O, THF) that tend to promote 
eliminations. Another factor plays an important role in favouring the elimination: 
temperature. In the second part of the procedure, addition of iodine was performed at -78˚C 
and the temperature was progressively raised up to room-temperature to bring lithium-
halogen exchange to completion. Unfortunately, increasing the temperature would also 
favour elimination processes leading to the formation of 58a. The optimisation of the 
reaction was therefore a compromise between completing the lithium-halogen exchange 
and the limiting elimination process. 
 
 
Scheme 4-8: Elimination process during ortho-metallation of 57 
 
The synthesis of the iodo-dimethylamine-ferrocene 58 was then followed by the extension 
of the methylpropanol arm, as described in the following section.  
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4.3.2 Part 2: Hydroxyl arm extension 
The development of the hydroxyl arm of the ferronucleobase involves six steps from the 
iodo-dimethylamine to the silylated-hydroxyl following the route previously adopted for 
FcNA monomers. (Scheme 4-9) 
 
 
Scheme 4-9: Extension of hydroxyl part of the ferronucleobase 
 
The di-substituted iodo-dimethylamine ferrocene (R,Sp)-58 was acetylated with acetic 
anhydride at 50 ˚C for 2 h to give the acetate (R,Sp)-59 in 87% yield. The latter was 
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hydrolysed with sodium hydroxide to give (R,Sp)-60, which was then methoxylated under 
acidic conditions to give (R,Sp)-61. Both reactions proceeded in very high yields. Formation of 
ester 61 via the vinylethoxytrimethylsylane with BF3.OEt2 acting as a promotor for the 
nucleophilic attack of the vinylethoxytrimethylsylane 38 on the ferrocene carbenium, gave 
(S,Sp)-62 in 61% yield. Reduction via DIBAL-H gave (S,Sp)-63 almost quantitatively, which was 
followed by protection of the hydroxyl group with TBDPSCl, giving (S,Sp)-64 in 95% yield. 
 
4.3.3 Part 3: Extension of three carbon linker 
The synthesis of the ferrocenyl precursor required for the nucleobase coupling step was 
straightforward. The three steps from the iodide derivative 64 led to the synthesis of the 
desired two-carbon linker alcohol 67 as shown in Scheme 4-10. 
 
 
Scheme 4-10: Third part of the synthesis 
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The lithiation of (S,Sp)-64 in presence of n-BuLi in ether was followed by addition of DMF to 
give (S,Sp)-65 in 92% yield. Wittig reaction on the aldehyde gave the vinyl derivative (S,Rp)-66 
in 89% yield and a change in the planar chirality configuration, according to Cahn-Ingold-
Prelog rules. The alcohol (S,Rp)-67 was obtained after hydroboration-oxidation of  the vinyl 
(S,Rp)-66 in 97% yield (Scheme 4-10). The enantiopurity of the synthesis was checked using 
chiral HPLC on compound 67. As shown in Figure 7-20, 67 gave a peak at 16.8 min 
corresponding to the (S,Rp) enantiomer and a second smaller peak at 14.4 min 
corresponding to the other enantiomer (R,Sp). However, the calculated enantiomeric excess 
of 96.6% was considered good enough to go on with the synthesis. The chiral HPLC graphs 
are shown in the appendix. (Figure 7-20, 7-21 and 7-22) 
 
4.3.4 Part 4: Nucleobase coupling 
Adenine and cytosine were linked to the di-substituted ferrocene via two different paths. As 
previously developed in Chapter 2 and 3, adenine was coupled via a Mitsunobu reaction and 
cytosine via a bromide substitution.  
 
4.3.4.1 Adenine coupling 
Coupling (S,Rp)-67 with the protected adenine 19 was achieved in THF in presence of DIAD at 
65˚C. The disubstituted ferrocenyl (S,Rp)-68 was obtained in 72% yield, which was then 
deprotected with TBAF to give (S,Rp)-69 in 80% yield followed by a debenzoylation with 
methylamine to give the target FEN-A (S,Rp)-70 in 73% yield. (Scheme 4-11) 
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Scheme 4-11: Adenine coupling and deprotection of the FEN-A 
 
4.3.4.2 Cytosine coupling 
Cytosine coupling was performed on the bromide derivative (S,Rp)-71 obtained from 
bromination of (S,Rp)-67 in 84% yield using NBS in presence of triphenylphosphine and 
pyridine. The coupling with the protected cytosine 21 was carried out in DMF at 50˚C in 
presence of NaH to give (S,Rp)-72 in 60% yield. TBDPS deprotection of the coupled ferrocene 
with TBAF led to (S,Rp)-73 in 93% and  the final debenzoylation of the nucleobases using 
methylamine gave the target FEN-C (S,Rp)-74 in 97% yield. (Scheme 4-12) 
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Scheme 4-12: Cytosine coupling and deprotection 
 
It is interesting to compare the yields of various cytosine derivatives synthesised as part of 
this thesis (Table 4-2). It appears that steric hindrance plays a significant role in the efficiency 
of the nucleophilic substitution. Substitution of one Cp only (28a and 72) is much easier than 
bis-substitution (28 and 53). 
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Table 4-2: Ferrocenyl cytosine derivatives 
 
Compound Yield Compound Yield 
 
68% 
 
60% 
 
25% 
 
16% 
 
In conclusion, the two targets, FEN-A and FEN-C, were successfully synthesised via the same 
synthetic route developed for the tetra-substituted ferrocenyl derivatives, although side-
reactions reduced the efficiency of two steps in the synthesis. FEN-T, FEN-A and other 
derivatives are currently undergoing cell line tests to investigate potential antitumor or 
antiviral activities. Preliminary results are described below. 
 
4.4 Biological results 
The biological studies conducted in the laboratories of Leuven and Birmingham consisted of 
evaluating the biological activity of FEN-T, FEN-A and some of their derivatives (Figure 4-18). 
The drug screening was conducted towards various infectious diseases such as hepatitis, 
AIDS, influenza virus (H1N1, H3N2), viccinia virus (VV), vesicular stomatitis virus (VSV), 
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herpes (HSV-1, 2) and against cancer cells. MTS, BrdU, AMES and adenylate assays were 
performed on different types of cells, including human embryonic lung cells (HEL), Madin-
Darby canine kidney epithelial Cells (MDCK), murine leukemia cells (L1210), human T-
lymphocyte cells (CEM), human cervix carcinoma cells (HeLa), Crandell-Rees Feline Kidney 
cells (CRFK) and Vero cells. 
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Figure 4-16: Targets 
The activity of these drug candidates was investigated to get a better understanding of the 
influence of the different moieties of the main target (FEN-T) on its biological activity.  
 
4.4.1 Antiviral activity 
The first results reported by the laboratory of virology of Leuven have indicated that FEN-T is 
quite a toxic compound against the majority of the cells tested but shows interesting 
antiviral activities against Herpes virus such as HSV-1, HSV-2, HSV-1 (HSV-1 TK- KOS ACV), VV 
and vesicular stomatitis virus in HEL cells. FEN-T activity seems to be comparable to known 
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clinical drugs such as Brivudine (BVDU) and Cidofovir (HPMPC) used as positive controls. 
(Table 4-3) 
Table 4-3: FEN-T antiviral activity against Herpes virus compared to Brivudine 
 
 
 
 
 
 
 
 
These results indicated that FEN-T is highly toxic in most the cell tested (HeLa, CRFK, Vero 
cells, MDCK) with MCC values of 9.88 μM compared with the 100-250 μM for certain 
commercially available drugs (Ribavirine, DHPA, DS 5000). Unfortunately, this appears to 
make FEN-T too cytotoxic and not specific enough to offer good antiviral activity. However, 
FEN-T did give a MMC value of 244 μM comparable to Brivudine cytotoxic activity (> 250 
μM) on HEL cells infected with HSV-1 or HSV-2. It was though that FEN-T was less cytotoxic 
due to these being monolayer confluent HEL cells. Under these conditions, these cells are 
not in a growth phase and are therefore less susceptible to the cytotoxic effect of the 
compound than rapidly proliferating CEM or MT-4 cells. An encouraging result under these 
conditions is that FEN-T gave a better EC50 value than Brivudine towards HSV-2 with EC50s of 
2.4 μM for FEN-T, against 183 μM for Brivudine. Furthermore, FEN-T shows comparable 
antiviral activity to Cidofovir against HSV-1 and 2 with 2.4 μM for FEN-T against 2 μM for 
Cidofovir. 
 
 MMC (μM) EC50 (μM) 
 HSV-1 HSV-2 HSV-1 HSV-2 
FEN-T 244 2.4 2.4 
Brivudine 250 0.02 183 
Cidofovir 250 2 2 
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FEN-T also gives competitive activities towards other viruses such as vaccinia virus (VV) and 
vesicular stomatitis virus (VSV). With a similar minimum cytotoxic concentration to the other 
drugs, the antiviral activity of FEN-T against VSV is better than Brivudine but not against VV 
as shown in Table 4-4. Furthermore, Cidofovir gives better results than FEN-T against VV but 
not against VSV. 
 
Table 4-4: FEN-T antiviral activity against vaccinia virus (VV) and vesicular stomatitis virus (VSV) 
compared to Brivudine and Cidofovir. 
 
 
 
 
 
 
 
 
 
To conclude, the preliminary results indicate that FEN-T is generally highly cytotoxic for a 
range of cell lines but without significant activity at subtoxic concentrations. However, on 
non-rapidly dividing cell lines the compound appears to inhibit herpes viruses 1 and 2 and 
the vesicular stomatitis virus. Furthermore, its antiviral activity can be similar or even better 
than certain commercial drugs such as Brivudine or Cidofovir. These results are promising 
and will be the subject of further investigations in the future.  
 
 MCC (μM) EC50 (μM) 
 VV VSV VV VSV 
FEN-T 244 21.6 48 
Brivudine 250 10 250 
Cidofovir 250 17 250 
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4.4.2 Antitumor activity 
Leuven and Birmingham laboratories worked in parallel to investigate the antitumor activity 
of FEN-T and FEN-A as well as some of their derivatives as presented in Figure 4-18. In 
Leuven, an investigation of the thymine compounds and their controls was carried out on 
the proliferation of murine leukemia cells (L1210), human cervix carcinoma cells (HeLa) and 
non-cancerous human T-lymphocyte cells (CEM). Cisplatin was used as a positive control to 
compare activities. 
 
As shown in Table 4-5, FEN-T showed to be the most promising candidate, giving the lowest 
IC50 against the three cell lines and shows higher cytotoxicity than cisplatin on L1210 cells 
with an IC50 of 0.78 μM compared to 1 μM for cisplatin. Interestingly FEN-T shows a 
comparable activity to cisplatin on the non-cancerous CEM, with an IC50 of 0.9 μM. However, 
the compound is not as active as cisplatin on HeLa cells. These results also highlighted the 
importance of the alcohol group with 16a being 15 times more toxic than the control (H2), 
but less active than FEN-T. 
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Table 4-5: Antitumoral activity of FEN-T and some of its analogues compared to cisplatin antitumoral 
activity 
 
 IC50 (μM) 
 L1210 CEM HeLa 
 
0.78 0.9 2.7 
Cisplatin 1 0.9 1.2 
Fe
OH
16a
 
25 43 52 
 
417 592 509 
 
99 149 100 
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Studies were also carried out on three oesophageal cancer cell lines in the School of 
Biosciences at the University of Birmingham. The results were broadly similar. The cell 
viability studies (MTT) showed that two oesophageal cancer cell lines (OE 19 and 21) were 
susceptible to FEN-T, FEN-A and to the other compounds to varying degrees, with 
preliminary results indicating FEN-T to be as active as cisplatin.  Interestingly not all the cell 
lines tested were susceptible, with OE 33 being resistant. Once again the combination of the 
hydroxyl group and the nucleobase was important, with FEN-T being the most active , 
followed by FEN-A. 
 
The potential mutagenicity of the compounds was evaluated via the AMES assay. It consists 
of using genetically modified bacteria (salmonella) that are unable to synthesise histidine. In 
the case of the substance induced mutations, the cell regains its ability to live without the 
help of growing factors such as histidine, which can be synthesised again by the cell. 
Preliminary AMES test data were encouraging in that they showed all the compounds to be 
negative.  
 
In vitro assays of cellular viability (MTT assay) and cell proliferation (BrdU assay) were also 
performed on three colorectal cancer cell lines (HT29, RKO and SW480) in the School of 
Cancer Sciences. The commercial nucleosidic anticancer agent fluorouracil (5-FU) was 
included as a positive control. As shown in Figure 4-19, the study compares the results 
obtained with the targets and 5-FU on the proliferation and the viability of collateral cancer 
cells after 48h of exposition. Once again, it shows that compounds FEN-A and FEN-T are the 
most promising compounds, giving a high potential of activity as anti-neoplastic agents in 
terms of effect on cellular proliferation in comparison with 5-FU.  
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Figure 4-17: MTT and BrdU assays for the evaluation of antitumoral activity of FEN-A and FEN-T 
compared to 5-FU 
 
The data again indicate that the compounds containing both a nucleobase and an alcohol 
group are the most active, suggesting they play a role in hindering cell proliferation by 
inhibiting DNA synthesis. 
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4.5 Conclusion 
These preliminary results demonstrate the potential antiviral activity of ferronucleobases, 
with FEN-T giving activities comparable to commercial drugs such as Brivudine and Cidofovir. 
Several of these compounds in particular those containing both a nucleobase and an alcohol 
group, appear to play a role in hindering cell proliferation by inhibiting DNA synthesis. 
However, the cytotoxicity of these compounds is an issue, which may preclude their use as 
antiviral agents. However, this cytotoxicity is advantageous when considering antitumor 
activity. Promising results have been obtained that are comparable to 5-FU, which is an 
anticancer drug that inhibits DNA synthesis rather like the antiviral drugs. However for these 
compounds to be effective, selectivity towards cancer cell lines over non-cancerous ones 
needs to be addressed and studied in more detail. 
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5 CHAPTER 5: CONCLUSIONS AND FUTURE WORK 
 
All along the development of this thesis, investigations on linking ferrocenyl derivatives with 
different nucleobases have been carried out. The main goal of this work at the outset was to 
synthesise nucleoside analogues containing ferrocene that could form metal containing 
nucleic acids. In order to achieve this goal, preliminary studies on bis-substituted ferrocenes 
were first of all carried out to investigate how ferrocene could be coupled to adenine, but 
also to uracil and cytosine. Further studies showed how the type and number of linkers as 
well as the type of nucleobases affects the electrochemical properties. The synthesis of the 
bis-substituted systems was then used to inform the systems of the tetra-substituted 
monomers that were required for FcNA synthesis. Routes for retaining chirality pure 
monomer units have now been established. Now that the monomers have been successfully 
made, future work will be directed towards their oligomerisation on an automated DNA 
synthesiser (Figure 5-1) and the formation of the corresponding duplexes will then be 
investigated.  
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Figure 5-1: Oligomerisation of the three synthesised monomers FcNA-A, FcNA-U and FcNA-C 
 
This work can also be considered as a starting point for further studies towards the 
development of other type of FcNAs monomers and FENs for biological activity. Different 
parameters can be considered such as the linker length between the ferrocenyl moiety and 
the nucleobase. For example, FcNAs monomers with three-carbons linker could be made by 
using the tetra-substituted bis-aldehyde ferrocene and a triethyl phosphonoacetate coupled 
via the Wittig reaction, followed by the hydrogenation of the corresponding double bond. 
The ester groups would then be reduced using LiAlH4 and nucleobases would be coupled to 
the corresponding alcohol via a Mitsunobu reaction as shown in Scheme 5-1.  
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Scheme 5-1: Synthetic route for the synthesis of a FcNA monomer with a three-carbon linker to the 
nucleobase. 
 
It would also be interesting to investigate the synthesis of the ferrocenyl nucleic analogue 
containing guanine (FcNA-G). Due to the low solubility of the nucleobase in usual organic 
solvents, a derivative of guanine such as the 2-amino-chloropurine could be considered for 
the coupling reaction with the ferrocenyl moiety. As previously described by Fletcher in 
2009,1 the purine derivative would then be converted into the natural guanine to obtain the 
final desired target as shown in Scheme 5-2.  
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Scheme 5-2: Synthetic route for the guanine coupling with ferrocenyl derivatives based on the work of 
Fletcher2 
 
Finally, routes to FcNA and FEN derivatives with only planar chirality should also be 
considered to evaluate the importance of chirality on the FcNA oligomer properties and the 
FEN biological activity. All these future studies should open the door to many new 
perspectives on the use of ferrocene in the bioorganometallic field. 
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6 CHAPTER 6: EXPERIMENTAL 
6.1 Synthesis 
All the products were used as received from Sigma-Aldrich, TCI, and Fisher Scientific. All the 
solvents were used as received from Fischer and Sigma-Aldrich. Dry solvents were collected 
from a Solvent Purification System. Thin layer chromatography were visualised under UV-
light and flash chromatography were performed on silica 60 with the specified eluent. 
Routine 1H NMR were recorded at 300 MHz on a Bruker AVIII300 or at 400 MHz on a Bruker 
AVIII400 spectrometer equipped with a 5 mm probe. 13C NMR and 2D NMR spectra (COSY, 
HSQC) were recorded at 101 MHz on a Bruker AVIII400 spectrometer. 31P NMR were 
recorded at 122 MHz on a Bruker AVIII300. All the spectra were recorded at 298 K. Chemical 
shifts (δ) are expressed in parts per million (ppm) to higher frequency compared to the 
methyls signal of trimethylsilane and the coupling constants (J) are expressed in Hertz (Hz). 
Data were processed using Bruker Topspin version 2.1 (300 and 400 MHz) and Mestrenova 
Light version 5.2.5. HRES MS were performed on a Waters/Micromass spectrometer using 
the ES+ method. Optical rotations were determined via a PolAAr 2001 digital polarimeter 
using a cell with a volume of 1 mL and a length of 0.25 dm. The polarimeter presents a 
instrumental error on the displayed optical angles of 0.5%.  
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6.1.1. (Hydroxymethyl)diphenylphosphine oxide 29  
In a 100 mL schlenk tube, 16 mL of conc. HCL was added slowly to 
diphenylphosphine chloride (1.68 mL, 9.06 mmol) followed by addition 
of 16 mL of HCOH (37% in water). The mixture was then heated up to 
50˚C and stirred overnight. The pale yellow mixture was then neutralised with 400 mL of 
saturated NaHCO3, extracted with DCM, dried on NaSO4 and evaporated. A white powder 
was obtained (1.756 g, 84%). 1H NMR (400 MHz, CDCl3) δ 7.79 – 7.71 (m, 4H), 7.54 – 7.48 (m, 
2H), 7.43 (td, J = 7.6, 2.8 Hz, 4H), 4.40 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 132.13 (Ph), 
131.44 (Ph), 131.35 (Ph), 130.98 (ipso Ph), 130.02 (ipso Ph), 128.71 (Ph), 128.60 (Ph), 61.62 
(CH2), 60.79 (CH2). MS (ES) (m/z) calcd for C13H13O2PNa 255.0551, found 255.0553. IR (cm
-1): 
3202 br (OH), 3080 (=CH), 2899 (CH2), 2817 (CH2), 1151 (P=O), 690 (C=C). Mp 136 °C - 138 °C.  
 
6.1.2. (Diphenylphosphoryl)methyl 4-nitrobenzenesulfonate 47 
The (hydroxymethyl)diphenylphosphine oxide 2 (1.5 g, 6.5 
mmol) was dissolved 15 mL of DCM. Nitrobenzylsufonate 
chloride (1.432 g, 6.5 mmol) was added to the mixture followed 
by TEA (1.35 mL, 9.7 mmol) and DMAP (0.079 g, 0.65 mmol). The reaction was stirred 
overnight under argon at room temperature. The crude was quenched with 10 mL of 
NaHCO3, extracted with DCM and dried over Na2SO4. Solvent was evaporated and the crude 
was purified via flash column chromatography (Gradient: 60% EtOAc in hexane to 100% 
EtOAc) to yield product. A white solid was obtained (1.489 g, 55%). 1H NMR (400 MHz, CDCl3) 
δ 8.32 – 8.26 (d, J = 6.2 Hz, 2H), 7.95 – 7.89 (d, J = 6.2 Hz, 2H), 7.76 – 7.68 (m, 4H), 7.66 – 
7.59 (m, 2H), 7.53 – 7.48 (m, 4H), 4.75 (d, J = 6.2 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 150.90 
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(ipso Ph), 140.32 (ipso Ph), 133.10 (Ph), 131.46 (Ph), 131.37 (Ph), 129.42 (Ph), 129.21 (ipso 
Ph), 129.06 (Ph), 128.94 (Ph), 128.17 (ipso Ph), 124.47 (Ph), 66.26 (CH2), 65.47 (CH2). MS (ES) 
(m/z) calcd for C19H16NO6PSNa 440.0334, found 440.0333. IR (cm
-1): 3061, 2941 (CH2), 1609 
(NO2), 1538 (NO2), 1371, 1085, 820 (CH=CH), 736. Mp 156 °C - 158 °C. Characterisation data 
is in agreement with the literature data. 
 
6.1.3. N-9-((Diphenylphosphoryl)methyl)-adenine 57 
Adenine (0.486 g, 3.6 mmol) was added in one portion to a solution of NaH 
(0.202 g, 5.04 mmol) dissolved in 20 mL of DMF. After being stirred for 3 h 
at room temperature, (diphenylphosphoryl)methyl 4-nitrobenzene 
sulfonate 4 (1.5 g, 3.6 mmol) previously dissolved in 10 mL of DMF are 
added to the mixture. After 2 days of stirring, the reaction was quenched with EtOH and the 
solvents were removed in vacuo and the crude was filtered and washed with an EtOH/EtOAc 
mix. The crude was purified via flash column chromatography (5% MeOH, 5% TEA in EtOAc) 
to yield product (0.669 g, 53%). 1H NMR (400 MHz, CDCl3) δ 8.26 (s, 1H), 8.25 (s, 1H), 7.86 – 
7.73 (m, 4H), 7.58 – 7.49 (m, 2H), 7.47 – 7.42 (m, 4H), 5.71 (s, 2H), 5.05 (d, J = 6.3 Hz, 2H). 13C 
NMR (101 MHz, CDCl3) δ 155.33 (ipso adenine), 152.85 (CH adenine), 149.95 (ipso adenine), 
140.81 (CH adenine), 132.84 (Ph), 131.16 (Ph), 131.06 (Ph), 129.61 (ipso Ph), 129.09 (ipso 
adenine), 128.99 (Ph), 128.87 (Ph), 43.26 (CH2), 42.54 (CH2).
 31P NMR (122 MHz, CDCl3) δ 
27.48.  
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6.1.4. N,N-6-Dibenzoyl-N-9-((diphenylphosphoryl)methyl)-adenine 6 
To a solution of 5 (0.100 g, 0.286 mmol) in Pyridine (4 mL) at 0 °C, was 
added 132 µL of benzoyl chloride. The solution was stirred for 5 min. The 
mixture was then warmed up to room temperature overnight. The pyridine 
was removed using high vacuum, the residue was dissolved in DCM, 
washed with 5% NaHCO3, dried on Na2SO4 and evaporated. The crude was 
purified via flash column chromatography packed with 30% hexane in EtOAc. A first gradient 
of EtOAc was applied (70% to 100% in hexane) to the column followed by a second gradient 
of MeOH (2% to 10 % MeOH in EtOAc). A white foam was obtained (0.124 g, 78%). 1H-NMR 
(400 MHz, CDCl3) δ 8.49 (s, 1H), 8.46 (s, 1H), 7.85 – 7.78 (m, 4H), 7.78 – 7.71 (m, 4H), 7.58 – 
7.51 (m, 2H), 7.49 – 7.42 (m, 6H), 7.34 – 7.32 (m, 4H), 5.08 (d, J = 6.2 Hz, 2H). 13C NMR (101 
MHz, CDCl3) δ 172.14 (C=O), 153.04 (ipso adenine), 151.88 (CH adenine), 151.74 (ipso 
adenine), 145.06 (CH adenine), 134.06 (ipso Bz), 133.02 (Bz), 131.14 (Ph), 129.41 (Bz), 129.09 
(Ph), 128.97 (Bz), 128.64 (Ph), 128.21 (ipso Ph), 126.54 (ipso adenine), 43.80 (CH2), 43.09 
(CH2).
 31P NMR (122 MHz, CDCl3) δ 26.75. MS (ES) (m/z) calcd for C32H24N5O3PNa 580.15, 
found 580.1511. IR (cm-1): 3059 (=CH), 2975, 2924 (CH2), 1696 (C=O), 1597, 1577, 1234, 
1120, 692 (C=C). Mp 108 °C - 110 °C.  
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6.1.5. N-1-((Diphenylphosphoryl)methyl)-cytosine 77 
NaH (0.129 g, 5.38 mmol) was dissolved 20 mL of DMF. Cytosine (0.427 g, 
3.84 mmol) was added in one portion and stirred under argon at room 
temperature for four hours. 4 (1.6 g, 3.84 mmol) previously dissolved in 10 
mL of DMF, was then slowly added to the reaction at room temperature. 
After two days, the solvent was evaporated and the crude was purified via 
flash column chromatography (5% MeOH, 5% TEA in DCM) to yield product. A white solid 
was obtained (0.831 g, 61%). MS (ES) (m/z) calcd for C17H17N3O2P 326.1058, found 326.1056 
(M+ + H). IR (cm-1): 3339 (NH), 3210 (NH), 3054 (=CH), 2988 (CH2), 2925 (CH2), 1665 (C=C), 
1624 (C=O), 1498, 1371 (CH2), 1261 (CN), 1175 (P=O), 712 (NH2), 691 (C=C). Mp 134 °C -136 
°C. 
 
6.1.6. N-4-Benzoyl-N-1-((diphenylphosphoryl)methyl)-cytosine 8 
7 (0.4 g, 1.23 mmol) was dissolved in 15 mL of pyridine. Benzoyl chloride 
(0.856 mL, 7.37 mmol) was added at 0 °C, stirred for 15 min and then 
warmed up to room temperature overnight under argon. After 
evaporation of pyridine, the residue was purified via flash column 
chromatography (3% MeOH in DCM) to yield product. A white solid was 
obtained (0.382 g, 72%). 1H NMR (400 MHz, CDCl3) δ 8.79 (s, 1H), 8.34 (d, J = 7.4 Hz, 1H), 7.88 
– 7.82 (m, 6H), 7.63 – 7.54 (m, 3H), 7.53 – 7.45 (m, 7H), 4.96 (d, J = 6.3 Hz, 2H). 13C NMR (101 
MHz, CDCl3) δ 162.18 (C=O), 149.19 (CH Cytosine), 133.18 (Bz), 132.87 (Ph), 131.21 (Bz), 
131.12 (Ph), 129.76 (ipso Bz), 129.04 (Bz), 128.99 (Ph), 128.92 (Bz), 128.75 (ipso Ph), 127.59 
(Ph), 97.23 (CH cytosine), 46.73 (CH2), 46.02 (CH2). MS (ES) (m/z) calcd for C24H21N3O3P 
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430.1321, found 430.1318 (M+ + H). IR (cm-1): 3210 (NH), 3061 (=CH), 2988 (CH2), 2925 (CH2), 
1675 (C=C), 1621 (C=O), 1477, 1347, 1239 (CN), 1167 (P=O), 693. Mp degrades at 178 °C. 
 
6.1.7. 1,1’-Bis-dicarboxaldehyde-ferrocene 912 
In a 50 mL schlenk flask, ferrocene (2 g, 10.75 mmol) was partially dissolved in 
Et2O under argon. After addition of TMEDA (3.845 mL, 25.8 mmol), the mixture 
went to dark orange. The reaction was stirred for 5 min and 11.18 mL of n-BuLi 
(27.9 mmol) was added to the mixture at room temperature. After overnight stirring, the 
mixture was cooled down to -78˚C and DMF (2.749 mL, 35.5 mmol) was added drop wise. 
After 10 min, the reaction was warmed up to room temperature and stirred for 1.5 h. The 
reaction was then quenched with water/Brine and extracted with DCM. The organic layers 
were combined, dried over MgSO4 and concentrated. The crude was purified via flash 
column chromatography (70% EtOAc in hexane) to yield a red foam (2.05 g, 78%). 1H NMR 
(400 MHz, Chloroform-d) δ 9.95 (s, 2H), 4.89 (t, J = 2.0 Hz, 4H), 4.70 – 4.64 (m, 4H). 13C NMR 
(101 MHz, CDCl3) δ 192.84 (C=O), 80.27 (ipso Cp), 77.32 (Fc), 74.19 (Fc), 70.86 (Fc). Mp 152 
°C - 154 °C. Characterisation data is in agreement with the literature data. 
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6.1.8. 1,1’-Bis-[(Z)-2-((N,N-6-dibenzoyl)-adenin-9-yl))ethylenyl]-ferrocene 10 
800 mg of 6 (1.43 mmol) were dissolved in 6 mL of pyridine. The solution 
was evaporated using high vacuum. The residue was then dissolved in 6 
mL of DMF under Argon. After 5 min of stirring, 36 mg of sodium hydride 
95% (1.505 mmol) were added in one portion at room temperature. The 
mixture was stirred at room temperature for 2 h. Then the bis-
carboxaldehyde 9 (0.116 g, 0.478 mmol) previously dissolved in 5 mL of 
DMF was added at room temperature. After overnight stirring, the 
reaction was quenched with water/EtOAc  (1/1) (20 mL) at 0 °C and extracted with Et2O. The 
organic layers were combined, dried over Na2SO4 and concentrated. The crude was purified 
via flash column chromatography packed with 60% EtOAc in hexane. The purification 
involved a gradient from 60% to 100% of EtOAc. An orange foam was obtained (0.084 g, 
32%). 1H-NMR (400 MHz, CDCl3) δ 8.75 (s, 2H), 8.09 (s, 2H), 7.89 (d, J = 7.1 Hz, 8H), 7.50 (t, J = 
7.5 Hz, 4H), 7.37 (t, J = 7.7 Hz, 8H), 6.84 (d, J = 8.7 Hz, 2H), 6.39 (d, J = 8.7 Hz, 2H), 4.20 – 4.17 
(t, J = 1.9 Hz, 4H), 3.85 (t, J = 1.9 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 172.25 (C=O), 152.99 
(ipso adenine), 152.81 (CH adenine), 152.00 (ipso adenine), 144.29 (CH adenine), 134.16 
(ipso Bz), 132.97 (Bz), 129.46 (Bz), 128.68 (Bz), 127.06 (ipso Bz), 126.29 (CH vinyl), 116.15 (CH 
vinyl), 77.67 (ipso Cp), 71.44 (Fc), 70.43 (Fc). MS (ES) (m/z) calcd for C52H36FeN10O4
56FeNa 
943.22, found 943.2198. IR (cm-1): 3063, 2923 (CH2), 2853 (CH2), 1697 (C=O), 1596, 1572, 
1229. Mp 106 °C - 108 °C. 
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6.1.9. 1,1’-Bis-[2-((N,N-6-dibenzoyl)-adenin-9-yl)ethyl]-ferrocene 11 
The bis-protected adenine ferrocenyl 10 (0.092 g, 0.099 mmol) 
was dissolved in 3 mL of EtOAc. 80.7 mg of pearlman’s catalyst 
(Pd/(OH)2) (2eq) were added to the solution. A balloon of H2 was 
plugged to the flask and the mixture was stirred overnight at room 
temperature. The reaction was stopped and filtered through a pad of celite. The crude was 
purified via flash column chromatography (30% hexane in EtOAc). A yellow solid was 
obtained (0.064 g, 72%). 1H-NMR (400 MHz, CDCl3) δ 8.70 (s, 2H), 7.85 (d, J = 7.1 Hz, 8H), 
7.76 (s, 2H), 7.49 (t, J = 7.5 Hz, 4H), 7.36 (t, J = 7.8 Hz, 8H), 4.34 (t, J = 6.9 Hz, 4H), 4.06 – 4.02 
(t, J = 1.8 Hz, 4H), 3.82 (t, J = 1.8 Hz, 4H), 2.88 (t, J = 6.8 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 
172.26 (C=O), 153.07 (ipso adenine), 152.10 (CH adenine), 151.67 (ipso adenine), 145.13 (CH 
adenine), 134.18 (ipso Bz), 132.89 (Bz), 129.44 (Bz), 128.65 (Bz), 127.48 (ipso adenine), 83.71 
(ipso Cp), 69.14 (Fc), 68.93 (Fc), 45.70 (CH2), 30.13 (CH2). MS (ES) (m/z) calcd for 
C52H40N10O4
56FeNa 947.25, found 947.2469. IR (cm-1): 3104, 1651 (C=O), 1605, 1522 (amide). 
Mp decomposed at 176 °C - 178 °C.  
 
Mitsunobu coupling: 1,1’-bis-[2-((N,N-6-dibenzoyl)-adenin-9-yl)ethyl]-ferrocene 22 
In a 50 mL schlenk tube, triphenylphosphine (0.861 g, 2.188 mmol) 
and the N,N-6-benzoyl-adenine 19 (0.651 g, 1.896 mmol) were 
dissolved in dry THF and stirred for 10 min at room temperature. 
16 (0.200 g, 0.729 mmol) was then added to the mixture pre-
dissolved in 5 mL of dry THF. The schlenk tube was then covered with foil and DIAD (0.476 
mL, 2.188 mmol) was added at room temperature before the mixture was warmed up to 65 
°C for 2 h. The reaction was evaporated, extracted with EtOAc, washed with brine followed 
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by water and dried over Na2SO4, solvent removed in vacuo and purified via flash column 
chromatography (2% MeOH in DCM) to yield product (0.311 g, 46%). (Data cf 11) 
 
6.1.10. 1,1’-Bis-[2-(adenin-9-yl)ethyl]-ferrocene 12 
The bis-protected adenine ferrocenyl 11 (0.055 g, 0.0595 mmol) 
was dissolved in 1 mL of methylamine. The mixture was stirred at 
room temperature for half an hour under argon. The methylamine 
was evaporated. The crude was purified via flash column 
chromatography (10% MeOH in DCM). A yellow solid was obtained (0.020 g, 66%). 1H-NMR 
(300 MHz, DMSO-d6) δ 8.15 (s, 2H), 8.02 (s, 2H), 7.17 (s, 4H), 4.28 (t, J = 7.4 Hz, 4H), 4.05 (t, J 
= 1.7, 4H), 4.01 (t, J = 1.6, 4H), 2.84 (t, J = 7.4 Hz, 4H). 13C NMR (75 MHz, DMSO-d6) δ 156.38 
(ipso adenine), 152.81 (CH adenine), 149.92 (ipso adenine), 141.22 (CH adenine), 119.25 
(ipso adenine), 84.99 (ipso Cp), 69.00 (Fc), 68.55 (Fc), 44.40 (CH2), 29.67 (CH2). MS (ES) (m/z) 
calcd for C24H25N10
56Fe+ 509.16, found 509.1638 (M+ + H+). IR (cm-1): 3109 (NH2), 2924 (CH2), 
2852 (CH2), 1659 (imine), 1598, 1571, 1305. Mp decomposed at 284 °C - 286 °C. 
 
6.1.11. 1,1’-Bis-[(Z)-2-(adenin-9-yl))ethylenyl]-ferrocene 13 
The bis-protected adenine ferrocenyl 10 (0.031 g, 0.034 mmol) was 
dissolved in 1 mL of methylamine. The mixture was stirred at room 
temperature for half an hour under argon. The methylamine was 
evaporated. The crude was purified via flash column chromatography 
(10% MeOH in DCM). An orange solid was obtained (0.013 g, 77%). 1H 
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NMR (300 MHz, DMSO-d6) δ 8.16 (s, 2H), 8.00 (s, 2H), 7.33 (s, 4H), 6.78 (d, J = 8.5 Hz, 2H), 
6.50 (d, J = 8.6 Hz, 2H), 4.21 – 4.09 (t, J = 1.8 Hz, 4H), 3.86 – 3.69 (t, J = 1.8 Hz, 4H). 13C NMR 
(75 MHz, DMSO-d6) δ 156.51 (ipso adenine), 153.50 (CH adenine), 150.00 (ipso adenine), 
140.27 (CH adenine), 127.74 (CH vinyl), 118.82 (ipso adenine), 117.63 (CH vinyl), 78.43 (ipso 
Cp), 71.16 (Fc), 70.46 (Fc). MS (ES) (m/z) calcd for C24H20N10
56FeNa 527.11, found 527.1138. 
IR (cm-1): 3303 (NH2), 3122, 1670 (imine), 1645, 1595, 1572. Mp decomposed at 256 °C - 258 
°C. 
 
6.1.12. 1,1’-Bis-vinyl-ferrocene 1517 
In a 100 mL schlenk tube, trimethylmethylphosphonium bromide (5.587 g, 
15.64 mmol), potassium tert-butoxide (1.75 g, 15.64 mmol) and a catalytic 
amount of dibenzo-18-crown-6-ether were dissolved in 14 mL of dry THF. The 
mixture was stirred for 30 min and 1,1’-bis-dicarboxaldehyde ferrocene 9 (1.893 g, 7.82 
mmol) previously dissolved in 28 mL of dry THF was added. The reaction was stirred 
overnight at room temperature, quenched with water and extracted with Et2O (20 mL). The 
combined ethereal fractions were dried over Na2SO4, solvent removed in vacuo and purified 
via flash column chromatography (40% EtOAc in hexane) to yield product (1.307 g, 70%). 1H 
NMR (400 MHz, CDCl3) δ 6.36 (dd, J = 17.5, 10.7 Hz, 2H), 5.29 (dd, J = 17.5, 1.6 Hz, 2H), 5.06 
(dd, J = 10.8, 1.6 Hz, 2H), 4.24 (t, J = 1.9 Hz, 4H), 4.16 (t, J = 1.9 Hz, 4H). 13C NMR (101 MHz, 
CDCl3) δ 134.07 (CH vinyl), 111.23 (CH2 vinyl), 84.15 (ipso Cp), 69.88 (Cp), 67.90 (Cp). MS (ES) 
(m/z) calcd for C14H14
56Fe 238.0445, found 238.0438. IR (cm-1): 3077 (=C-H), 3009 (CH2), 2978 
(CH2), 2915 (CH2), 1631 (C=C), 994 (-CH=CH2), 893 (C=C), 817 (C=C), 726 (CH Ar). Mp 48 °C - 
50 °C. Characterisation data is in agreement with the literature data. 
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6.1.13. Vinyl-ferrocene 15a 
In 50 mL schlenk tube, trimethylmethylphosphonium bromide (1.836 g, 5.14 
mmol), potassium tert-butoxide (0.577 g, 5.14 mmol) and a catalytic amount of 
dibenzo-18-crown-6-ether were dissolved in 15 mL of dry THF. The mixture was 
stirred for 30 min and carboxaldehydeferrocene 9a (1 g, 4.67 mmol) previously dissolved in 
10 mL of dry THF was added. The reaction was stirred overnight at room temperature, 
quenched with water and extracted with Et2O (10 mL). The combined ethereal fractions 
were dried over MgSO4, solvent removed in vacuo and purified via flash column 
chromatography (40% EtOAc in hexane) to yield product (0.768 g, 78%). 1H NMR (400 MHz, 
CDCl3) δ 6.45 (dd, J = 17.5, 10.7 Hz, 1H), 5.33 (dd, J = 17.4, 1.6 Hz, 1H), 5.02 (dd, J = 10.7, 1.6 
Hz, 1H), 4.35 (t, J = 1.8 Hz, 2H), 4.20 (t, J = 1.9 Hz, 2H), 4.10 (s, 5H). 13C NMR (101 MHz, CDCl3) 
δ 134.65 (CH vinyl), 111.05 (CH2 vinyl), 83.56 (ipso Cp), 69.21 (Fc), 68.66 (Fc), 66.66 (Fc). MS 
(ES) (m/z) calcd for C12H12
56Fe 212.0288, found 212.0275. IR (cm-1): 3082 (=C-H), 3006 (CH2), 
2993 (CH2), 2851 (CH2), 1623 (C=C), 1408 (C=CH2), 998 (-CH=CH2), 895, 822 (C=C), 726 (CH 
Ar). Mp 50 °C - 52 °C. 
 
6.1.14. 1,1’-Bis-hydroxypropyl-ferrocene 1617 
In 100 mL schlenk tube, 15 (0.252 g, 1.058 mmol) was dissolved in 15 mL 
of dry THF.BH3 in THF (6.01 mL, 0.634 mmol) was then added drop wise 
at room temperature and stirred for 2 h. 7.15 mL of EtOH, 7.15 mL of 
NaOH (3M) and 5.29 mL of H2O2 (30%) were then successively added to 
the reaction and stirred for 1 h at room temperature. The reaction was extracted with DCM, 
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washed with brine and dried over Na2SO4, solvent removed in vacuo and purified via flash 
column chromatography (70% EtOAc in hexane) to yield product (0.200 g, 69%). 1H NMR 
(400 MHz, CDCl3) δ 4.05 (s, 8H), 3.69 (t, J = 6.6 Hz, 4H), 2.56 (t, J = 6.6 Hz, 4H), 2.04 (s, 2H). 
13C NMR (101 MHz, CDCl3) δ 84.99 (ipso Cp), 69.16 (Fc), 68.41 (Fc), 63.48 (CH2), 32.65 (CH2). 
MS (ES) (m/z) calcd for C14H18O2
56FeNa 297.0554, found 297.0558. IR (cm-1): 3249 (OH), 3092 
(=C-H), 2924 (CH2), 2883 (CH2), 2847 (CH2), 1468 (CH2), 1053 (OH), 805 (C=C). Mp 40 °C - 42 
°C.  Characterisation data is in agreement with the literature data. 
 
6.1.15. 1-Hydroxypropyl-ferrocene 16a16 
In 200 mL schlenk tube, 15a (0.600 g, 3.1 mmol) was dissolved in 30 mL of 
dry THF. BH3,THF (17.62 mL, 9.3 mmol) was then added drop wise at room 
temperature and stirred for 2 h. 10.45 mL of EtOH, 10.45 mL of NaOH (3M) 
and 7.74 mL of H2O2 (30%) were then successively added to the reaction and stirred for 1 h 
at room temperature. The reaction was extracted with DCM, washed with brine and dried 
over MgSO4, solvent removed in vacuo and purified via flash column chromatography (30% 
EtOAc in hexane) to yield product (0.554 g, 65%). 1H NMR (400 MHz, CDCl3) δ 4.15 – 4.09 (m, 
7H), 4.10 (d, J = 1.8 Hz, 2H), 3.73 (t, J = 6.2 Hz, 2H), 2.60 (t, J = 6.5 Hz, 2H), 1.64 – 1.54 (m, 
1H). 13C NMR (101 MHz, CDCl3) δ 84.77 (ipso Cp), 68.60 (Fc), 68.42 (Fc), 67.67 (Fc), 63.49 
(CH2), 32.82 (CH2). MS (ES) (m/z) calcd for C12H14O
56Fe 230.0394, found 230.0398. IR (cm-1): 
3220 (OH), 3082 (=C-H), 2948 (CH2), 2906 (CH2), 2868 (CH2), 1341 (OH), 1053 (C-OH), 805 
(CH=CH), 721 (CH Ar).  Mp 41 °C - 42 °C. Characterisation data is in agreement with the 
literature data. 
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6.1.16. N-9-Trityl-adenine 1718,19 
Adenine (2.5 g, 18.5 mmol) was dissolved in a mixture of 15 mL and 30 
mL of DMF and Pyridine respectively. The mixture was stirred at room 
temperature for 10 min under argon. Tritylmethyl chloride (5.157 g, 18.5 
mmol) was added to the suspension. The reaction was stirred overnight 
under argon. The reaction was quenched with 100 mL of EtOAc and 50 mL of water. The 
organic layer was washed five times with water. Filtration of the organic layer led to a 
colourless precipitate corresponding to the desired compound (6 g, 86%). 1H NMR (400 MHz, 
CDCl3) δ 7.99 (s, 1H), 7.68 (s, 1H), 7.25 – 7.23 (m, 9H), 7.12 – 7.07 (m, 6H), 5.73 (s, 2H). 
13C 
NMR (101 MHz, CDCl3) δ 155.75 (ipso adenine), 152.34 (CH adenine), 151.40 (ipso adenine), 
141.93 (CH adenine), 141.33 (ipso Ph), 129.79 (Ph), 128.06 (Ph), 127.91 (Ph), 121.17 (ipso 
adenine), 75.80 (ipso Tr). MS (ES) (m/z) calcd for C24H19N5Na 400.1538, found 400.1537. IR 
(cm-1): 3302 (NH2), 3137 (NH2), 3027 (=CH), 1666 (C=C), 1650 (NH2), 1598 (NH2), 1565 (C-C), 
1445, 747 (CH Ar), 696 (C=C). Mp 258 °C - 262 °C. Characterisation data is in agreement with 
the literature data. 
 
6.1.17. N,N-6-Dibenzoyl-N-9-trityl-adenine 18 
17 (1.197 g, 3.17 mmol) was dissolved in 60 mL of pyridine. The 
solution should turn to clear. Benzoyl chloride (0.919 mL, 7.93 
mmol) was added at 0 °C, stirred for 15 min and then warmed up 
to room temperature overnight under argon. After evaporation of 
pyridine, the residue was dissolved in DCM and washed with water 
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and brine. The crude was purified via flash column chromatography (30% EtOAc in hexane) 
to yield product. A white foam was obtained (1.438 g, 77%). 1H NMR (400 MHz, CDCl3) δ 8.40 
(s, 1H), 8.03 (s, 1H), 7.84 – 7.78 (m, 4H), 7.49 – 7.43 (m, 2H), 7.35 – 7.26 (m, 9H + 4H), 7.16 – 
7.10 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 172.29 (C=O), 154.44 (ipso adenine), 152.19 (ipso 
adenine), 151.70 (CH adenine), 146.25 (CH adenine), 140.76 (ipso Ph), 134.29 (ipso Bz), 
132.88 (Bz), 129.64 (Ph), 129.41 (Bz), 129.02 (ipso adenine), 128.58 (Bz), 128.19 (Ph). MS (ES) 
(m/z) calcd for C38H27N5O2Na 608.2062, found 608.2064. IR (cm
-1): 3071 (=CH), 1699 (C=O), 
1595 (amide), 1567 (C=N), 1446, 1385 (Cq), 1177, 1073, 693 (C=C). Mp 104 °C - 108 °C. 
 
6.1.18. N,N-6-Dibenzoyl-adenine 19 
18 (3 g, 5.12 mmol) was dissolved in 15 mL of DCM under argon. TFA 
(0.592 mL, 7.68 mmol) was added at 0 °C, stirred for 3 h and then 
warmed up to room temperature overnight under argon. After 
evaporation of TFA and co-evaporation with CHCl3, the crude was 
purified via flash column chromatography (2% MeOH in DCM) to yield product. A white foam 
was obtained (1.198 g, 68%). 1H NMR (400 MHz, CDCl3) δ 11.79 (s, 1H), 8.65 (s, 1H), 8.27 (s, 
1H), 7.82 – 7.78 (m, 4H), 7.46 – 7.41 (m, 2H), 7.32 – 7.27 (m, 4H). 13C NMR (101 MHz, CDCl3) 
δ 172.31 (C=O), 154.86 (ipso adenine), 151.91 (CH adenine), 150.70 (ipso adenine), 144.27 
(CH adenine), 133.85 (ipso Bz), 133.20 (Bz), 129.35 (Bz), 128.79 (Bz), 125.12 (ipso adenine). 
MS (ES) (m/z) calcd for C19H14N5O2 344.1147, found 344.1131. IR (cm
-1): 3069 (=CH), 1691 
(C=O), 1580 (NH), 1399, 1230, 1175, 1074, 693 (C=C). Mp 98 °C - 100 °C. 
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6.1.19. N-3-Benzoyluracil 2020 
Uracil (3 g, 26.76 mmol) was dissolved in 33 mL of a mixture of 
acetonitrile and Pyridine with a 5/2 ratio. Benzoyl chloride (6.819 mL, 
58.8 mmol) was added (turn to purple) and stirred overnight under argon 
at room temperature. The crude was then filtered off and washed with acetonitrile. Solvent 
was evaporated and the crude was purified via flash column chromatography (2% MeOH in 
DCM with a gradient of MeOH from 2% to 5%) to yield product. A white solid was obtained 
(1.437 g, 25%). Rf (9/1 DCM/MeOH) = 0.33. 1H NMR (400 MHz, DMSO-d6) δ 11.61 (s, 1H), 
7.99 – 7.93 (d, J = 7.0 Hz, 2H), 7.78 (d, J = 7.5 Hz, 1H), 7.67 (d, J = 7.8 Hz, 1H), 7.61 – 7.58 (t, J 
= 7.3 Hz, 2H), 5.75 (d, J = 7.7 Hz, 1H). 13C NMR (101 MHz, DMSO) δ 169.96 (C=O Bz), 162.87 
(C=O uracil), 150.01 (C=O uracil), 143.27 (CH uracil), 135.35 (Bz), 131.28 (ipso Bz), 130.15 
(Bz), 129.44 (Bz), 100.04 (CH uracil). MS (ES) (m/z) calcd for C11H8N2O3Na 239.0433, found 
239.0434. IR (cm-1): 3218 (NH), 3178 (NH), 3083 (=CH), 1745 (C=O), 1703 (amide/urea), 1648 
(amide), 1625 (C=N), 1595 (NH), 1414, 782 (CH Ar Bz), 693 (C=C). Mp 149 °C - 150 °C. 
Characterisation data is in agreement with the literature data. 
  
6.1.20. N-4-Benzoyl cytosine 2121 
Cytosine was co-evaporated with pyridine and suspended in 67.5 mL of 
pyridine. 15.66 mL of benzoyl chloride were added drop wise and the 
reaction was stirred overnight at room temperature. 13.5 mL of water were 
added and the solvent was evaporated. The residue was then dissolved in 
189 mL of water containing 14.85 g of NaOH. The mixture was stirred for one hour after 
complete dissolution. HCl was then added in order to obtain a pH=4. A White precipitate was 
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collected and boiled in 270 mL of EtOH and cooled to room temperature and filtered. 1H 
NMR (300 MHz, DMSO-d6) δ 11.68 (s, 1H), 11.14 (s, 1H), 8.02 (d, J = 7.2 Hz 2H), 7.98 – 7.88 
(m, 1H), 7.63 (d, J = 7.0 Hz, 1H), 7.51 (t, J = 7.9 Hz, 2H), 7.22 (s, 1H). MS (ES) (m/z) calcd for 
C11H9N3O2Na 238.0592, found 238.0581. IR (cm
-1): 3225 (amide), 3156 (amide), 3062 (=CH 
Fc), 2604 (+NHBz), 1693 (amide/urea), 1621 (NH), 1460 (C=N), 1242, 812 (CH Ar), 701 (C=C). 
Mp degrades at >300˚C. 
6.1.21. 1-[2-((N,N-6-Dibenzoyl)-adenin-9-yl)ethyl]-ferrocene 22a 
In a 50 mL schlenk tube, triphenylphosphine (0.383 g, 1.46 
mmol) and the N,N-6-dibenzoyl-adenine 19 (0.500 g, 1.46 
mmol) were dissolved in dry THF and stirred for 10 min at room 
temperature. 16a (0.2 g, 0.729 mmol) was dissolved in 7 mL of dry THF and added to the 
mixture. The schlenk tube was then covered with foil and DIAD (0.240 mL, 1.176 mmol) was 
added at room temperature before the mixture was warmed up to 65 °C for 2 h. The 
reaction was evaporated, extracted with EtOAc, washed with brine followed by water and 
dried over Na2SO4, solvent removed in vacuo and purified via flash column chromatography 
(40% EtOAc in hexane) to yield product (0.134 g, 33%). 1H NMR (400 MHz, CDCl3) δ 8.69 (s, 
1H), 7.86 (d, J = 7.0 Hz, 4H), 7.76 (s, 1H), 7.48 (t, J = 7.5 Hz, 2H), 7.34 (t, J = 7.8 Hz, 4H), 4.34 
(t, J = 7.0 Hz, 2H), 4.11 (s, 5H), 4.06 (t, J = 1.8 Hz, 2H), 3.86 (t, J = 1.8 Hz, 2H), 2.90 (t, J = 7.0 
Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 172.26 (C=O Bz), 153.13 (ipso adenine), 152.07 (CH 
adenine), 151.64 (ipso adenine), 145.18 (CH adenine), 134.19 (ipso Bz), 132.87 (Bz), 129.44 
(Bz), 128.64 (Bz), 127.54 (ipso adenine), 83.42 (ipso Cp), 68.69 (Fc), 68.16 (Fc), 45.69 (CH2), 
30.36 (CH2). MS (ES) (m/z) calcd for C31H25N5O2
56Fe 555.1358, found 555.1354. IR (cm-1): 
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3087 (=CH Fc), 2926 (CH2), 2926 (CH2), 2856 (CH2), 1696 (C=O), 1598 (amide Bz), 1574 (NH2), 
1448 (CH2), 1235, 830 (CH Ar), 692 (C=C). Mp 82 °C - 84 °C. 
 
6.1.22. 1-[2-(Adenin-9-yl)ethyl]-ferrocene 23a 
The bis-protected adenine ferrocenyl 22a (0.055 g, 0.1 mmol) 
was dissolved in 3 mL of methylamine. The mixture was stirred 
at room temperature for half an hour under argon. The 
methylamine was then evaporated. The crude was purified on a silica gel chromatographic 
column with a 95/5 DCM/MeOH mix solvent. A yellow solid was obtained (0.019 g, 58%). 1H 
NMR (400 MHz, DMSO-d6) δ 8.17 (s, 1H), 8.05 (s, 1H), 7.17 (s, 2H), 4.31 (dd, J = 8.2, 6.8 Hz, 
2H), 4.15 (s, 5H), 4.08 – 4.02 (m, 4H), 2.85 (t, J = 7.5 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 
155.89 (ipso adenine), 152.35 (CH adenine), 149.40 (ipso adenine), 140.76 (CH adenine), 
118.73 (ipso adenine), 84.39 (ipso Cp), 69.00 (Fc), 68.55 (Fc), 43.75 (CH2), 29.34 (CH2). MS 
(ES) (m/z) calcd for C17H18N5
56Fe 348.0912, found 348.0920 (M+ + H+). IR (cm-1): 3399 (NH2), 
3316 (NH2), 3084 (=CH Fc), 2980 (CH2), 2931 (CH2), 2907 (CH2), 1653 (C=C), 1596 (NH2), 1435 
(CH2), 1245, 797 (CH Ar). Mp degrades at 142 °C.  
 
6.1.23. 1-[2-((N-3-Benzoyl)-uracil-1-yl)ethyl]-ferrocene 24a 
In a 50 mL schlenk tube, triphenylphosphine (0.570 g, 2.173 
mmol) and the N-3-benzoyl-uracil 20 (0.469 g, 2.173 mmol) were 
dissolved in 15 mL of dry THF and stirred for 10 min at room 
temperature. 16a (0.250 g, 1.087 mmol) was then added to the mixture pre-dissolved in 5 
mL of dry THF. The schlenk tube was then covered with foil and DIAD (0.508 mL, 2.312 
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mmol) was added at room temperature before the mixture was warmed up to 65 °C for 2 h. 
The reaction was evaporated, extracted with EtOAc, washed with brine followed by water 
and dried over Na2SO4, solvent removed in vacuo and purified via flash column 
chromatography (40% EtOAc in hexane) to yield product (0.388 g, 83%). 1H NMR (400 MHz, 
CDCl3) δ 7.92 (d, J = 7.1 Hz, 2H), 7.66 (t, J = 7.4 Hz, 1H), 7.51 (dd, J = 8.3, 7.4 Hz, 2H), 6.93 (d, J 
= 8.0 Hz, 1H), 5.65 (d, J = 8.0 Hz, 1H), 4.13 (s, 5H+2H), 4.04 (t, J = 1.8 Hz, 2H), 3.84 (t, J = 7.0 
Hz, 2H), 2.76 (t, J = 7.0 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 168.83 (C=O Bz), 162.51 (C=O), 
149.62 (C=O), 144.57 (CH uracil), 135.08 (Bz), 131.51 (ipso Bz), 130.48 (Bz), 129.16 (Bz), 
101.42 (CH uracil), 83.25 (ipso Cp), 68.75 (Fc), 68.46 (Fc), 68.17 (Fc), 50.80 (CH2), 29.10 (CH2). 
MS (ES) (m/z) calcd for C23H20N2O3
56FeNa 451.0721, found 451.0717. IR (cm-1): 3086 (=CH 
Fc), 2964 (CH2), 2932 (CH2), 1733 (cyclic ketone), 1702 (C=O), 1653 (amide/urea), 1597 
(amide), 1441 (CH2), 1342, 1256, 1175, 809 (CH Ar), 682 (C=C). Mp 130 °C - 132 °C. 
 
6.1.24. 1,1’-Bis-[2-((N-3-benzoyl)-uracil-1-yl)ethyl]-ferrocene 24 
In a 50 mL schlenk tube, triphenylphosphine (0.574 g, 2.188 mmol) 
and the N-3-benzoyl-uracil 20 (0.410 g, 1.896 mmol) were dissolved 
in 10 mL of dry THF and stirred for 10 min at room temperature. 16 
(0.200 g, 0.729 mmol) was then added to the mixture pre-dissolved 
in 5 mL of dry THF. The schlenk tube was then covered with foil and 
DIAD (0.476 mL, 2.328 mmol) was added at room temperature before the mixture was 
warmed up to 65 °C for 2 h. The reaction was evaporated, extracted with EtOAc, washed 
with brine followed by water and dried over Na2SO4, solvent removed in vacuo. The residue 
was dissolved in DCM and filtrated to yield product (0.260 g, 53%). 1H NMR (400 MHz, CDCl3) 
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δ 7.92 (d, J = 7.1 Hz, 4H), 7.66 (t, J = 7.4 Hz, 2H), 7.51 (t, J = 7.8 Hz, 4H), 6.94 (d, J = 8.0 Hz, 
2H), 5.65 (d, J = 8.0 Hz, 2H), 4.11 (t, J = 1.8 Hz, 4H), 4.00 (t, J = 1.8 Hz, 4H), 3.83 (t, J = 7.0 Hz, 
4H), 2.73 (t, J = 7.0 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 168.85 (C=O Bz), 162.46 (C=O), 
149.65 (C=O), 144.51 (CH uracil), 135.15 (Bz), 131.44 (ipso Bz), 130.49 (Bz), 129.20 (Bz), 
101.57 (CH uracil), 83.65 (ipso Cp), 69.21 (Fc), 69.08 (Fc), 50.71 (CH2), 28.75 (CH2). MS (ES) 
(m/z) calcd for C36H30N4O6
56FeNa 693.1412, found 693.1416 (M+ + Na+). IR (cm-1): 3096 (=CH 
Fc), 2976 (CH2), 2933 (CH2), 2872 (CH2), 1724 (C=O), 1597 (Amide bz), 1461 (CH2), 1173, 821 
(CH Ar). Mp 179 °C - 180 °C. 
 
6.1.25. 1-[2-(Uracil-1-yl)ethyl]-ferrocene 25a 
The mono-protected uracil ferrocenyl 24a (0.1 g, 0.234 mmol) 
was dissolved in 4 mL of methylamine. The mixture was stirred 
at room temperature for half an hour under argon. The 
methylamine was evaporated and the residue was purified on a silica gel chromatographic 
column with a 98/2 DCM/MeOH mix solvent. A yellow solid was obtained (0.076 g, 100%). 1H 
NMR (400 MHz, CDCl3) δ 8.56 (s, 1H), 6.79 (d, J = 7.9 Hz, 1H), 5.54 (d, J = 7.8 Hz, 1H), 4.13 (s, 
4H), 4.10 (t, J = 1.8 Hz, 2H), 4.02 (t, J = 1.9 Hz, 2H), 3.80 (t, J = 6.8 Hz, 2H), 2.74 (t, J = 6.8 Hz, 
2H). 13C NMR (101 MHz, CDCl3) δ 163.42 (C=O), 150.46 (C=O), 144.99 (CH uracil), 101.36 (CH 
uracil), 83.42 (ipso Cp), 68.72 (Fc), 68.49 (Fc), 68.14 (Fc), 50.75 (CH2), 29.21 (CH2). MS (ES) 
(m/z) calcd for C16H16N2O2
56FeNa 347.0459, found 347.0457. IR (cm-1): 3323 (NH), 3086 (=CH 
Fc), 2980 (CH2), 2802 (CH2), 1744 (cyclic ketone), 1700 (C=O), 1647 (amide/urea), 1550 (NH), 
1344, 1176, 803 (CH Ar), 695 (C=C). Mp degrades at 158°C - 160 °C.  
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6.1.26. 1,1’-Bis-[2-(uracil-1-yl)ethyl]-ferrocene 25 
The 1,1’-bis-benzoyl-uracil ferrocene 24 (0.1 g, 0.149 mmol) was 
dissolved in 4 mL of methylamine. The mixture was stirred at room 
temperature for half an hour under argon. The methylamine was 
evaporated. The crude was filtered and washed with DCM. A yellow 
solid was obtained (0.069 g, 100%). The compound was not soluble in DMSO. MS (ES) (m/z) 
calcd for C22H22N4O4
56FeNa 485.0888, found 485.0872 (M+ + Na+). IR (cm-1): 3323 (NH), 3084 
(=CH Fc), 2981 (CH2), 2934 (CH2), 2802 (CH2), 1744 (Cyclic ketone), 1699 (C=O), 1658 
(amide/Urea), 1602 (NH), 1550 (amide), 1343, 807 (C=C), 684 (C=C). Mp degrades at 178 °C.  
6.1.27. 1,1’-Bis-(2-(bromo)ethyl)-ferrocene 27 
In a 50 mL schlenk tube, NBS (0.195 g, 1.094 mmol) was suspended in dry 
DCM. A DCM solution of triphenylphosphine (0.268 g, 1.021 mmol) was 
added drop wise to it. The resulting orange mixture was stirred for 5 min 
before addition of 0.043 mL (0.437 mmol) of pyridine. The mixture went black. 16 (0.05 g, 
0.182 mmol) dissolved in 1 mL of dry DCM was added to the mixture. After overnight 
reaction, the solvent was removed in vacuo and the crude was purified via flash column 
chromatography (10% EtOAc in hexane) to yield product (0.450 g, 97%). 1H NMR (400 MHz, 
CDCl3) δ 4.07 (s, 8H), 3.41 (t, J = 7.7 Hz, 4H), 2.88 (t, J = 7.6 Hz, 4H). 
13C NMR (101 MHz, 
CDCl3) δ 85.65 (ipso Cp), 69.01 (Fc), 68.55 (Fc), 33.48 (CH2), 32.52 (CH2). MS (ES) (m/z) calcd 
for C14H16
56Fe79Br2 399.8948, found 399.8946. IR (cm
-1): 3067 (=C-H), 3002 (CH2), 2964 (CH2), 
2930 (CH2), 2854 (CH2), 1432 (CH2), 822 (-CH=CH2), 693 (CH Ar). Mp 52 °C - 54 °C. 
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6.1.28. 1-(2-(Bromo)ethyl)-ferrocene 27a 
In a 50 mL schlenk tube, NBS (0.487 g, 2.735 mmol) was suspended in 9 
mL of dry DCM. A 3 mL DCM solution of triphenylphosphine (0.669 g, 
2.553 mmol) was added drop wise to it. The resulting orange mixture was 
stirred for 5 min before addition of 0.215 mL (2.188 mmol) of pyridine. The mixture goes 
brown. 16a (0.250 g, 0.911 mmol) dissolved in 3 mL of dry DCM was added to the mixture. 
After overnight reaction, the solvent was removed in vacuo and the crude was purified via 
flash column chromatography (60% Et2O in hexane) to yield product (0.244 g, 91%). 
1H NMR 
(300 MHz, Chloroform-d) δ 4.13 (s, 5H+2H), 4.11 – 4.09 (m, 2H), 3.43 (dd, J = 8.1, 7.3 Hz, 2H), 
2.90 (t, J = 7.7 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 85.52 (ipso Cp), 68.64 (Fc), 68.30 (Fc), 
67.69 (Fc), 33.66 (CH2), 32.44 (CH2). MS (ES) (m/z) calcd for C12H13
56Fe79Br 291.9550, found 
291.9557. IR (cm-1): 3092 (=C-H), 2971 (CH2), 2909 (CH2), 2853 (CH2), 1466 (CH2), 1441 (CH2), 
1103, 806 (CH=CH), 714 (CH Ar). Mp 65 - 66 °C. 
 
6.1.29. 1-[2-((N-4-Benzoyl)-cytosin-1-yl)ethyl]-ferrocene 28a 
In a 50 mL schlenk tube, the N-3-benzoyl-cytosine 21 (0.165 g, 
0.768 mmol) was stirred vigorously in 6 mL of dry DMF and NaH 
(0.0184 g, 0.768 mmol) were added to the suspension in one 
portion. After hydrogen production has stopped, 27a (0.150 g, 0.512 mmol) was added to 
the mixture pre-dissolved in 3 mL of dry DMF. The reaction was stirred overnight. The 
reaction was evaporated, extracted with EtOAc, washed with brine followed by water and 
dried over Na2SO4, solvent removed in vacuo and purified via flash column chromatography 
(2% MeOH in DCM) to yield product (0.154 g, 68%). 1H NMR (300 MHz, CDCl3) δ 8.62 (s, 1H), 
Chapter 6: Experimental 
 199
7.89 (d, J = 7.3 Hz, 2H), 7.62 (t, J = 7.4 Hz, 1H), 7.52 (t, J = 7.7 Hz, 2H), 7.34 – 7.28 (m, 1H), 
7.22 (d, J = 7.1 Hz, 1H), 4.12 (s, 5H), 4.09 (t, J = 1.8 Hz, 2H), 3.97 (t, J = 1.9 Hz, 2H+2H), 2.85 (t, 
J = 6.6 Hz, 2H). 13C NMR (101 MHz, CDCl3 + MeOD) δ 166.94 (C=O), 162.81 (C=O), 156.31 (C-
N), 149.13 (CH cytosine), 132.91 (Bz), 128.70 (Bz), 127.72 (Bz), 96.38 (CH cytosine), 83.51 
(ipso Cp), 68.60 (Fc), 68.43 (Fc), 68.02 (Fc), 52.83 (CH2), 28.80 (CH2). MS (ES) (m/z) calcd for 
C23H22N3O2
56Fe 428.1061, found 428.1059. IR (cm-1): 3229 (NH), 3089 (=CH Ar), 2945 (CH2), 
2914 (CH2), 2852 (CH2), 1692 (C=O), 1647 (amide/urea), 1611 (NH), 1552 (amide), 1485 
(C=N), 1427 (CH2), 1359, 808 (CH Ar), 686 (C=C). Mp degrades at 184 °C.  
 
6.1.30. 1,1’-Bis-[2-((N-4-benzoyl)-cytosin-1-yl)ethyl]-ferrocene 28 
In a 50 mL schlenk tube, the N-4-benzoyl-cytosine 21 (0.157 g, 
0.730 mmol) was stirred vigorously in 6 mL of dry DMF and NaH 
(0.0175 g, 0.730 mmol) was added to the suspension in one 
portion. After hydrogen production stopped, 27 (0.097 g, 0.240 
mmol) was added to the mixture pre-dissolved in 2 mL of dry 
DMF. The reaction was stirred overnight at 50 °C. The reaction was evaporated, extracted 
with EtOAc, washed with brine followed by water and dried over Na2SO4, solvent removed in 
vacuo and purified via flash column chromatography (2% MeOH in DCM) to yield product 
(0.039 g, 25%). 1H NMR (400 MHz, CDCl3) δ 8.58 (s, 2H), 7.88 (d, J = 7.6 Hz, 4H), 7.62 (t, J =7.5 
Hz, 2H), 7.52 (dd, J = 8.4, 7.0 Hz, 4H), 7.35 (s, 2H), 7.23 (d, J = 7.2 Hz, 2H), 4.06 (t, J = 1.8 Hz, 
4H), 3.99 – 3.92 (m, 4H+4H), 2.81 (t, J = 6.7 Hz, 4H). 13C NMR (101 MHz, CDCl3 + MeOD) δ 
167.12 (C=O Bz), 162.87 (C=O), 156.27 (C-N), 149.14 (CH cytosine), 132.95 (Bz), 128.75 (Bz), 
127.77 (Bz), 96.50 (CH cytosine), 83.89 (ipso Cp), 69.17 (Fc), 68.97 (Fc), 52.79 (CH2), 28.55 
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(CH2). MS (ES) (m/z) calcd for C36H32N6O4
56FeNa 691.1732, found 691.1739. IR (cm-1): 3240 
(NH), 3083 (=CH Fc), 2920 (CH2), 2856 (CH2), 1744 (cyclic ketone), 1692 (C=O), 1650 
(amide/urea), 1613 (NH), 1485 (C=N), 1428 (CH2), 1359, 786 (CH Ar), 685 (C=C). Mp degrades 
at 162 °C. 
 
6.1.31. 1-[2-(Cytosin-1-yl)ethyl]-ferrocene 29a 
28a (0.040 g, 0.0936 mmol) was dissolved in 1 mL of 
methylamine. The mixture was stirred at room temperature for 
half an hour under argon. The methylamine was evaporated. 
The crude was purified on a silica gel chromatographic column (10% MeOH in DCM). A 
yellow solid was obtained (0.020 g, 61%). 1H NMR (400 MHz, DMSO-d6) δ 7.44 (d, J = 7.1 Hz, 
1H), 6.94 (s, 2H), 5.57 (d, J = 7.1 Hz, 1H), 4.17 (s, 5H), 4.08 (s, 4H), 3.78 (t, J = 7.6 Hz, 2H), 2.58 
(t, J = 7.5 Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 165.90 (C=O), 155.63 (C-N), 146.02 (CH 
cytosine), 92.80 (CH cytosine), 84.72 (ipso Cp), 68.34 (Fc), 67.83 (Fc), 67.08 (Fc), 49.64 (CH2), 
28.45 (CH2). MS (ES) (m/z) calcd for C16H17N3O2
56FeNa 346.0619, found 346.0625. IR (cm-1): 
3345 (NH), 3289 (NH), 3091 (=CH Fc), 2958 (CH2), 2916 (CH2), 2853 (CH2), 1744 (Cyclic 
ketone), 1697 (C=O), 1657 (amide/urea), 1619 (NH), 1475 (C=N), 1434 (CH2), 1385, 790 (CH 
Ar), 681 (C=C). Mp degrades at 184 °C.  
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6.1.32. 1,1’-Bis-acetyl-ferrocene 305 
The acetyl chloride (10.58 mL, 149 mmol) was added to a suspension of 
aluminium (III) chloride (17.63 g, 132 mmol) in DCM at 0 °C. The ferrocene (10 
g, 53.7 mmol) in DCM was then added drop wise within 20 min. The reaction 
was stirred for 2 h and warmed at room temperature. When the reaction was complete, the 
reaction was quenched by drop wise addition of ice-cold water at 0 °C. The mixture was then 
diluted with DCM, washed carefully (gas evolution) (2 x) with saturated aqueous K2CO3 and 
brine. The crude was dried on Mg2SO4 and evaporated. The crude was purified via flash 
column chromatography (25% EtOAc in hexane) to yield yellow-orange solid (12.38 g, 85%). 
1H NMR (400 MHz, Chloroform-d) δ 4.77 (s, 4H), 4.51 (s, 4H), 2.36 (s, 6H). 13C NMR (101 MHz, 
CDCl3) δ 201.11 (C=O), 80.68 (ipso Cp), 73.60 (Fc), 70.96 (Fc), 27.64 (CH3). MS (ES) (m/z) calcd 
for C14H14O2
56FeNa 293.0239, found 293.0241. IR (cm-1): 3087 (=CH Ar), 1654 (C=O), 1373 
(CH3), 1353, 824 (C=C). Characterisation data is in agreement with the literature data. 
 
6.1.33. (R,R)-1,1’-Bis-(α-hydroxyethyl)-ferrocene 314 
A solution of (S)-CBS (5 g, 18 mmol) in THF was cooled down to 0 °C under 
argon. To this solution, BH3.SMe2 (30 mL) was added in two steps. First 8.5 
mL was added to the mixture in order to create the catalyst system. The 
solution was stirred for 5-10 min. Then 21.5 mL of BH3.SMe2 was added 
simultaneously with a solution of 1,1-diacyl ferrocene 30 (8.12 g, 30 mmol) in THF (150 mL) 
drop wise using a cannula. After 30 min of stirring at 0 °C, the excess of BH3.SMe2 was 
quenched by drop wise addition of MeOH (40 mL, gas evolution). The crude was poured into 
300 mL of NH4
+Cl-, washed with ether, water, brine and dried on Na2SO4. The crude was 
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purified via flash column chromatography (75% Et2O in hexane). A yellow-orange solid was 
obtained (7.56 g, 93%). 1H NMR (400 MHz, Chloroform-d) δ 4.66 (q, J = 6.4 Hz, 2H), 4.32 (t, J 
= 3.4 Hz, 2H), 4.19 (t, J = 1.9 Hz, 4H), 4.20 – 4.18 (m, 2H), 4.15 – 4.12 (m, 2H), 1.39 (d, J = 6.4 
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 95.20 (ipso Cp), 67.67 (Fc), 67.56 (Fc), 66.14 (Fc), 65.99 
(Fc), 65.62 (CH*), 25.63 (CH3). MS (ES) (m/z) calcd for C14H18O2
56FeNa 297.0550, found 
297.0554. [α]D (c = 0.0065 g/mL, DCM) = -51.7. Characterisation data is in agreement with 
the literature data. 
 
6.1.34. (R,R)-1,1’-Bis-(α-acetoxyethyl)-ferrocene 324 
The 1,1’-Bis-(α-hydroxyethyl) ferrocene 31 (4.728 g, 17.4 mmol) was 
dissolved in dry DCM (60 mL) and stirred for 5 min. 4 mL (4.435 g, 43.4 
mmol) of acetic anhydride, 6 mL (4.395 g, 43.4 mmol) of TEA and catalytic 
amount of DMAP were added successively to the mixture. The reaction was stirred at room 
temperature overnight. After completion of the reaction, it was quenched with NaHCO3 (80 
mL) and extracted with DCM. The aqueous layer was washed with DCM (3 x 100 mL) and 
then dried on Mg2SO4 and evaporated. The crude was purified via flash column 
chromatography (25% EtOAc and 1% TEA in hexane). A yellow-orange solid was obtained 
(4.898 g, 79%). 1H NMR (400 MHz, CDCl3) δ 5.81 (q, J = 6.5 Hz, 2H), 4.24 (t, J = 1.7 Hz, 2H), 
4.19 (t, J = 1.8 Hz, 2H), 4.14 (t, J = 1.9 Hz, 4H), 2.05 (s, 6H), 1.54 (d, J = 6.5 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ 170.44 (C=O), 88.69 (ipso Cp), 69.23 (Fc), 68.96 (Fc), 68.85 (Fc), 68.59 
(Fc), 66.63 (CH*), 21.39 (CH3), 20.27 (CH3). IR (cm
-1): 3087 (=C-H), 2997 (CH2), 2947 (CH2), 
1721 (C=O), 1445 (CH3), 1367 (OCOCH3), 836 (CH=CH), 703 (CH Ar). Mp 55 °C – 58 °C. 
Characterisation data is in agreement with the literature data. 
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6.1.35. (R,R)-1,1’-Bis-(α-N,N-dimethylaminoethyl)-ferrocene 334 
 The 1,1’-Bis-ethylacetate ferrocene 32 (2.099 g, 59 mmol) was dissolved in 
10 mL of MeOH. 10.8 mL of dimethylamine was added and stirred 
overnight at room temperature. The reaction was quenched with 20 mL of 
water and extracted with DCM (3x60 mL), dried on MgSO4, solvent removed in vacuo and 
purified via flash column chromatography (5% MeOH, 2% TEA in DCM) to yield product. A 
brown-orange oil was obtained (1.474 g, 76%). 1H NMR (300 MHz, CDCl3) δ 3.97 – 3.95 (m, 
8H), 3.49 (q, J = 7 Hz, 2H), 1.98 (s, 12H), 1.34 (d, J = 7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 
87.28 (ipso Cp), 70.31 (Fc), 68.47 (Fc), 68.22 (Fc), 67.09, 58.62 (CH*), 40.70 (CH3), 16.16 
(CH3). MS (ES) (m/z) calcd for C18H28N2
56FeNa 351.1500, found 351.1487. [α]D (c = 0.006 
g/mL, DCM) = +16.0. Characterisation data is in agreement with the literature data. 
 
6.1.36. (R,R,Sp,Sp)-1,1’-Bis-(α-N,N-dimethylaminoethyl)-2-2’-bis-bromo-ferrocene 34a 
To a stirred solution of dimethylaminoethyl ferrocene 33 (1.474 g, 4.49 
mmol) in ether, a solution of n-BuLi in hexane (7.75 mL, 17.9 mmol) was 
added drop wise over 15 min at room temperature. After few minutes, the 
colour of the mixture should have turned red. After over night stirring, the 
reaction was cooled down to -78 °C using a dry ice and acetone mix bath. A solution of 
dibromotetrachloroethane (6.584 g, 20.2 mmol) in THF was then added drop wise over 15 
min. The resulting yellow-dark suspension was allowed to warm up to room temperature 
over 90 min, stirred for 1 h and then quenched with NaS2O3 (20 mL) at 0 °C. The mixture was 
washed with water and brine and extracted with ether (30 mL), solvent removed in vacuo 
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and purified via flash column chromatography (5% MeOH, 5% TEA in DCM) to yield product. 
A brown-yellow oil was obtained (1.2 g, 55%). 1H NMR (400 MHz, Chloroform-d) δ 4.27 (t, J = 
2.0 Hz, 2H), 4.12 (s, 4H), 3.74 (q, J = 6.8 Hz, 2H), 2.12 (s, 12H), 1.47 (d, J = 6.8 Hz, 6H). 13C 
NMR (101 MHz, CDCl3) δ 88.22 (ipso Cp), 81.37 (ipso Cp), 75.63 (Fc), 68.90 (Fc), 66.89 (Fc), 
55.40 (CH*), 41.05 (CH3), 16.47 (CH3). MS (ES) (m/z) calcd for C18H26N2
56FeBr2 506.9710, 
found 506.9720.  
6.1.37. (R,R,Sp,Sp)-1,1’-Bis-(α-N,N-dimethylaminoethyl)-2,2’-bis-iodo-ferrocene 34 
In a 200 mL schlenk tube, 33 (2.01 g, 5.62 mmol) was dissolved in Et2O (30 
mL) at room temperature, n-BuLi (8.99 mL, 22.46 mmol) was added to the 
mixture at that temperature and stirred overnight under an inert 
atmosphere. The reaction mixture was cooled to -78 °C and iodine (6.41 g, 
25.27 mmol) dissolved in THF (60 mL) was added over the course of 10 min. The reaction 
was stirred at -78 °C for 90 min before allowing to warm to room temperature, at which 
point it was allowed to stirred for an additional 90 min before quenching at 0 °C with sodium 
thiosulfate(aq) (50 mL, 25% w/v). Dilute with Et2O (30 mL), the layers were separated and the 
aqueous layer was further extracted with Et2O (50 mL). The combined organic fractions were 
dried over MgSO4 solvent remove in vacuo and purified via flash column chromatography 
(55% EtOAc, 5% TEA in hexane) to yield product (2.607 g, 80%). 1H NMR (300 MHz, CDCl3) δ 
4.18 – 4.15 (m, 6H), 3.58 (q, J = 7 Hz, 2H), 2.14 (s, 12H), 1.43 (d, J = 7 Hz, 6H). 13C NMR (101 
MHz, CDCl3) δ 90.8 (ipso Cp), 82.2 (Fc), 72.2 (Fc), 67.8 (Fc), 56.9 (CH*), 47.58 (ipso Cp), 41.08 
(CH3), 15.6 (CH3). MS (ES) (m/z) calcd for C18H27N2
56FeI2 580.9613, found 580.9619 (M
+ + H). 
Mp 66 °C - 68 °C. [α]D (c = 0.0053 g/mL, DCM) = +178.8. Opposite enantiomer synthesised by 
Dr. Nguyen [α]D (c = 0.0054 g/mL, DCM) = -192.5. 
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6.1.38. (R,R,Sp,Sp)-1,1’-Bis-(α-N,N-acetoxyethyl)-2,2’-bis-iodo-ferrocene 35 
In a 100 mL schlenk tube, 34 (1.52 g, 2.49 mmol) and acetic anhydride (5 mL, 
52.99 mmol) was heated at 50 °C under an inert atmosphere for 2.5 h. The 
excess acetic anhydrides were removed under high vacuum (0.1 mm Hg). 
Purified via flash column chromatography (5% TEA in hexane) to yield 
product (1.18 g, 78%). 1H NMR (300 MHz, CDCl3) δ 5.83 (q, J = 6.5 Hz, 2H), 4.37(dd, J = 2.5, 
1.3 Hz, 2H), 4.32 (d, J = 2.5, 1.4 Hz, 2H), 4.23(t, J = 2.6 Hz, 2H), 2.04 (s, 6H), 1.63 (d, J = 6.5 Hz, 
6H). 13C NMR (101 MHz, CDCl3) δ 170.1 (C=O), 88.9 (ipso Cp), 82.2 (Fc), 73.2 (Fc), 68.6 (Fc), 
67.8 (CH*), 45.51 (ipso Cp) 21.1 (CH3), 18.8 (CH3). MS (ES) (m/z) calcd for C18H20O4
56FeI2Na 
632.8698, found 632.8689. Mp 126 °C - 128 °C.  
 
6.1.39. (R,R,Sp,Sp)-1,1’-Bis-(α-hydroxyethyl)-2,2’-bis-iodo-ferrocene 36 
In a 250 mL round bottom flask 35 (1.24 g, 2.36 mmol) was dissolved in EtOH 
(20 mL). NaOH(aq) (40 mL, 10% w/v) was added and the reaction was heated 
at 95 °C for 10 min. The reaction was allowed to cool to room temperature 
and organic layer was extracted with EtOAc (50 mL x 2). The organic layers 
were dried over Na2SO4, solvent removed in vacuo and purified via flash column 
chromatography (25% EtOAc in hexane) to yield product (1.19 g, 96%) 1H NMR (300 MHz, 
CDCl3) δ 4.78 (qd, J = 6.4, 3.9 Hz, 2H), 4.30 – 4.27 (m, 4H), 4.19 (t, J = 2.6 Hz, 2H), 2.08 (d, J = 
4.1 Hz, 2H), 1.57 (d, J = 6.5 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 92.8 (ipso Cp), 80.6 (Fc), 72.5 
(Fc), 67.2 (Fc), 65.6 (CH*), 45.0 (ipso Cp), 21.7 (CH3). MS (ES) (m/z) calcd for C14H16O2
56FeI2Na 
548.8487, found 548.8493. Mp 98 - 100 °C. [α]D (c = 0.0061 g/mL DCM) = +95.1. Opposite 
enantiomer [α]D (c = 0.0060/mL g, DCM)= -92.0. 
Fe
OH
I
I
OH
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6.1.40. (R,R,Sp,Sp)-1,1’-Bis-(α-methoxyethyl)-2,2’-bis-iodo-ferrocene 37 
In a 100 mL round bottom flask, 36 (2.12 g, 4.03 mmol) was dissolved in a 
MeOH/AcOH (20 mL, 9:1) mixture, the reaction was stirred at room 
temperature for three days. The reaction was quenched with water (10 mL) 
and extract with DCM (20 mL x 2). The combined organic fractions were 
dried over MgSO4, solvent removed in vacuo and purified via flash column chromatography 
(25% EtOAc in hexane) to yield product (2.05 g, 81%). 1H NMR (300 MHz, CDCl3) 4.43 (q, J = 
6.5 Hz, 2H), 4.30 – 4.28 (m, 2H), 4.25 – 4.23 (m, 2H), 4.17 (t, J = 2.6 Hz, 2H), 3.27 (s, 6H), 1.63 
(d, J = 6.5 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 90.8 (ipso Cp), 81.5 (Fc), 73.5 (Fc), 72.7 (Fc), 
67.4 (CH*), 56.2 (CH3), 47.1 (ipso C-I), 19.4 (CH3). MS (ES) (m/z) calcd for C16H20O2
56FeI2Na 
576.8800, found 576.8807. Mp 65 °C - 67 °C. [α]D (c = 0.0054 g/mL, DCM) = +149.6. Opposite 
enantiomer [α]D (c = 0.0054 g/mL, DCM) = -155.6. 
 
6.1.41. [(1-Ethoxyvinyl)oxy]trimethylsilane 3821 
A solution of diisopropylamine (4 g, 39.5 mol) in 30 mL of THF was added 
to a 2.5 M hexane solution of butyl Lithium (15.857 mL, 39.5 mol) at 0 °C 
and stirred for 20 min at this temperature. 3.85 mL of EtOAc (35.5 mmol) 
was then added to the mixture at -78 °C using a dry ice/acetone bath. After 30 min of 
stirring, 5.51 mL of TMSCl (43 mmol) were added to the mixture at the same temperature. 
After another 30 min, the mixture was warmed up to RT and stirred for 1 h. The solution was 
then poured into 80 mL of hexane and 40 mL of water. The organic layer was washed with 
brine and dried on MgSO4. The pale yellow oil obtained was purified using a glass oven 
O
O
Si
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(Kugelrohr) with the following conditions: 50 °C, high vacuum, 10 to 15 min. A white oil was 
collected (1.225 g, 20%). 1H NMR (300 MHz, CDCl3) δ 3.53 (q, J = 7 Hz, 2H), 2.97 (d, J = 3 Hz, 
1H), 2.83 (d, J = 3 Hz, 1H), 1.07 (t, J = 7 Hz, 3H), 1.01 (t, J = 7 Hz, 3H), 0.00 (s, 9H). The 
compound was not fully characterised for purity reasons. 
 
6.1.42. (S,S,Sp,Sp)-1,1’-Bis-[α-methyl(2-ethylpropanoate)]-2,2’-bis-iodo-ferrocene 39  
In a 250 mL schlenk tube, 37 (2.05 g, 3.92 mmol) and 1-
ethoxyvinyloxytrimethylsilane 38 (2.53 g, 15.68 mmol) were dissolved in 
DCM (100 mL). The mixture was cooled to -78 °C and BF3.OEt2 (1.11 mL, 
8.62 mmol) was added drop wise. The reaction mixture was stirred for 15 
min at -78 °C before allowing to be warmed to room temperature. Quenched with saturated 
NaHCO3 (40 mL), the organic layer was separated and the aqueous layer was further 
extracted with DCM (40 mL). The combined organic fractions were dried over MgSO4, 
solvent removed in vacuo and purified via flash column chromatography (10% EtOAc in 
hexane) to yield product (2.40 g, 92%). 1H NMR (300 MHz, CDCl3) δ 4.21 – 4.09 (m, 6H+4H), 
3.14 – 2.99 (m, 2H), 2.53 (dd, J = 15.0, 3.7 Hz, 2H), 2.12 (dd, J = 15.0, 10.1 Hz, 2H), 1.40 (d, J = 
6.8 Hz, 6H), 1.26 (t, J = 7.1 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 171.84 (C=O), 94.59 (ipso 
Cp), 81.12 (Fc), 71.78 (Fc), 66.38 (Fc), 60.30 (CH2), 46.19 (ipso Cp), 42.80 (CH2), 29.91 (CH*), 
18.84 (CH3), 14.25 (CH3). MS (ES) (m/z) calcd for C22H28O4
56FeI2Na 688.9324, found 688.9321. 
IR (cm-1): 3095 (=C-H), 2976 (CH2), 2932 (CH2), 2872 (CH2), 1724 (C=O), 1368 (CH3), 1172 
(ester), 1150 (ester), 821 (CH=CH). Mp 62 °C - 64 °C. [α]D (c = 0.0063 g/mL, DCM) = +128.9. 
Opposite enantiomer [α]D (c = 0.0064 g/mL, DCM) = -105.6. 
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6.1.43. (S,S,Sp,Sp)-1,1’-Bis-[α-methyl-(3-(hydroxyl)propyl)]-2,2’-bis-iodo-ferrocene 40 
In a 100 mL schlenk tube, 39 (2.01 g, 3.02 mmol) was dissolved in Et2O (50 
mL), cooled to 0 °C and stand for 5 min. Diisobutylalumminum hydride 
(18.1 mL, 18.12 mmol) was added to the reaction slowly at that 
temperature. The reaction was allowed to stir at 0 °C for 1 h before 
quenched with aqueous sodium potassium tartrate (30 mL). The layers were separated and 
the aqueous layer was further extract with Et2O (30 mL). The combined organic fractions 
were dried over Na2SO4, solvent remove in vacuo and purified via flash column 
chromatography (70% EtOAc in hexane) to yield product (1.56 g, 89%). 1H NMR (300 MHz, 
CDCl3) 4.16 (t, J = 2.0 Hz, 2H), 4.14 – 4.12 (m, 4H), 3.59 (t, J = 6.6 Hz, 4H), 2.76 – 2.65 (m, 2H), 
1.71 – 1.63 (m, 2H), 1.58 (s, 2H), 1.57 – 1.50 (m, 2H), 1.37 (d, J = 6.9 Hz, 6H). 13C NMR (101 
MHz, CDCl3) δ 96.29 (ipso Cp), 80.78 (Fc), 71.62 (Fc), 66.04 (Fc), 60.76 (CH2), 46.90 (ipso Cp), 
41.82 (CH2), 29.10 (CH*), 19.55 (CH3). MS (ES) (m/z) calcd for C18H24O2
56FeI2Na 604.9113, 
found 604.9108. IR (cm-1): 3406-3110 (OH), 2963, 1029. Mp 87 °C - 89 °C. [α]D (c = 0.0019 
g/mL, DCM) = +145.3. Opposite enantiomer [α]D (c = 0.0017 g/mL, DCM) = -112.9. 
 
6.1.44. (S,S,Sp,Sp)-1,1’-Bis-[α-methyl-(3-(benzyloxy)propyl)]-2,2’-bis-iodo-ferrocene 41  
In a 100 mL two necks round bottom flask filled with argon, to the 
diol 40 (1.01 g, 1.74 mmol) dissolved in DMF (20 mL) was added 
NaH (0.35 g, 8.70 mmol, 60% w/w in mineral oil) slowly. The 
reaction was stirred at room temperature for 1 h, after which it 
was quenched with water (100 mL) and extracted with Et2O (40 mL × 3). The combined 
ethereal fractions were washed with brine (60 mL), dried over MgSO4, solvent removed in 
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vacuo and purified via flash column chromatography (30% EtOAc in hexane) to yield the 
yellow oily product (1.06 g, 80%). 1H NMR δ H (300 MHz, CDCl3) 7.34 – 7.26 (m, 10H), 4.47 
(dd, J = 30.8, 11.9 Hz, 4H), 4.14 (t, J = 2.0 Hz, 2H), 4.11 – 4.08 (m, 4H), 3.49 – 3.39 (m, 4H), 
2.75 – 2.65 (m, 2H), 1.86 – 1.47 (m, 4H), 1.34 (d, J = 6.9 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 
138.65 (ipso Ph), 128.30 (Ph), 127.61 (Ph), 127.42 (Ph), 96.40 (ipso Cp), 80.81 (Fc), 72.69 
(CH2), 71.58 (Fc), 68.33 (CH2), 66.18 (Fc), 46.73 (ipso Cp), 38.35 (CH2), 29.70 (CH*), 19.48 
(CH3). IR (cm
-1): 2930 (CH2), 2854 (CH2), 1092. MS (ES) (m/z) calcd for C32H36O2
56FeI2Na 
785.0052, found 785.0055.  
 
6.1.45. (S,S,Sp,Sp)-1,1’-Bis-[α-methyl-(3-(benzyloxy)propyl)]-2,2’-bis-aldehyde-ferrocene 42  
In a 100 mL schlenk tube, 41 (0.80 g, 1.05 mmol) was dissolved in 
Et2O (30 mL), the mixture was cooled to -78 °C and n-BuLi (1.47 mL, 
3.66 mmol) was added. After 30 min DMF (0.34 mL, 4.40 mmol) 
was added and the reaction was stirred at -78 °C for another 30 
min before allowing to warm to room temperature, at which point it was quenched with 
water (10 mL). The phrases were separated and the aqueous layer was extracted with 
further Et2O (10 mL). The combined ethereal fractions were dried over Na2SO4, solvent 
removed in vacuo and purified via flash column chromatography (2% EtOAc in hexane) to 
yield the red oily product (0.54 g, 91%). 1H NMR (400 MHz, Chloroform-d) δ 10.04 (s, 2H), 
7.37 – 7.26 (m, 10H), 4.82 (t, J = 2.1 Hz, 2H), 4.49 – 4.47 (m, 4H), 4.46 – 4.31 (dd, J = 30.7, 
11.8 Hz, 4H), 3.38 – 3.28 (m, 4H), 3.12 (h, J = 6.8 Hz, 2H), 1.74 – 1.58 (m, 4H), 1.36 (d, J = 6.9 
Hz, 6H). 13C NMR δ 193.1 (C=O), 138.3 (ipso Ph), 128.4 (Ph), 127.8 (Ph), 127.6 (Ph), 99.4 (ipso 
Cp), 77.7 (ipso Cp), 72.9 (CH2), 72.7 (Fc), 72.0 (Fc), 71.5 (Fc), 67.8 (CH2), 39.9 (CH2), 27.6 
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(CH*), 19.4 (CH3). MS (ES) (m/z) calcd for C34H38O4
56FeNa 589.2017, found 589.2024. IR (cm-
1): 2928 (CH2), 2864 (CH2), 1716 (CHO), 1097 (ether).  
 
6.1.46. (S,S,Rp,Rp)- 1,1’-Bis-[α-methyl-(3-(benzyloxy)propyl)]-2,2’-bis-[(Z)-2-((N,N-6-
dibenzoyl)-adenin-9-yl))ethylenyl]-ferrocene 43 
In a 100 mL schlenk tube, 6 (0.768 g, 1.37 mmol) was dissolved in 3 
mL of pyridine. The mixture was evaporated on high vacuum. The 
mixture was then dissolved in 12 mL of dry DMF and NaH (0.035 g, 
0.137 mmol) was added in one portion at room temperature. The 
solution was stirred for 2 h. The aldehyde 42 was dissolved in 7 mL 
of DMF and added to the mixture, which was stirred overnight at 
room temperature. The reaction was quenched with 60 mL of a 1:1 EtOAc /water mixture. 
The phrases were separated and the aqueous layer was extracted with further Et2O. The 
combined ethereal fractions were dried over Na2SO4, solvent removed in vacuo and purified 
via flash column chromatography (30% EtOAc, 20% Et2O in hexane) to yield product (0.25 g, 
43%). 1H NMR (400 MHz, CDCl3) δ 8.70 (s, 2H), 8.02 (s, 2H), 7.87 (d, J = 7.0 Hz, 8H), 7.47 (t, J = 
7.5 Hz, 4H), 7.35 (t, J = 7.8 Hz, 8H), 7.31 – 7.19 (m, 10H), 6.90 (d, J = 8.8 Hz, 2H), 6.43 (d, J = 
8.9 Hz, 2H), 4.49 – 4.37 (m, 4H), 4.08 (dd, J = 2.6, 1.3 Hz, 2H), 4.01 (t, J = 2.6 Hz, 2H), 3.41 – 
3.27 (m, 4H), 3.24 – 3.19 (m, 2H), 2.70 – 2.59 (m, 2H), 1.65 – 1.52 (m, 4H), 1.12 (d, J = 6.8 Hz, 
6H). 13C NMR (101 MHz, CDCl3) δ 172.24 (C=O), 152.98 (ipso adenine), 152.79 (CH adenine), 
151.89 (ipso adenine), 144.13 (CH adenine), 138.33 (ipso Ph), 134.20 (ipso Bz), 132.93 (Bz), 
129.45 (Bz), 128.68 (Bz), 128.37 (Ph), 127.58 (Ph), 127.01 (ipso adenine), 123.78 (=CH), 
116.60 (=CH), 97.49 (ipso Cp), 72.96 (ipso Cp), 69.92 (Fc), 69.29 (Fc), 67.82 (CH2), 67.29 (Fc), 
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39.76 (CH2), 27.93 (CH*), 19.27 (CH3). MS (ES) (m/z) calcd for C74H64N10O6
56FeNa 1267.4257, 
found 1267.4255. IR (cm-1): 3063 (=CH Fc), 2961 (CH2), 2925 (CH2), 2853 (CH2), 1698 (C=O), 
1596 (Amide), 1575 (C=N), 1449 (CH2), 1091 (ether), 1073 (ether), 824 (CH Ar), 699 (C=C). 
Mp 84 °C - 86 °C. 
 
6.1.47. (S,S,Sp,Sp)-1,1’-Bis-[α-methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2,2’-bis-iodo-
ferrocene 44 
In a 100 mL schlenk tube, the diol 40 (1.2 g, 2.06 mmol) was dissolved 
in 20 mL DCM at room temperature. TEA (0.861 mL, 6.18 mmol), tert-
Butyldiphenylsilyl chloride (1.607 mL, 6.18 mmol) and DMAP in 
catalytic amount were added successively to the mixture. The solution 
was stirred overnight at room temperature and quenched with water. The phrases were 
separated and the aqueous layer was extracted with further Et2O. The combined ethereal 
fractions were dried over Na2SO4, solvent removed in vacuo and purified via flash column 
chromatography (10% EtOAc in hexane) to yield the oily yellow product (2 g, 95%). 1H NMR 
(400 MHz, CDCl3) δ 7.67 (m, 8H), 7.42 – 7.33 (m, 12H), 4.12 (t, J = 1.8 Hz, 2H), 4.06 – 4.01 (m, 
4H), 3.66 (dd, J = 7.7, 5.6 Hz, 4H), 2.74 – 2.69 (m, 2H), 1.85 – 1.80 (m, 2H), 1.37 – 1.26 (m, 
2H), 1.27 (d, J = 6.9 Hz, 6H), 1.05 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 135.64 (Ph), 134.06 
(ipso Ph), 134.01 (Ph), 129.50 (Ph), 127.60 (Ph), 96.62 (ipso Cp), 80.28 (Fc), 71.16 (Fc), 66.12 
(Fc), 61.97 (CH2), 46.67 (ipso Cp), 41.26 (CH2), 29.06 (CH*), 26.95 (tBu), 19.24 (ipso tBu), 
18.72 (CH3). MS (ES) (m/z) calcd for C50H60O2
56FeI2Si2Na 1081.1469, found 1081.1481. IR (cm
-
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1): 3071 (=CH Fc), 2958 (CH2), 2930 (CH2), 2856 (CH2), 1589, 1471, 1427 (CH2), 1387 (tBu), 
1106 (Si-OR), 1084 (Si-OR), 821 (CH Ar), 699 (C=C). [α]D (c = 0.0056 g/mL, DCM) = +84.3. 
 
6.1.48. (S,S,Sp,Sp)-1,1’-Bis-[α-methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2,2’-bis-aldehyde-
ferrocene 45 
In a 100 mL schlenk tube, 44 (2 g, 1.94 mmol) was dissolved in Et2O (40 
mL), the mixture was cooled to -78 °C and n-BuLi (2.27 mL, 6.82 mmol) 
was added. After 30 min DMF (0.63 mL, 8.20 mmol) was added and the 
reaction was stirred at -78 °C for another 30 min before allowing too 
warm to room temperature, at which point it was quenched with water (20 mL). The phrases 
were separated and the aqueous layer was extracted with further Et2O (20 mL). The 
combined ethereal fractions were dried over Na2SO4, solvent removed in vacuo and purified 
via flash column chromatography (20% EtOAc in hexane) to yield the red oily product (1.31 g, 
78%). 1H NMR (400 MHz, CDCl3) δ 10.04 (s, 2H), 7.65 – 7.59 (m, 8H), 7.45 – 7.32 (m, 12H), 
4.78 (dd, J = 2.7, 1.5 Hz, 2H), 4.44 – 4.40 (m, 4H), 3.64 – 3.52 (m, 4H), 3.16 – 3.02 (m, 2H), 
1.68 – 1.62 (m, 2H), 1.55 – 1.48 (m, 2H), 1.28 (d, J = 6.9 Hz, 6H), 1.03 (s, 18H). 13C NMR (101 
MHz, CDCl3) δ 192.85 (C=O), 135.55 (Ph), 133.81 (ipso Ph), 133.70 (ipso Ph), 129.58 (Ph), 
127.63 (Ph), 99.78 (ipso Cp), 76.69 (ipso Cp), 72.41 (Fc), 72.08 (Fc), 71.52 (Fc), 61.56 (CH2), 
43.04 (CH2), 27.40 (CH*), 26.86 (tBu), 19.13 (ipso tBu), 18.67 (CH3). MS (ES) (m/z) calcd for 
C52H62O4
56FeSi2Na 885.3434, found 885.3444. IR (cm
-1): 3071 (=CH Fc), 2930 (CH2), 2857 
(CH2), 1673 (CHO), 1427 (CH2), 1378 (tBu), 1106 (Si-OR), 1085 (Si-OR), 822 (CH Ar), 699 (C=C).  
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6.1.49. (S,S,Rp,Rp)-1,1’-Bis-[α-methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2,2’-bis-vinyl-
ferrocene 46 
In a 100 mL schlenk tube, trimethylmethylphosphonium bromide 
(1.293 g, 3.62 mmol), potassium tert-butoxide (0.406, 3.62 mmol) and 
a catalytic amount of dibenzo-18-crown-6-ether were dissolved in 25 
mL of dry THF. The mixture was stirred for 30 min and 45 (1.042 g, 1.21 
mmol) previously dissolved in 30 mL of dry THF was added. The reaction was stirred 
overnight at room temperature, quenched with water and extracted with Et2O (20 mL). The 
combined ethereal fractions were dried over Na2SO4, solvent removed in vacuo and purified 
via flash column chromatography (10% EtOAc in hexane) to yield the yellow oily product 
(1.017 g, 98%). 1H NMR (400 MHz, CDCl3) δ 7.72 – 7.59 (m, 8H), 7.44 – 7.32 (m, 12H), 6.48 
(dd, J = 17.4, 10.8 Hz, 2H), 5.25 (dd, J = 17.4, 1.7 Hz, 2H), 5.08 (dd, J = 10.8, 1.7 Hz, 2H), 4.20 – 
4.18 (m, 2H), 4.04 – 4.01 (m, 4H), 3.63 – 3.59 (m, 4H), 2.87 – 2.82 (m, 2H), 1.72 – 1.61 (m, 
2H), 1.36 – 1.30 (m, 2H), 1.25 (d, J = 6.9 Hz, 6H), 1.05 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 
135.58 (Ph), 134.08 (ipso Ph), 134.00 (ipso Ph), 132.82 (CH vinyl), 129.49 (Ph), 127.57 (Ph), 
111.04 (CH2 vinyl), 94.55 (ipso Cp), 82.30 (ipso Cp), 67.86 (Fc), 67.57 (Fc), 66.41 (Fc), 61.79 
(CH2), 42.62 (CH2), 26.86 (tBu), 26.67 (CH*), 19.21 (ipso tBu), 18.43 (CH3). MS (ES) (m/z) calcd 
for C54H66O2
56FeSi2 858.3951, found 858.3973. IR (cm
-1): 3071 (=CH Fc), 2929 (CH2), 2858 
(CH2), 1624 (Ar), 1589, 1427 (CH2), 1276 (CH3), 1106 (Si-OR), 1086 (Si-OR), 821 (CH Ar), 699 
(vinyl/C=C). 
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6.1.50. (S,S,Rp,Rp)-1,1’-Bis-[α-methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2,2’-bis-[2-
(hydroxyl)ethyl]-ferrocene 47 
In a 100 mL schlenk tube, 46 (1 g, 1.165 mmol) was dissolved in 30 mL 
of dry THF. BH3,THF (6.61 mL, 0.661 mmol) was then added drop wise 
at room temperature and stirred for 2 h. 1.5 mL of EtOH, 1.5 mL of 
NaOH (3M) and 1.1 mL of H2O2 (30%) were then successively added to 
the reaction and stirred for 1h at room temperature. The reaction was extracted with DCM, 
washed with brine and dried over Na2SO4, solvent removed in vacuo and purified via flash 
column chromatography (30% EtOAc in hexane) to yield product (0.814 g, 78%). 1H NMR 
(400 MHz, CDCl3) δ 7.68 – 7.63 (m, 8H), 7.45 – 7.35 (m, 12H), 3.94 (s, 2H), 3.89 (s, 4H), 3.73 – 
3.61 (m, 4H+4H), 2.69 – 2.65 (m, 2H), 2.53 (t, J = 6.7 Hz, 4H), 1.71 – 1.68 (m, 2H), 1.40 – 1.20 
(m, 2H), 1.21 (d, J = 6.7 Hz, 6H), 1.06 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 135.61 (Ph), 
133.94 (ipso Ph), 129.60 (Ph), 127.64 (Ph), 94.66 (ipso Cp), 82.51 (ipso Cp), 70.58 (Fc), 67.39 
(Fc), 65.93 (Fc), 63.11 (CH2), 61.98 (CH2), 42.61 (CH2), 30.73 (CH2), 27.29 (CH*), 26.92 (tBu), 
19.51 (CH3), 19.23 (ipso tBu). MS (ES) (m/z) calcd for C54H70O4
56FeSi2Na 917.4060, found 
917.4020. IR (cm-1): 3309 (OH), 3071 (=CH Fc), 2929 (CH2), 2858 (CH2), 1599 (Ar system), 
1566, 1427 (CH2), 1106 (Si-OR), 1077 (Si-OR), 739 (CH-Ar), 699 (C=C). Mp 106 °C - 107 °C. [α]D 
(c = 0.0066 g/mL, DCM) = -7.80. 
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6.1.51. (S,S,Rp,Rp)-1,1’-Bis-[α-methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2-2’-bis-[2-((N,N-6-
dibenzoyl)-adenin-9-yl)ethyl]-ferrocene 48 
In a 50 mL schlenk tube, triphenylphosphine (0.309 g, 1.176 mmol) 
and the N,N-6-benzoyl-adenine 19 (0.350 g, 1.101 mmol) were 
dissolved in dry THF and stirred for 10 min at room temperature. 47 
(0.351 g, 0.392 mmol) was then added to the mixture pre-dissolved 
in 7 mL of dry THF. The schlenk tube was then covered with foil and 
DIAD (0.240 mL, 1.176 mmol) was added at room temperature 
before the mixture was warmed up to 65 °C for 2 h. The reaction was evaporated, extracted 
with EtOAc, washed with brine followed by water and dried over Na2SO4, solvent removed in 
vacuo and purified via flash column chromatography (40% EtOAc in hexane) to yield product 
(0.311 g, 52%). 1H NMR (400 MHz, CDCl3) δ 8.54 (s, 2H), 7.86 (d, J = 7.1 Hz, 8H), 7.77 (s, 2H), 
7.63 – 7.54 (m, 8H), 7.44 (t, J = 7.5 Hz, 4H), 7.36 – 7.26 (m, 20H), 4.28 – 4.09 (m, 4H), 3.96 – 
3.91 (m, 2H), 3.82 (t, J = 2.5 Hz, 2H), 3.66 (dd, J = 7.5, 5.3 Hz, 4H), 3.47 (t, J = 1.7 Hz, 2H), 2.86 
– 2.75 (m, 4H), 2.67 – 2.59 (m, 2H), 1.66 – 1.58 (m, 2H), 1.46 – 1.42 (m, 2H), 1.23 (d, J = 6.8 
Hz, 6H), 1.00 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 172.27 (C=O), 153.14 (ipso adenine), 
152.11 (CH adenine), 151.62 (ipso adenine), 144.96 (CH adenine), 135.53 (Ph), 134.22 (ipso 
Ph), 133.71 (ipso Bz), 132.87 (Bz), 129.65 (Ph), 129.46 (Bz), 128.65 (Bz), 127.65 (Ph), 127.35 
(ipso adenine), 94.83 (ipso Cp), 80.95 (ipso Cp), 69.74 (Fc), 67.97 (Fc), 66.66 (Fc), 61.97 (CH2), 
44.68 (CH2), 42.88 (CH2), 28.26 (CH2), 27.28 (CH*), 26.85 (tBu), 19.97 (CH3), 19.16 (ipso tBu). 
MS (ES) (m/z) calcd for C92H92N10O6
56FeSi2Na 1567.5987, found 1567.5985. IR (cm
-1): 3070 
(=CH Fc), 2931 (CH2), 2857 (CH2), 1704 (C=O), 1598 (amide), 1575 (C=N), 1448 (CH2), 1235 
(CH3), 1106 (Si-OR), 1087 (Si-OR), 699 (C=C). Mp 92 °C - 94 °C. [α]D (c = 0.0051 g/mL, DCM) = -
25.1. 
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6.1.52. (S,S,Rp,Rp)-1,1’-Bis-[α-methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2-2’-bis-[2-((N-4-
benzoyl)-uracil-1-yl)ethyl]-ferrocene 49 
In a 50 mL schlenk tube, triphenylphosphine (0.148 g, 0.563 mmol) 
and N-3-benzoyluracil 20 (0.105 g, 0.4879 mmol) were dissolved in 
dry THF and stirred for 10 min at room temperature. 47 (0.168 g, 
0.187 mmol) was then added to the mixture pre-dissolved in 4 mL of 
dry THF. The schlenk tube was then covered with foil and DIAD (0.122 
mL, 0.563 mmol) was added at room temperature before the mixture 
was warmed up to 65 °C for 2 h. The reaction was evaporated, extracted with EtOAc, washed 
with brine followed by water and dried over Na2SO4, solvent removed in vacuo and purified 
via flash column chromatography (50% EtOAc in hexane) to yield product (0.180 g, 75%). 1H 
NMR (400 MHz, CDCl3) δ 7.82 (d, J = 7.1 Hz, 4H), 7.57 – 7.49 (m, 10H), 7.38 (t, J = 7.8 Hz, 4H), 
7.35 – 7.29 (m, 4H), 7.29 – 7.23  (m, 8H), 6.79 (d, J = 8.0 Hz, 2H), 5.45 (d, J = 7.9 Hz, 2H), 3.90 
– 3.84 (m, 2H), 3.78 (t, J = 2.5 Hz, 2H), 3.71 – 3.61 (m, 6H), 3.57 – 3.54 (m, 4H), 2.67 – 2.51 
(m, 6H), 1.57 – 1,52 (m, 2H), 1.40 – 1.29 (m, 2H), 1.16 (d, J = 1.6 Hz, 6H), 0.94 (s, 18H). 13C 
NMR (101 MHz, CDCl3) δ 168.90 (C=O Bz), 162.47 (C=O uracil), 149.66 (C=O uracil), 144.29 
(CH uracil), 135.52 (Ph), 135.14 (Bz), 133.89 (ipso Ph), 133.76 (ipso Ph), 131.45 (ipso Bz), 
130.50 (Ph), 129.74 (Bz), 129.18 (Bz), 127.72 (Ph), 101.78 (CH uracil), 94.46 (ipso Cp), 81.03 
(ipso Cp), 70.27 (Fc), 68.14 (Fc), 66.34 (Fc), 61.88 (CH2), 49.55 (CH2), 42.77 (CH2), 27.28 (CH*), 
27.11 (CH2), 26.92 (tBu), 19.89 (CH3), 19.26 (ipso tBu). MS (ES) (m/z) calcd for 
C76H82N4O8Si2Fe
56Na 1313.4918, found 1313.4945. IR (cm-1): 3071 (=CH Fc/CONH), 2930 
(CH2), 2857 (CH2), 1747 (C=C-C=O), 1704 (C=O), 1660 (amide), 1428 (CH2), 1382 (CH3), 1107 
(Si-OR), 1084 (Si-OR), 700 (C=C). Mp 84 °C - 86 °C. [α]D (c = 0.0067 g/mL, DCM) = -9.6. 
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6.1.53. (S,S,Rp,Rp)-1,1’-Bis-[α-methyl-(3-(hydroxy)propyl)]-2-2’-bis-[2-((N-6-benzoyl)-adenin-
9-yl)ethyl]-ferrocene 50 
In a 50 mL schlenk tube, 48 (0.5 g, 0.322 mmol) was dissolved in 20 
mL of dry THF and Tetra-Butylamino fluoride (0.305 g, 0.967 mmol) 
was added to the solution. After overnight stirring, the reaction 
was quenched with water, extracted with DCM, washed with brine, 
water and dried over Na2SO4. The solvent was removed in vacuo 
and the crude was purified via flash column chromatography (2% 
MeOH in DCM) to yield product (0.259 g, 92%). 1H NMR (400 MHz, CDCl3) δ 9.35 (s, 2H), 8.72 
(s, 2H), 8.03 (d, J = 7.3 Hz, 4H), 7.98 (s, 2H), 7.58 (t, J = 6.7 Hz, 2H), 7.49 (t, J = 6.7 Hz, 4H), 
4.38 – 4.23 (m, 4H), 4.04 (dd, J = 2.4, 1.2 Hz, 2H), 3.96 (t, J = 2.5 Hz, 2H), 3.78 – 3.73 (m, 2H), 
3.68 – 3.57 (m, 4H), 3.17 (s, 2H), 3.01 – 2.94 (m, 2H), 2.87 – 2.78 (m, 4H), 1.62 – 1.46 (m, 4H), 
1.35 (d, J = 6.7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 164.83 (C=O), 152.41 (CH adenine), 
151.63 (ipso adenine), 149.71 (ipso adenine), 143.13 (CH adenine), 133.54 (ipso Bz), 132.78 
(Bz), 128.80 (Bz), 127.97 (Bz), 122.95 (ipso adenine), 94.81 (ipso Cp), 81.10 (ipso Cp), 70.41 
(Fc), 68.08 (Fc), 66.20 (Fc), 59.99 (CH2), 45.16 (CH2), 43.47 (CH2), 28.60 (CH2), 26.70 (CH*), 
19.96 (CH3). MS (ES) (m/z) calcd for C46H48N10O4
56FeNa 883.3107, found 883.3100. IR (cm-1): 
3266 (OH), 3070 (=CH Fc), 2931 (CH2), 2857 (CH2), 1694 (C=O), 1608 (amide), 1580 (C=N), 
1452 (CH2), 1246 (CH3), 1030 (Si-OR), 796 (CH Ar), 706 (C=C).  Mp 122 °C - 125 °C. 
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6.1.54. (S,S,Rp,Rp)-1,1’-Bis-[α-methyl-(3-(hydroxy)propyl)]-2-2’-bis-[2-((N-4-benzoyl)-uracil-1-
yl)ethyl]-ferrocene 51 
In a 50 mL schlenk tube, 49 (0.198 g, 0.153 mmol) was dissolved in 20 
mL of dry THF and Tetra-Butylamino fluoride (0.145 g, 0.459 mmol) 
was added to the solution. After overnight stirring, the reaction was 
quenched with water, extracted with DCM, washed with brine, water 
and dried over Na2SO4. The solvent was removed in vacuo and the 
crude was purified via flash column chromatography (7% MeOH in DCM) to yield the oily 
product (0.025 g, 34%). 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 7.1 Hz, 4H), 7.66 (t, J = 7.5 Hz, 
2H), 7.51 (t, J = 7.8 Hz, 4H), 7.31 (d, J = 7.9 Hz, 2H), 5.72 (d, J = 7.9 Hz, 2H), 4.03 (s, 2H), 3.96 
(s, 2H), 3.90 – 3.77 (m, 4H+2H), 3.56 (dd, J = 7.0, 4.7 Hz, 4H), 2.79 (t, J = 7.9 Hz, 4H+2H), 1.60 
– 1.41 (m, 4H), 1.33 (d, J = 6.7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 168.94 (C=O), 162.40 
(C=O), 150.03 (C=O), 144.53 (CH uracil), 135.30 (Bz), 131.32  (ipso Bz), 130.52 (Bz), 129.26 
(Bz), 102.21 (CH uracil), 94.63 (ipso Cp), 81.10 (ipso Cp), 70.93 (Fc), 68.39 (Fc), 65.98 (Fc), 
60.21 (CH2), 50.02 (CH2), 43.13 (CH2), 27.24 (CH2), 26.84 (CH*), 19.67 (CH3). MS (ES) (m/z) 
calcd for C44H46N4O8Fe
56Na 837.2563, found 837.2559. IR (cm-1): 3387 (OH), 3088 (=CH Fc), 
2930 (CH2), 2871 (CH2), 1734 (C=C-C=O), 1693 (C=O), 1641 (amide), 1597 (C=N), 1439 (CH2), 
1348 (CH3), 788 (CH Ar), 687 C=C). Mp 138 °C - 142 °C. 
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6.1.55. (S,S,Rp,Rp)-1,1’-Bis-[α-methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2,2’-bis-[2-
(bromo)ethyl]-ferrocene 52 
In a 100 mL schlenk tube, NBS (0.483 g, 2.714 mmol) was suspended in 
dry DCM. A DCM solution of triphenylphosphine (0.682 g, 2.533 mmol) 
was added drop wise to it. The resulting orange mixture was stirred for 5 
min before addition of 0.109 mL (1.805 mmol) of pyridine. The mixture 
goes brown. 47 (0.405 g, 0.452 mmol) dissolved in 5 mL of dry DCM was 
added to the mixture. After overnight reaction, the solvent was removed in vacuo and the 
crude was purified via flash column chromatography (3% EtOAc in hexane) to yield the 
yellow-brown oily product (0.450 g, 97%). 1H NMR (400 MHz, CDCl3) δ 7.68 – 7.63 (m, 8H), 
7.45 – 7.36 (m, 12H), 3.94 – 3.89 (m, 4H), 3.87 (t, J = 2.5 Hz, 2H), 3.66 – 3.58 (m, 4H), 3.46 – 
3.33 (m, 4H), 2.95 – 2.78 (m, 4H), 2.71 – 2.63 (m, 2H), 1.68 – 1.60 (m, 2H), 1.38 – 1.22 (m, 
2H), 1.22 (d, J = 6.8 Hz, 6H), 1.07 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 135.61 (Ph), 133.91 
(ipso Ph), 133.82 (ipso Ph), 129.62 (Ph), 127.67 (Ph), 94.43 (ipso Cp), 83.16 (ipso Cp), 70.18 
(Fc), 67.42 (Fc), 66.15 (Fc), 61.72 (CH2), 42.76 (CH2), 31.63 (2xCH2), 27.21 (CH*), 26.97 (tBu), 
19.50 (CH3), 19.22 (ipso tBu). MS (ES) (m/z) calcd for C54H68O2
56FeSi2
79Br81BrNa 1020.2454, 
found 1020.2458. IR (cm-1): 3070 (=CH Fc), 2958 (CH2), 2930 (CH2), 2856 (CH2), 1589, 1575, 
1472, 1427 (CH2), 1235 (CH3), 1105 (Si-OR), 1085 (Si-OR), 822 (CH Ar), 699 (C=C).  
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6.1.56. (S,S,Rp,Rp)-1,1’-Bis-[α-methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2-2’-Bis-[2-((N-4-
benzoyl)-cytosin-1-yl)ethyl]-ferrocene 53  
In a 50 mL schlenk tube, 21 (0.126 g, 0.588 mmol) was stirred 
vigorously in suspension in 2 mL of DMF for 5 min. NaH (0.014 g, 
0.588 mmol) was added to the mixture in one portion and stirred 
for 1 h. At this point the solution was clear. 52 (0.2 g, 0.196 mmol) 
was dissolved in 1 mL of DMF and added to the mixture. After 
overnight stirring at 50 °C, the reaction was quenched with water, 
extracted with chloroform, dried on MgSO4. The solvent was removed in vacuo and the 
crude was purified via flash column chromatography (2% MeOH in DCM) to yield product 
(0.039 g, 16%). 1H NMR (400 MHz, CDCl3) δ 8.71 (s, 2H), 7.90 (d, J = 7.7 Hz, 4H), 7.70 – 7.56 
(m, 10H), 7.50 (t, J = 8.0 Hz, 4H), 7.44 – 7.29 (m, 14H), 7.20 (d, J = 7.0 Hz, 2H), 4.05 – 3.97 (m, 
2H), 3.96 (s, 2H), 3.88 (s, 2H), 3.78 (s, 2H), 3.74 (m, 2H), 3.75 (t, J = 5.7 Hz, 4H), 2.82 (s, 2H), 
2.72 – 2.59 (m, 4H), 1.67 – 1.42 (m, 2H), 1.25 (d, J = 6.9 Hz, 6H), 1.02 (s, 18H). 13C NMR (101 
MHz, CDCl3) δ 166.19 (ipso C-N), 162.09 (C=O Bz), 155.49 (C=O cytosine), 149.11 (CH 
cytosine), 135.55 (Ph), 133.88 (ipso Ph), 133.81 (ipso Bz), 133.05 (Bz), 129.70 (Bz), 128.98 
(Ph), 127.70 (Bz), 127.61 (Ph), 96.20 (CH cytosine), 94.67 (ipso Cp), 81.65 (ipso Cp), 70.59 
(Fc), 68.19 (Fc), 66.55 (Fc), 61.99 (CH2), 51.41 (CH2), 42.68 (CH2), 27.32 (CH*), 26.91 (tBu), 
20.07 (CH3), 19.20 (ipso tBu). MS (ES) (m/z) calcd for C76H85N6O656Fe 1289.5419, found 
1289.5415 (M+H+). IR (cm-1): 3071 (=CH Fc), 2958 CH2), 2930 (CH2), 2856 (CH2), 1661 (C=O), 
1625 (C=N), 1552 (Amide), 1482 (C=N), 1427 (CH2), 1361 (tBu), 1236 (Si-tBu), 1106 (Si-OR), 
1086 (Si-OR), 822 (CH Ar), 700 (C=C). Mp 86 °C - 88 °C. 
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6.1.57. 1-Acyl-ferrocene 545 
The compound was not synthesised but was recovered from previous work 
done within the group. It was characterised to check its purity. 1H NMR (300 
MHz, Chloroform-d) δ 4.81 – 4.74 (m, 2H), 4.54 – 4.48 (m, 2H), 4.21 (s, 5H), 
2.40 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 202.11 (C=O), 79.29 (ipso Cp), 72.35 (Fc), 69.88 (Fc), 
69.62 (Fc), 27.45 (CH3). Mp 82 °C - 86 °C. Characterisation data is in agreement with the 
literature data. 
 
6.1.58. (R)-1-(α-Hydroxyethyl)-ferrocene 552 
A solution of (S)-CBS (1.82 g, 6.57 mmol) in THF was cooled down to 0 °C 
under argon. To this solution, BH3.SMe2 (11.066 mL) was added in two steps. 
First, 2.2 mL were added to the mixture to form the catalyst system. The 
solution was stirred for 5-10 min. Then 8.85 mL of BH3.SMe2 were added simultaneously 
with a solution of ketone-ferrocene 54 (5 g, 21.9 mmol) in THF (50 mL) drop wise using a 
cannula. After 30 min of stirring at 0 °C, the excess of BH3.SMe2 was carefully quenched with 
MeOH (25 mL, gas evolution). The crude was poured into 100 mL of NH4
+Cl-, washed with 
ether, water, brine and dried on Na2SO4. The solvent was removed in vacuo and the crude 
was purified via flash column chromatography (75% Et2O in hexane) to yield product (4.29 g, 
85%). 1H NMR (400 MHz, CDCl3) δ 4.55 (q, J = 6.3 Hz, 1H), 4.22 (d, J = 5.3 Hz, 2H), 4.19 (s, 5H), 
4.16 (t, J = 1.9 Hz, 2H), 1.44 (d, J = 6.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 94.82 (ipso Cp), 
68.30 (Fc), 67.89 (Fc), 66.09 (Fc), 65.59 (C*H), 23.73 (CH3). MS (ES) (m/z) calcd for 
C12H14O
56Fe 230.0394, found 230.0389. Mp melt at 82 °C - 84 °C. [α]D (c = 0.0053 g/mL, DCM) 
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= +21.9. Opposite enantiomer [α]D (c = 0.0052 g/mL, DCM) = -22.3. Characterisation data is in 
agreement with the literature data. 
 
6.1.59. (R)-1-(α-Acetoxyethyl)-ferrocene 562 
The diol 55 (5.49 g, 23.8 mmol) was dissolved in dry DCM (60 mL) and stirred 
for 5 min. Then 3.37 mL (3.65 g, 35.8 mmol) of acetic anhydride, 4.99 mL 
(3.62 g, 35.8 mmol) of TEA and catalytic amount of DMAP were added 
successively. The reaction was stirred at room temperature overnight. After completion of 
the reaction, it was quenched with NaHCO3 (50 mL) and extracted with DCM. The aqueous 
layer was washed with DCM (60 mL x 3) and then dried on Mg2SO4 and evaporated. The 
solvent was removed in vacuo and the crude was purified via flash column chromatography 
(25% EtOAc in hexane) to yield the yellow-orange product (5.61 g, 86%). 1H NMR (400 MHz, 
CDCl3) δ 5.83 (q, J = 6.5 Hz, 1H), 4.26 (dt, J = 2.7, 1.4 Hz, 1H), 4.22 (dt, J = 2.7, 1.5 Hz, 1H), 
4.18 – 4.13 (m, 5H+2H), 2.03 (s, 3H), 1.56 (d, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
170.51 (C=O), 87.92 (ipso Cp), 68.91 (Fc), 68.73 (Fc), 68.39 (Fc), 68.34 (Fc), 67.99 (Fc), 66.00 
(CH*), 21.43 (CH3), 19.99 (CH3). MS (ES) (m/z) calcd for C14H16O2
56Fe 272.0500, found 
272.0497. IR (cm-1): 3087 (=C-H), 2998 (CH2), 2982 (CH2), 2940 (CH2), 1724 (C=O), 1441 (CH3), 
1366 (ester), 825 (CH=CH), 722 (CH Ar). Mp 76 °C - 78 °C. [α]D (c = 0.0064 g/mL, DCM) = 
+41.3. Opposite enantiomer [α]D (c = 0.0066 g/mL, DCM)  = -38.2. Characterisation data is in 
agreement with the literature data. 
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6.1.60. (R)-1-(α-N,N-Dimethylaminoethyl)-ferrocene 572 
The (ethylacetate)-ferrocene 56 (5.61 g, 20.6 mmol) was dissolved in 40 mL 
of MeOH. 37.86 mL of dimethylamine were added and the mixture was 
stirred overnight at room temperature. The reaction was quenched with 20 
mL of water and extracted with DCM (40 mL x 3), dried on MgSO4 and evaporated. The 
solvent was removed in vacuo and the crude was purified via flash column chromatography 
(5% MeOH, 5% TEA in DCM) to yield a brown-orange oil (4.027 g; 76%). 1H NMR (400 MHz, 
CDCl3) δ 4.15 – 4.09 (m, 9H), 3.59 (q, J = 6.9 Hz, 1H), 2.08 (s, 6H), 1.45 (d, J = 6.8 Hz, 3H).
 13C 
NMR (101 MHz, CDCl3) δ 87.28 (ipso Cp), 69.36 (Fc), 68.57 (Fc), 67.33 (Fc), 67.19 (Fc), 66.87 
(Fc), 58.64 (CH*), 40.72 (NCH3), 16.11 (CH3). IR (cm
-1): 3426 (amine), 3082 (=C-H), 2990 (CH2), 
2930 (CH2), 1461 (CH3), 1381 (CH3), 819 (CH=CH). MS (ES) (m/z) calcd for C14H19N
56Fe 
257.0867, found 257.0857. Mp 120 °C - 122 °C. Characterisation data is in agreement with 
the literature data. 
 
6.1.61. Side product: (R)-1-(α-Methoxyethyl)-ferrocene 57a20 
 1H NMR (400 MHz, Chloroform-d) δ 4.23 – 4.16 (m, 4H), 4.12 (s, 6H), 3.24 (s, 
3H), 1.53 (d, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 89.12 (ipso Cp), 
74.97 (Fc), 68.66 (Fc), 68.01 (Fc), 67.72 (Fc), 65.81 (CH*), 55.71 (CH3), 20.16 
(CH3). Characterisation data is in agreement with the literature data. 
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6.1.62. (R,Sp)-1-(α-N,N-Dimethylaminoethyl)-2-iodo-ferrocene 58 
In a 200 mL schlenk tube, 57 (4 g, 15 mmol) was dissolved in Et2O (50 mL) at 
room temperature, n-BuLi (12 mL, 30 mmol) was added to the mixture at that 
temperature and stirred overnight under an inert atmosphere. The reaction 
mixture was cooled to -78 °C and Iodine (9.52 g, 37.5 mmol) dissolved in THF (60 mL) was 
added over the course of 10 min. The reaction was stirred at -78 °C for 90 min before 
allowing to warm to room temperature, at which point it was allowed to stirred for an 
additional 90 min before quenching at 0 °C with sodium thiosulfate(aq) (50 mL, 25% w/v). 
Dilute with Et2O (30 mL), the layers were separated and the aqueous layer was further 
extracted with ether (50 mL x 3). The combined organic fractions were dried over MgSO4 
solvent remove in vacuo and purified via flash column chromatography (5% MeOH, 5% TEA 
in DCM) to yield product (3.18 g, 55%). 1H NMR (400 MHz, CDCl3) δ 4.46 (dd, J = 2.4, 1.4 Hz, 
1H), 4.24 (t, J = 2.6 Hz, 1H), 4.15 (dd, J = 2.7, 1.3 Hz, 1H), 4.12 (s, 5H), 3.62 (q, J = 6.8 Hz, 1H), 
2.15 (s, 6H), 1.50 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 90.21 (ipso Cp), 74.32 (Fc), 
71.67 (Fc), 68.19 (Fc), 65.59 (Fc), 57.59 (CH*), 45.49 (ipso Cp), 41.22 (CH3), 16.01 (CH3). MS 
(ES) (m/z) calcd for C14H18N
56FeI 382.9833, found 382.9820. IR (cm-1): 3078 (=C-H), 2931 
(CH2), 2878 (CH2), 2809 (CH2), 1446 (CH3), 1371 (CH3), 1243, 1087, 821 (CH=CH), 732 (CH Ar). 
Mp 58 °C - 60 °C. [α]D (c = 0.0022 g/mL, DCM) = +7.3. 
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I
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6.1.63. Side product: (Sp)-1-Vinyl-2-idodo-ferrocene 58a 
1H NMR (400 MHz, CDCl3) δ 6.54 (dd, J = 17.5, 10.8 Hz, 1H), 5.46 (dd, J = 17.5, 
1.5 Hz, 1H), 5.18 (dd, J = 10.8, 1.5 Hz, 1H), 4.52 (dd, J = 2.7, 1.4 Hz, 1H), 4.50 (dd, 
J = 2.5, 1.4 Hz, 1H), 4.31 (td, J = 2.6, 0.6 Hz, 1H), 4.11 (s, 4H). 13C NMR (101 MHz, 
CDCl3) δ 134.13 (CH vinyl), 113.13 (CH2 vinyl), 84.16 (ipso Cp), 75.26 (Fc), 72.26 (Fc), 69.43 
(Fc), 63.70 (Fc), 44.82 (ipso Cp). MS (ES) (m/z) calcd for C12H11
56FeI 337.9255, found 
337.9252. IR (cm-1): 3085 (=C-H), 2954 (CH2), 2922 (CH2), 2851 (CH2), 1628 (C=C), 820 
(CH=CH), 715 (CH Ar), 644. 
 
6.1.64. (R,Sp)-1-(α-Acetoxyethyl)-2-iodo-ferrocene 59 
In a 100 mL schlenk tube, 58 (3.26 g, 8.51 mmol) and acetic anhydride (25.68 
mL, 272.17 mmol) were heated at 50 °C under inert atmosphere for 2 h. The 
excess acetic anhydrides were removed under high vacuum (0.1 mmHg). 
Purified via flash column chromatography (10% EtOAc in hexane) to yield the yellow-brown 
oily product (2.94 g, 87%). 1H NMR (400 MHz, CDCl3) δ 5.89 (q, J = 6.4 Hz, 1H), 4.51 (dd, J = 
2.6, 1.4 Hz, 1H), 4.33 (dd, J = 2.8, 1.4 Hz, 1H), 4.28 (t, J = 2.6 Hz, 1H), 4.15 (s, 5H), 2.01 (s, 3H), 
1.66 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 170.30 (C=O), 87.54 (ipso Cp), 75.63 (Fc), 
71.76 (Fc), 69.71 (Fc), 68.94 (Fc), 65.80 (CH*), 44.03 (ipso Cp), 21.16 (CH3), 18.66 (CH3). IR 
(cm-1): 3095 (=C-H), 2972 (CH2), 2928 (CH2), 2866 (CH2), 1729 (C=O), 1445 (CH3), 1371 (CH3), 
1085, 820 (CH=CH), 703 (CH Ar). [α]D (c = 0.0086 g/mL, DCM) = -38.1. 
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6.1.65. (R,Sp)-1-(α-Hydroxyethyl)-2-iodo-ferrocene 60 
In a 200 mL round bottom flask 59 (2.937 g, 7.37 mmol) was dissolved in EtOH 
(35 mL). NaOH(aq) (30 mL, 10% w/v) was added and the reaction was heated at 95 
°C for 15 min. The reaction was allowed to cool to room temperature and 
organic layer was extracted with EtOAc (40 mL x 2). The organic layers were dried over 
Na2SO4, solvent removed in vacuo and purified via flash column chromatography (25% EtOAc 
in hexane) to yield the yellow oily product (2.43 g, 92%) 1H NMR (400 MHz, CDCl3) δ 4.85 (qd, 
J = 6.5, 2.8 Hz, 1H), 4.46 (dd, J = 2.5, 1.4 Hz, 1H), 4.29 (dd, J = 2.7, 1.3 Hz, 1H), 4.25 (t, J = 2.6 
Hz, 1H), 4.14 (s, 5H), 1.88 (d, J = 3.6 Hz, 1H), 1.62 (d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 91.61 (ipso Cp), 75.01 (Fc), 71.59 (Fc), 68.72 (Fc), 66.51 (Fc), 64.98 (CH*), 43.62 (ipso 
Cp), 21.31 (CH3). MS (ES) (m/z) calcd for C12H13O
56FeI 355.9361, found 355.9352. IR (cm-1): 
3255 (OH), 3093 (=C-H), 2967 (CH2), 2920 (CH2), 1445 (CH3), 1369 (CH3), 1099 (C-OH), 816 
(CH=CH), 684 (CH=CH). [α]D (c = 0.002 g/mL, DCM) = +12.0. Opposite enantiomer [α]D (c = 
0.006 g/mL, DCM) = -24.7.  
 
6.1.66. (R,Sp)-1-(α-Methoxyethyl)-2-iodo-ferrocene 61 
In a 100 mL round bottom flask, 60 (2.43 g, 6.826 mmol) was dissolved in a 
MeOH/AcOH (20 mL, 9:1) mixture and the reaction was stirred at room 
temperature for 48 h. The reaction was quenched with water (10 mL) and 
extract with DCM (2×20 mL). The combined organic fractions were dried over MgSO4, 
solvent removed in vacuo and purified via flash column chromatography (25% EtOAc in 
hexane) to yield the yellow oily product (2.37 g, 94%). 1H NMR (400 MHz, CDCl3) δ 4.49 (dd, J 
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= 2.4, 1.4 Hz, 1H), 4.34 (q, J = 6.5 Hz, 1H), 4.29 – 4.25 (m, 2H), 4.13 (s, 5H), 3.26 (s, 3H), 1.64 
(d, J = 6.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 89.78 (ipso Cp), 74.78 (Fc), 74.22 (Fc), 71.66 
(Fc), 68.86 (Fc), 65.35 (CH*), 56.00 (CH3), 39.48 (ipso Cp), 19.63 (CH3). MS (ES) (m/z) calcd for 
C13H15O
56FeI 369.9517, found 369.9513. IR (cm-1): 3094 (=C-H), 2974 (CH2), 2926 (CH2), 2871 
(CH2), 2815 (CH2), 1448 (CH3), 1371 (CH3), 1085 (C-O-C), 820 (CH=CH). [α]D (c = 0.0048 g/mL, 
DCM) = -16.7. Opposite enantiomer [α]D (c = 0.003 g/mL, DCM) = +33.3.  
 
6.1.67. (S,Sp)-1-[α-Methyl(2-ethylpropanoate)]-2-iodo-ferrocene 62 
In a 250 mL schlenk tube, 61 (2.37 g, 6.42 mmol) and 1-
ethoxyvinyloxytrimethylsilane 38 (8.234 g, 51.37 mmol) were dissolved in 
DCM (30 mL). The mixture was cooled to -78 °C and BF3.OEt2 (1.774 mL, 
14.12 mmol) was added drop wise. The reaction mixture was stirred for 15 
min at -78 °C before allowing to be warmed to room temperature. Quenched with saturated 
NaHCO3 (40 mL), the organic layer was separated and the aqueous layer was further 
extracted with DCM (40 mL). The combined organic fractions were dried over MgSO4, 
solvent removed in vacuo and purified via flash column chromatography (10% EtOAc in 
hexane) to yield the yellow oily product (1.676 g, 61%). 1H NMR (400 MHz, CDCl3) δ 4.42 (dd, 
J = 2.4, 1.4 Hz, 1H), 4.18 – 4.08 (m, 8H+2H), 3.14 – 3.05 (m, 1H), 2.53 (dd, J = 15.0, 3.7 Hz, 
1H), 2.11 (dd, J = 15.0, 10.3 Hz, 1H), 1.43 (d, J = 6.9 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H). 13C NMR 
(101 MHz, CDCl3) δ 172.00 (C=O), 94.07 (ipso Cp), 74.12 (Fc), 71.52 (Fc), 67.84 (Fc), 64.58 
(Fc), 60.26 (CH2), 44.08 (ipso Cp), 43.19 (CH2), 30.72 (CH*), 18.90 (CH3), 14.27 (CH3). MS (ES) 
(m/z) calcd for C16H19O2
56FeI 425.9779, found 425.9782. 
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6.1.68. (S,Sp)-1-[α-Methyl-(3-(hydroxyl)propyl)]-2-iodo-ferrocene 63 
In a 100 mL schlenk tube 62 (1.592 g, 3.73 mmol) was dissolved in Et2O (50 
mL), cooled to 0 °C and stand for 5 min. Diisobutylalumminum hydride (11.2 
mL, 11.2 mmol) was added to the reaction slowly at that temperature. The 
reaction was allowed to stir at 0 °C for 1 h before quenched with aqueous sodium potassium 
tartrate (30 mL). The layers were separated and the aqueous layer was further extract with 
Et2O (30 mL). The combined organic fractions were dried over Na2SO4, solvent remove in 
vacuo and purified via flash column chromatography (50% EtOAc in hexane) to yield product 
(1.413 g, 99%). 1H NMR (400 MHz, CDCl3) δ 4.42 (dd, J = 2.4, 1.4 Hz, 1H), 4.17 (td, J = 2.6, 0.6 
Hz, 1H), 4.13 (s, 5H), 4.06 (dd, J = 2.7, 1.3 Hz, 1H), 3.59 (t, J = 6.6 Hz, 2H), 2.78 – 2.69 (m, 1H), 
1.72 – 1.52 (m, 2H), 1.41 (d, J = 7.0 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 95.87 (ipso Cp), 
73.76 (Fc), 71.47 (Fc), 67.87 (Fc), 64.18 (Fc), 60.84 (CH2), 44.73 (ipso Cp), 42.09 (CH2), 29.81 
(CH*), 19.69 (CH3). MS (ES) (m/z) calcd for C14H17O
56FeI 383.9674, found 383.9678. IR (cm-1): 
3282 br (OH), 3088 (=CH Fc), 2971 (CH2), 2932 (CH2), 2854 (CH2), 1556, 1452 (CH2), 1376 
(CH3), 680 (C=C). Mp 96 °C - 98 °C. [α]D (c = 0.0083 g/mL, DCM) = +16.9.  
 
6.1.69. (S,Sp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-2-iodo-ferrocene 64 
In a 100 mL schlenk tube 63 (1.413 g, 3.67 mmol) was dissolved in 20 mL 
DCM at room temperature. TEA (0.769 mL, 5.52 mmol), tert-
Butyldiphenylsilyl chloride (1.435 mL, 5.51 mmol) and DMAP in catalytic 
amount were added successively to the mixture. The solution was stirred overnight at room 
temperature and quenched with water. The phrases were separated and the aqueous layer 
was extracted with further Et2O. The combined ethereal fractions were dried over Na2SO4, 
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solvent removed in vacuo and purified via flash column chromatography (10% EtOAc in 
hexane) to yield a yellow oily product (2 g, 95%). 1H NMR (400 MHz, CDCl3) δ 7.70 – 7.65 (m, 
4H), 7.43 – 7.32 (m, 6H), 4.38 (dd, J = 2.4, 1.3 Hz, 1H), 4.10 (s, 5H+1H), 4.00 (dd, J = 2.7, 1.3 
Hz, 1H), 3.70 – 3.65 (m, 2H), 2.77 – 2.68 (m, 1H), 1.88 – 1.80 (m, 1H), 1.43 – 1.34 (m, 1H), 
1.31 (d, J = 6.9 Hz, 3H), 1.05 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 135.63 (Ph), 134.10 (ipso 
Ph), 134.05 (ipso Ph), 129.47 (Ph), 127.58 (Ph), 96.25 (ipso Cp), 73.81 (Fc), 71.38 (Fc), 67.61 
(Fc), 64.27(Fc), 62.10 (CH2), 44.45 (ipso Cp), 41.60 (CH2), 30.03 (CH*), 26.94 (tBu), 19.24 (ipso 
tBu), 18.91 (CH3). MS (ES) (m/z) calcd for C30H35O
56FeISiNa 622.0851, found 622.0846. IR (cm-
1): 3071 (=CH Fc), 2958 (CH2), 2929 (CH2), 2856 (CH2), 1472 (CH2), 1387 (CH3), 1361, 1106, 
1085, 821 (CH Ar TBDPS), 700 (C=C). [α]D (c = 0.008 g/mL, DCM) = -5.5. 
 
6.1.70. (S,Sp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-2-aldehyde-ferrocene 65 
In a 100 mL schlenk tube 64 (2.182 g, 3.505 mmol) was dissolved in Et2O 
(30 mL), the mixture was cooled to -78 °C and n-BuLi (2.32 mL, 7.011 
mmol) was added. After 30 min, DMF (0.675 mL, 8.764 mmol) was 
added and the reaction was stirred at -78 °C for another 30 min before allowing too warm to 
room temperature, and then quenched with water (20 mL). The phases were separated and 
the aqueous layer was extracted with Et2O (20 mL). The combined ethereal fractions were 
dried over Na2SO4, solvent removed in vacuo and purified via flash column chromatography 
(10% EtOAc in hexane) to yield the red oily product (1.686 g, 92%). 1H NMR (400 MHz, CDCl3) 
δ 10.11 (s, 1H), 7.68 – 7.59 (m, 4H), 7.42 – 7.33 (m, 6H), 4.75 (dd, J = 2.7, 1.4 Hz, 1H), 4.48 (t, 
J = 2.6 Hz, 1H), 4.43 (dd, J = 2.6, 1.4 Hz, 1H), 4.21 (s, 5H), 3.61 (t, J = 7.1, 2H), 3.21 – 3.10 (m, 
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1H), 1.73 – 1.50 (m, 2H), 1.34 (d, J = 6.9 Hz, 3H), 1.04 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
193.25 (C=O), 135.55 (Ph), 133.94 (ipso Ph), 133.80 (ipso Ph), 129.55 (Ph), 127.61 (Ph), 99.14 
(ipso Cp), 76.31 (ipso Cp), 71.04 (Fc), 70.80 (Fc), 70.03 (Fc), 68.89 (Fc), 61.75 (CH2), 43.28 
(CH2), 27.90 (CH*), 26.89 (tBu), 22.66 (ipso tBu), 19.17 (CH3). MS (ES) (m/z) calcd for 
C31H36O2
56FeSiNa 547.1732, found 547.1727. IR (cm-1): 3071 (=CH Fc), 2958 (CH2), 2929 (CH2), 
2856 (CH2), 1673 (C=O), 1589 (C=N), 1427 (CH2), 1376 (tBu), 1106 (Si-OR), 1086 (Si-OR), 821 
(CH Ar Ph), 700 (C=C). 
 
6.1.71. (S,Rp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-2-vinyl-ferrocene 66 
In a 100 mL schlenk tube, trimethylmethylphosphonium bromide (1.722 
g, 4.821 mmol), potassium tert-butoxide (0.541 g, 4.821 mmol) and a 
catalytic amount of dibenzo-18-crown-6-ether were dissolved in 20 mL 
of dry THF. The mixture was stirred for 30 min and 65 (1.686 g, 3.214 mmol) was dissolved in 
30 mL of dry THF and added to the mixture. The reaction was stirred overnight at room 
temperature, quenched with water and extracted with Et2O (20 mL). The combined ethereal 
fractions were dried over Na2SO4, solvent removed in vacuo and purified via flash column 
chromatography (5% EtOAc in hexane) to yield the yellow oily product (1.497 g, 89%). 1H 
NMR (400 MHz, CDCl3) δ 7.69 – 7.63 (m, 4H), 7.44 – 7.33 (m, 6H), 6.62 (dd, J = 17.4, 10.8 Hz, 
1H), 5.34 (dd, J = 17.5, 1.8 Hz, 1H), 5.01 (dd, J = 10.8, 1.7 Hz, 1H), 4.43 (dd, J = 2.5, 1.4 Hz, 
1H), 4.12 (t, J = 2.6 Hz, 1H), 4.06 (dd, J = 2.5, 1.4 Hz, 1H), 4.03 (s, 5H), 3.62 (dd, J = 7.2, 5.4 Hz, 
2H), 2.94 – 2.86 (m, 1H), 1.72 – 1.61 (m, 1H), 1.45 – 1.37 (m, 1H), 1.30 (d, J = 6.8 Hz, 3H), 1.06 
(s, 9H). 13C NMR (101 MHz, CDCl3) δ 135.59 (Ph), 134.08 (ipso Ph), 134.02 (ipso Ph), 133.50 
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(CH vinyl), 129.49 (Ph), 127.56 (Ph), 110.96 (CH2 vinyl), 94.84 (ipso Cp), 81.37 (ipso Cp), 69.66 
(Fc), 66.55 (Fc), 66.27 (Fc), 64.08 (Fc), 61.89 (CH2), 42.80 (CH2), 27.65 (CH*), 26.89 (tBu), 
19.23 (ipso tBu), 18.92 (CH3). MS (ES) (m/z) calcd for C32H38O
56FeSi 522.2041, found 
522.2055. IR (cm-1): 3072 (=CH Fc), 2958 (CH2) 2930 (CH2), 2857 (CH2), 1625 (Ar Ph), 1589, 
1427 (CH2), 1388 (CH3), 1105 (Si-OR), 1086 (Si-OR), 821 (CH Ar), 699 (vinyl/C=C). 
 
6.1.72. (S,Rp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyloxy)propyl)]-2-[2-(hydroxyl)ethyl]-
ferrocene 67 
In a 100 mL schlenk tube, 66 (1.497 g, 2.865 mmol) was dissolved in 30 
mL of dry THF. BH3,THF (8.186 mL, 0.818 mmol) was then added drop 
wise at room temperature and stirred for 2 h. 9.762 mL of EtOH, 9.762 
mL of NaOH (3M) and 7.174 mL of H2O2 (30%) were then successively added to the reaction 
and stirred for 1 h at room temperature. The reaction was extracted with DCM, washed with 
brine and dried over Na2SO4, solvent removed in vacuo and purified via flash column 
chromatography (10% EtOAc in hexane) to yield the yellow oily product (1.434 g, 97%). 1H 
NMR (400 MHz, CDCl3) δ 7.68 – 7.64 (m, 4H), 7.43 – 7.36 (m, 6H), 4.11 – 4.09 (m, 1H), 4.05 (s, 
5H), 4.00 (t, J = 2.5 Hz, 1H), 3.97 (dd, J = 2.5, 1.3 Hz, 1H), 3.75 (tq, J = 6.8, 2.6 Hz, 2H), 3.67 – 
3.63 (m, 2H), 2.77 – 2.68 (m, 1H), 2.66 – 2.49 (m, 2H), 1.74 – 1.66 (m, 1H), 1.43 – 1.32 (m, 
1H), 1.26 (d, J = 6.8 Hz, 3H), 1.06 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 135.56 (Ph), 133.96 
(ipso Ph), 129.59 (Ph), 127.63 (Ph), 95.01 (ipso Cp), 82.31 (ipso Cp), 69.03 (Fc), 67.36 (Fc), 
65.39 (Fc), 65.15 (Fc), 63.00 (CH2), 61.98 (CH2), 42.43 (CH2), 30.93 (CH2), 27.51 (CH*), 26.91 
(tBu), 19.37 (CH3), 19.22 (ipso tBu). MS (ES) (m/z) calcd for C32H40O2
56FeSiNa 563.2045, found 
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563.2039. IR (cm-1): 3378 br (OH), 3072 (=CH Fc), 2930 (CH2), 2857 (CH2), 1589, 1472 (CH3), 
1427 (CH2), 1388 (tBu), 1361, 1105 (Si-OR), 1086 (Si-OR), 819 (CH Ar Ph), 705 (C=C). [α]D (c = 
0.0056 g/mL, DCM) = -11.4. Opposite enantiomer [α]D (c = 0.0058 g/mL, DCM) = +23.5. 
 
6.1.73. (S,Rp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2-[2-((N,N-6-dibenzoyl)-adenin-
9-yl)ethyl]-ferrocene 68 
In a 50 mL schlenk tube, triphenylphosphine (0.291 g, 1.109 mmol) 
and 19 (0.381 g, 1.109 mmol) were dissolved in dry THF and stirred 
for 10 min at room temperature. 67 (0.300 g, 0.555 mmol) was then 
added to the mixture pre-dissolved in 5 mL of dry THF. The schlenk 
tube was then covered with foil and DIAD (0.244 mL, 1.109 mmol) was added at room 
temperature before the mixture was warmed up to 65 °C for 2 h. The reaction was 
evaporated, extracted with EtOAc, washed with brine followed by water and dried over 
Na2SO4, solvent removed in vacuo and purified via flash column chromatography (30% EtOAc 
in hexane) to yield product (0.343 g, 72%). 1H NMR (400 MHz, CDCl3) δ 8.64 (s, 1H), 7.89 – 
7.85 (m, 4H), 7.80 (s, 1H), 7.63 – 7.58 (m, 4H), 7.50 – 7.44 (m, 2H), 7.37 – 7.27 (m, 6H+4H), 
4.38 – 4.21 (m, 2H), 4.06 (s, 5H), 3.98 (dd, J = 2.4, 1.3 Hz, 1H), 3.96 (t, J = 2.5 Hz, 1H), 3.69 – 
3.63 (m, 2H+1H), 2.96 – 2.80 (m, 2H), 2.76 – 2.68 (m, 1H), 1.68 – 1.61 (m, 1H), 1.49 – 1.41 
(m, 1H), 1.28 (d, J = 6.7 Hz, 3H), 1.00 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 172.27 (C=O), 
153.19 (ipso adenine), 152.15 (CH adenine), 151.63 (ipso adenine), 144.97 (CH adenine), 
135.55 (Ph), 134.21 (ipso Bz), 133.75 (ipso adenine), 132.88 (Bz), 129.64 (Ph), 129.46 (Bz), 
128.66 (Bz), 127.64 (Ph), 94.99 (ipso Cp), 80.88 (ipso Cp), 69.12 (Fc), 67.09 (Fc), 65.86 (Fc), 
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65.55 (Fc), 61.96 (CH2), 44.71 (CH2), 42.77 (CH2), 28.52 (CH2), 27.53 (CH*), 26.84 (tBu), 19.68 
(CH3), 19.16 (ipso tBu). MS (ES) (m/z) calcd for C51H51N5O3
56FeSiNa 888.3008, found 
888.3015. IR (cm-1): 3264 (OH), 3074 (=CH Fc), 2930 (CH2), 2871 (CH2), 1697 (C=O), 1603 
(C=C), 1579, 1450, 1242, 1104, 1091, 821, 705 (C=C). Mp 86 °C - 88 °C. [α]D (c = 0.0056 g/mL, 
DCM) = -36.4. 
 
6.1.74. (S,Rp)-1-[α-methyl-(3-(hydroxy)propyl)]-2-[2-((N-6-benzoyl)-adenin-9-yl)ethyl]-
ferrocene 69 
In a 50 mL schlenk tube, 68 (0.3 g, 0.346 mmol) was dissolved in 5 
mL of dry THF and tetra-Butylamino fluoride (0.328 g, 1.039 mmol) 
was added to the solution. After overnight stirring, the reaction 
was quenched with water, extracted with DCM, washed with brine, 
water and dried over Na2SO4. The solvent was removed in vacuo and the crude was purified 
via flash column chromatography (3% MeOH in DCM) to yield product (0.146 g, 80%). 1H 
NMR (400 MHz, CDCl3) δ 9.11 (s, 1H), 8.81 (s, 1H), 8.03 (d, J = 7.2 Hz, 2H), 8.00 (s, 1H), 7.60 (t, 
J = 7.5 Hz, 1H), 7.52 (t, J = 7.9 Hz, 2H), 4.41 – 4.36 (m, 2H), 4.08 (s, 5H), 4.07 – 4.04 (m, 2H), 
4.01 (t, J = 1.7 Hz, 1H), 3.65 – 3.61 (m, 2H), 3.10 – 2.89 (m, 2H), 2.88 – 2.83 (m, 1H), 1.64 – 
1.48 (m, 2H), 1.39 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 164.62 (C=O), 152.54 (CH 
adenine), 151.78 (ipso adenine), 149.60 (ipso adenine), 143.08 (CH adenine), 133.60 (ipso 
Ph), 132.80 (Bz), 128.86 (Bz), 127.89 (Bz), 123.03 (ipso adenine), 95.14 (ipso Cp), 80.75 (ipso 
Cp), 69.29 (Fc), 67.55 (Fc), 66.13 (Fc), 65.42 (Fc), 60.11 (CH2), 45.10 (CH2), 43.26 (CH2), 29.30 
(CH2), 27.04 (CH*), 19.88 (CH3). MS (ES) (m/z) calcd for C28H29N5O2
56FeNa 546.1568, found 
546.1570. IR (cm-1): 3264 br (OH), 3074 (=CH Fc), 2930 (CH2), 2871 (CH2), 1697 (C=O), 1603 
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(Amide), 1579 (C=N), 1452 (CH3), 796 (CH Ar Bz), 705 (C=C). Mp: 104 °C – 106 °C. [α]D (c = 
0.0044 g/mL, DCM) = -40.9. 
 
6.1.75. (S,Rp)-1-[α-Methyl-(3-(hydroxy)propyl)]-2-[2-(-adenin-9-yl)ethyl]-ferrocene 70 
69 (0.043 g, 0.082 mmol) was dissolved in 2 mL of methylamine. The 
mixture was stirred at room temperature for half an hour under 
argon. The methylamine was evaporated. The crude was purified via 
flash column chromatography (5% MeOH in DCM) to yield product. 
A yellow solid was obtained (0.025 g, 73%). 1H NMR (400 MHz, DMSO-d6) δ 8.19 (s, 1H), 8.17 
(s, 1H), 7.21 (s, 2H), 4.41 – 4.33 (m, 2H+1H (OH)), 4.11 (s, 5H), 4.02 (d, J = 2.4 Hz, 2H), 3.99 (t, 
J = 2.4 Hz, 1H), 3.42 – 3.28 (m, 2H), 2.97 – 2.75 (m, 2H), 2.75 – 2.67 (m, 1H), 1.53 – 1.45 (m, 
1H), 1.32 (d, J = 6.8 Hz, 3H+1H). 13C NMR (101 MHz, DMSO-d6) δ 155.95 (ipso adenine), 
152.43 (CH adenine), 149.39 (ipso adenine), 140.71 (CH adenine), 118.75 (ipso adenine), 
94.43 (ipso Cp), 81.89 (ipso Cp), 68.80, 66.46, 64.92, 64.74, 58.66, 43.10, 42.43, 27.98, 27.10 
(CH*), 19.38 (CH3). MS (ES) (m/z) calcd for C21H26N5O
56Fe 420.1487, found 420.1484. IR (cm-
1): 3348 br (OH), 3270 (NH2), 3240 (NH2), 3098 (=CH Fc), 2955 (CH2), 2926 (CH2), 2871 (CH2), 
1674 (C=N), 1604 (NH2), 1574 (NH2), 1305 (OH), 1076 (C-O), 814 (CH Ar). Mp 90 °C - 92 °C.  
1
H NMR with addition of D2O: 
1H NMR (300 MHz, DMSO-d6) δ 8.18 (s, 1H), 8.16 (s, 1H), 7.22 
(s, 0.5H disappearing with D2O), 4.37 (dd, J = 8.7, 7.1 Hz, 2H), 4.10 (s, 5H), 4.01 (d, J = 2.4 Hz, 
2H), 3.99 – 3.96 (m, 1H), 3.40 – 3.28 (m, 2H), 2.95 – 2.73 (m, 2H), 2.72 – 2.66 (m, 1H), 1.53 – 
1.42 (m, 1H), 1.30 (d, J = 6.7 Hz, 3H+1H).  
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6.1.76. (S,Rp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2-[2-(bromo)ethyl]-ferrocene 
71 
In a 50 mL schlenk tube, NBS (0.198 g, 1.1098 mmol) was suspended in dry 
DCM. A DCM solution of triphenylphosphine (0.272 g, 1.036 mmol) was 
added drop wise to it. The resulting orange mixture was stirred for 5 min 
before addition of 0.045 mL (0.444 mmol) of pyridine. The mixture goes 
brown. 67 (0.200 g, 0.369 mmol) previously dissolved in 2.5 mL of dry DCM, was added to 
the mixture. After overnight reaction, the solvent was removed in vacuo and the crude was 
purified via flash column chromatography (10% EtOAc in hexane) to yield the yellow oily 
product (0.187 g, 84%). 1H NMR (400 MHz, CDCl3) δ 7.68 – 7.64 (m, 4H), 7.44 – 7.37 (m, 6H), 
4.10 (dd, J = 2.5, 1.3 Hz, 1H), 4.05 (s, 5H), 4.00 (t, J = 2.5 Hz, 1H), 3.95 (dd, J = 2.6, 1.4 Hz, 1H), 
3.66 – 3.60 (m, 2H), 3.46 (dd, J = 8.6, 7.5 Hz, 2H), 2.90 (td, J = 7.8, 2.8 Hz, 2H), 2.76 – 2.67 (m, 
1H), 1.70 – 1.61 (m, 1H), 1.40 – 1.32 (m, 1H), 1.26 (d, J = 6.9 Hz, 3H), 1.07 (s, 9H). 13C NMR 
(101 MHz, CDCl3) δ 135.61 (Ph), 133.95 (ipso Ph), 133.86 (ipso Ph), 129.61 (Ph), 127.68 (Ph), 
94.78 (ipso Cp), 83.19 (ipso Cp), 69.06 (Fc), 67.26 (Fc), 65.49 (Fc), 65.22 (Fc), 61.79 (CH2), 
42.59 (CH2), 31.94 (CH2), 31.54 (CH2), 27.47 (CH*), 26.99 (tBu), 19.36 (CH3), 19.24 (ipso tBu). 
MS (ES) (m/z) calcd for C32H39OFe
56Si81Br 604.1282, found 604.1286. IR (cm-1): 3071 (=CH Fc), 
2958 (CH2), 2930 (CH2), 1589, 1472, 1427 (CH2), 1389 (tBu), 1105, 1086, 820 CH Ar Ph), 700 
(C=C). [α]D (c = 0.0056 g/mL, DCM) = -28.6.  
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6.1.77. (S,Rp)-1-[α-Methyl-(3-(tert-butyldiphenylsilyl)propyl)]-2-[2-((N-4-benzoyl)-cytosin-1-
yl)ethyl]-ferrocene 72 
In a 50 mL schlenk tube, the N-4-benzoyl-cytosine 21 (0.072 g, 0.331 
mmol) was stirred vigorously in suspension in 3 mL of DMF for 5 
min. NaH (0.00795 g, 0.331 mmol) was added to the mixture in one 
portion and stirred for 1 h. At this point the solution was clear. 71 
(0.100 g, 0.166 mmol) was dissolved in 2 mL of DMF and added to the mixture. After 
overnight stirring at room temperature, the reaction was quenched with water, extracted 
with chloroform, dried on MgSO4. The solvent was removed in vacuo and the crude was 
purified via flash column chromatography (40% EtOAc in hexane) to yield product (0.061 g, 
60%). 1H NMR (400 MHz, CDCl3) δ 8.61 (s, 1H), 7.90 (d, J = 7.7 Hz, 2H), 7.67 – 7.59 (m, 
4H+2H), 7.53 (dd, J = 8.4, 7.0 Hz, 2H), 7.45 – 7.34 (m, 4H+2H+1H), 7.14 (d, J = 7.1 Hz, 1H), 
4.07 (s, 5H), 4.06 – 4.01 (m, 1H (CH2•)), 3.99 (dd, J = 5.4, 2.9 Hz, 2H), 3.88 (s, 1H), 3.81 – 3.71 
(m, 1H (CH2•)), 3.71 – 3.64 (m, 2H), 2.96 – 2.88 (m, 1H), 2.76 – 2.71 (m, 1H), 2.70 – 2.63 (m, 
1H), 1.70 – 1.61 (m, 1H), 1.52 – 1.43 (m, 1H), 1.29 (d, J = 6.6 Hz, 3H), 1.04 (s, 9H). 13C NMR 
(101 MHz, CDCl3) δ 182.20 (C=O), 162.02 (C=O), 149.13 (CH cytosine), 135.55 (Ph), 133.87 
(ipso Bz), 133.80 (Bz), 133.16 (ipso Ph), 129.72 (Ph), 129.07 (Bz), 127.71 (Bz), 127.47 (Ph), 
95.8 (CH cytosine), 94.8 (ipso Cp), 81.2 (ipso Cp), 69.21 (Fc), 67.80 (Fc), 65.84 (Fc), 65.48 (Fc) 
, 61.96 (CH2), 51.71 (CH2), 42.90 (CH2), 27.44 (CH2), 27.19 (CH*), 26.91 (tBu), 19.76 (CH3), 
19.22 (ipso tBu). The CN (ipso) peak could not be characterised. MS (ES) (m/z) calcd for 
C43H47N3O3
56FeSiNa 760.2634, found 760.2617. IR (cm-1): 3071 (=CH Fc), 2958 (CH2), 2930 
(CH2), 2857 (CH2), 1662 (C=O), 1625 (amide), 1553 (C=N), 1484 (CH2), 1363 (tBu), 1237, 1175, 
1105 (Si-OR), 785 (CH Ar Ph), 700 (C=C). Mp 72 °C. 
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6.1.78. (S,Rp)-1-[α-Methyl-(3-(hydroxy)propyl)]-2-[2-((N-4-benzoyl)-cytosin-1-yl)ethyl]-
ferrocene 73 
In a 50 mL schlenk tube, 72 (0.053 g, 0.0859 mmol) was dissolved in 
2 mL of dry THF and tetra-Butylamino fluoride (0.054 g, 0172 mmol) 
was added to the solution. After overnight stirring, the reaction was 
quenched with water, extracted with DCM, washed with brine, 
water and dried over Na2SO4. The solvent was removed in vacuo and the crude was purified 
via flash column chromatography (3% MeOH in DCM) to yield product (0.040 g, 93%). 1H 
NMR (400 MHz, CDCl3) δ 8.91 (s, 1H), 7.93 – 7.88 (m, 2H), 7.68 (d, J = 7.2 Hz, 1H (CH 
cytosine)), 7.64 – 7.58 (m, 1H), 7.54 – 7.47 (m, 2H+1H (CH cytosine)), 4.16 – 4.09 (m, 1H 
(CH2•)), 4.07 (s, 7H), 4.04 (d, J = 2.2 Hz, 1H), 3.85 – 3.78 (m, 1H (CH2•)), 3.72 – 3.60 (m, 
1H+1H), 2.98 – 2.76 (m, 2H+1H), 1.71 – 1.62 (m, 1H), 1.51 – 1.43 (m, 1H), 1.36 (d, J = 6.7 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 165.97 (ipso CN), 162.34 (C=O Bz), 155.7 (C=O cytosine), 
149.11 (CH cytosine), 133.20 (Bz), 133.00 (ipso Bz), 129.03 (Bz), 127.58  (Bz), 96.75 (CH 
cytosine), 95.49 (ipso Cp), 80.93 (ipso Cp), 69.33 (Fc), 67.76 (Fc), 66.01 (Fc), 65.33 (Fc), 60.27 
(CH2), 52.36 (CH2), 43.44 (CH2), 27.84 (CH2), 26.92 (CH*), 19.19 (CH3). MS (ES) (m/z) calcd for 
C27H29N3O3
56FeNa 522.1458, found 522.1456. IR (cm-1): 3315 br (OH), 3075 (=CH Fc), 2958 
(CH2), 2929 (CH2), 2874 (CH2), 1692 (C=O), 1646 (Amide), 1623 (C=N), 1555 (NH), 1483, 1363, 
1237, 785, 702 (C=C). Mp 90 °C - 92 °C. [α]D (c = 0.0065 g/mL, DCM) = -4.3. 
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6.1.79. (S,Rp)-1-[α-Methyl-(3-(hydroxy)propyl)]-2-[2-(cytosin-1-yl)ethyl]-ferrocene 74 
73 (0.018 g, 0.036 mmol) was dissolved in 2 mL of methylamine. The 
mixture was stirred at room temperature for half an hour under 
argon. The methylamine was evaporated. The crude was purified via 
flash column chromatography (10% MeOH in DCM) to yield product. 
A yellow solid was obtained (0.014 g, 98%). 1H NMR (400 MHz, CDCl3) δ 7.24 (s, 1H 
(overlapped by CDCl3 peak), 5.72 (d, J = 7.1 Hz, 1H), 4.07 (dd, J = 2.4, 1.3 Hz, 1H), 4.04 (s, 
5H+1H), 4.01 (t, J = 1.3 Hz, 1H), 3.99 – 3.91 (m, 1H (CH2•)), 3.69 (dt, J = 10.1, 4.8 Hz, 1H), 3.65 
– 3.60 (m, 1H), 3.58 (dd, J = 8.4, 3.5 Hz, 1H (CH2•)), 2.94 – 2.83 (m, 2H), 2.74 – 2.64 (m, 1H), 
1.73 – 1.62 (m, 1H), 1.46 – 1.40 (m, 1H), 1.35 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
165.97 (ipso CN), 156.54 (C=O cytosine), 145.71 (CH cytosine), 95.58 (ipso Cp), 94.40 (CH 
cytosine), 81.28 (ipso Cp), 69.21 (Fc), 67.60 (Fc), 65.77 (Fc), 65.13 (Fc), 60.22 (CH2), 51.77 
(CH2), 43.50 (CH2), 28.03 (CH2), 26.82 (CH*), 18.96 (CH3). MS (ES) (m/z) calcd for 
C20H25N3O2
56FeNa 418.1194, found 418.1198. IR (cm-1): 3333 br (OH), 3210 (NH2), 3097 (=CH 
Fc), 2917 (CH2), 2851 (CH2), 1650 (amide/urea), 1614 (NH2), 1528, 1483 (C=N), 1383 (CH3), 
1237, 1180, 1106 (C-O), 785 (CH Ar), 718 (C=C).  Mp 162 °C - 164 °C. 
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6.2 Electrochemistry 
The electrochemical experiments were carried out in DCM solution under an atmosphere of 
argon containing TBA∙PF6 (0.1 M) as supporting electrolyte and decamethylferrocene as an 
internal reference. DCM was previously dried using Solvent Purification System. A three-
electrode cell was used, with Pt as the working electrode, Ag/AgCl as the reference electrode 
and Pt wire as the auxiliary electrode. All the glassware was cleaned using an 
ammonia/hydrogen peroxide 1:1 solution for 3-6 hours and then rinsed with MilliQ® water. 
Before each experiment, the working electrode was polished with an alumina slurry, rinsed 
with MilliQ water and dried and the auxiliary electrode was cleaned with a Bunsen flame.  
The solutions were purged with nitrogen before each run. A BAS 100 potentiostat and BAS 
100 software were used to record the voltammograms. The confidence limits in the 
electrode potential values were ±5 mV for CV. For each voltammogram, the reversibility of 
the redox wave of the analyte broadly matched that of decamethylferrocene under the 
same experimental conditions (ΔEp = 70-100 mV). As the solubility of each compound at ca. 1 
mM in DCM was low, each sample required filtration through a Whatman 13mm GD/X 
syringe filter beforehand. 
 
6.2.1 Cells and glassware care 
The cell and all the glassware used during the experiments were cleaned using one of the 
following methods: 
• Ammonia : Hydrogen peroxide 1:1 (3/6 h) 
• Piranha solution (sulfuric acid : H2O2 3:1) (1 h) 
• Nitric acid : sulfuric acid 1:1 at 200 ˚C (1 h) 
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After any of the above methods the glassware should be rinsed several times (ca. 10) with 
MilliQ® water and dried in an oven overnight.  
 
6.2.2 Working Electrodes pre-treatment 
Pt and Au electrodes were mechanically polished before any experiment using an alumina 
water slurry on a microcloth pad, performing a figure of eight pattern for not less than 
5 min. Every 2-3 months of usage (or in case major scratches are present) each electrode 
was polished with a diamond powder solution 3 μm (on a nylon pad). The scans should be 
carried out until the voltammogram is reproducible. In all cases the electrode was rinsed 
with MilliQ water and dried under a nitrogen flow. 
 
6.3 Crystal structures 
Suitable crystals were selected and datasets from the following structures were 
measured by the EPSRC UK National Crystallography Service1 on a Rigaku AFC12 
goniometer equipped with an enhanced sensitivity (HG) Saturn 724+ detector mounted 
at the window of an FR-E+ SuperBright molybdenum rotating anode generator (λMo-Kα = 
0.71075 Å) with HF Varimax optics The data collections were driven and processed, and 
absorption corrections applied by CrystalClear-SM Expert 3.1 b13a2. The structures were 
all solved in SHELXS-973 and were refined by a full-matrix least-squares procedure on F2 
in SHELXL-97.3 All non-hydrogen atoms were refined with anisotropic displacement 
parameters. The hydrogen atoms were added at calculated positions and refined by use 
of a riding model with isotropic displacement parameters based on the equivalent 
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isotropic displacement parameter (Ueq) of the parent atom. Figures were produced using 
OLEX24 and structural analysis was carried out in Mercury 3.0.5  
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Crystal Data for 12:  
 
Table 6-1: Crystal data and structure refinement for 12. 
Empirical formula  C24 H24 Fe N10 
Formula weight  508.38 
Temperature  120 (2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 2(1)/c 
Unit cell dimensions 
a = 6.3611 (6) Å 
b = 8.0936 (11) Å 
c = 20.680 (3) Å 
α = 90°. 
β= 90.135(8)°. 
γ = 90°. 
Volume 1064.7 (2) Å3 
Z 2 
Density (calculated) 1.586 Mg/m3 
Absorption coefficient 0.747 mm-1 
F(000) 528 
Crystal size 0.36 x 0.03 x 0.01 mm3 
Theta range for data collection 2.96 to 25.00°. 
Index ranges -7<=h<=7, -8<=k<=9, -24<=l<=24 
Reflections collected 7494 
Independent reflections 1860 [R(int) = 0.0739] 
Completeness to theta = 25.00° 98.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9926 and 0.7747 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1860 / 0 / 161 
Goodness-of-fit on F2 1.158 
Final R indices [I>2sigma(I)] R1 = 0.0674, wR2 = 0.1285 
R indices (all data) R1 = 0.0932, wR2 = 0.1461 
Largest diff. peak and hole 0.546 and -0.437 e.Å-3 
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The iron atom of the molecule is located on an inversion centre such that only half of the 
molecule is crystallographically unique. The structure is a merohedral twin with the 
refined ratio of the two domains being 52:48 and the twin law relating these domains 
being (1 0 0 0 -1 0 0 0 -1). The hydrogen atoms were fixed as riding models. 
 
Figure 6-1: Crystal structure of 12 with ellipsoids drawn at the 50 % probability level. The 
iron atom is located on an inversion centre such that only half of the molecule is 
crystallographically independent. 
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Crystal Data for 39:  
Table 6-2: Crystal data and structure refinement for 39 
Empirical formula C22H28FeI2O4 
Formula weight 666.09 
Temperature 120(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P21  
Unit cell dimensions 
a = 14.1877 (7) Å 
b = 8.3380 (2) Å 
c = 20.9652 (9) Å 
α = 90°. 
β = 101.305 (2)°. 
γ = 90°. 
Volume 2432.00(17) Å3 
Z 4 
Density (calculated) 1.819 Mg/m3 
Absorption coefficient 3.183 mm-1 
F(000) 1296 
Crystal size 0.45 x 0.14 x 0.03 mm3 
Theta range for data collection 2.92 to 27.48°. 
Index ranges -17<=h<=18, -10<=k<=9, -27<=l<=27 
Reflections collected 29532 
Independent reflections 10419 [R(int) = 0.0542] 
Completeness to theta = 27.48° 98.5 % 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9106 and 0.3285 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 10419 / 474 / 624 
Goodness-of-fit on F2 1.039 
Final R indices [I>2sigma(I)] R1 = 0.0464, wR2 = 0.0962 
R indices (all data) R1 = 0.0654, wR2 = 0.1054 
Largest diff. peak and hole 1.604 and -0.860 e.Å-3 
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The structure contains two crystallographically independent molecules. The methyl 
group C(16) / C(16’) is disordered over two positions at a percentage occupancy ratio of 
73(3):27(3) respectively. The groups C(114)-C(116), O(101), O(102) / C(04’)-C(06’), 
O(01’), O(02’) and C(120)-C(122), O(103), O(104) / C(20’)-C(22’), O(03’), O(04’) are 
disordered over two positions both at the percentage occupancy ratio of 70(2): 30(2). 
 
Figure 6-2: Crystal structure of the two crystallographically independent molecules of 39 
with ellipsoids drawn at the 50 % probability level. The methyl group C(16) / C(16’) and 
the groups C(114)-C(116), O(101), O(102) / C(04’)-C(06’), O(01’), O(02’) and C(120)-
C(122), O(103), O(104) / C(20’)-C(22’), O(03’), O(04’) are disordered over two positions. 
The minor positions and all hydrogen atoms have been omitted for clarity. 
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Crystal Data for 47:  
Table 6-3: Crystal data and structure refinement for 47 
Empirical formula  C54H70FeO4Si2 
Formula weight  895.13 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Triclinic 
Space group  P 1  
Unit cell dimensions 
a = 8.651(7) Å 
b = 15.747(15) Å 
c = 19.038(17) Å 
α = 83.74(4)° 
β = 80.13(5)° 
γ = 87.42(5)° 
Volume 2539(4) Å3 
Z 2 
Density (calculated) 1.171 Mg/m3 
Absorption coefficient 0.386 mm-1 
F(000) 960 
Crystal size 0.28 x 0.03 x 0.03 mm3 
Theta range for data collection 2.93 to 27.48°. 
Index ranges -9<=h<=11, -20<=k<=20, -24<=l<=24 
Reflections collected 45083 
Independent reflections 19748 [R(int) = 0.0494] 
Completeness to theta = 27.48° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9885 and 0.8995 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 19748 / 3 / 1119 
Goodness-of-fit on F2 1.088 
Final R indices [I>2sigma(I)] R1 = 0.0534, wR2 = 0.0809 
R indices (all data) R1 = 0.0617, wR2 = 0.0848 
Largest diff. peak and hole 0.364 and -0.437 e.Å-3 
 
 
Chapter 6: Experimental 
 247
The structure of 47 contains two crystallographically independent molecules, with the 
molecular geometry being the same within experimental error. 
 
Figure 6-3: Crystal structure of the second of the crystallographically independent molecules of 47 
with ellipsoids drawn at the 50 % probability level. 
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Crystal Data for 51:  
Table 6-4: Crystal data and structure refinement for 47 
Empirical formula  C44H46FeN4O8, CDCl3  
Formula weight  935.10 
Temperature  100(2) K 
Wavelength  0.71075 Å 
Crystal system  Orthorhombic 
Space group  P 21 2121  
Unit cell dimensions 
a = 11.808(5) Å 
b = 13.709(6) Å 
c = 26.047(11) Å 
α= 90° 
β= 90° 
γ = 90° 
Volume 4216(3) Å3 
Z 4 
Density (calculated) 1.473 Mg/m3 
Absorption coefficient 0.608 mm-1 
F(000) 1944 
Crystal size 0.11 x 0.11 x 0.02 mm3 
Theta range for data collection 2.91 to 27.48°. 
Index ranges -15<=h<=15, -17<=k<=17, -33<=l<=33 
Reflections collected 86280 
Independent reflections 9657 [R(int) = 0.0433] 
Completeness to theta = 27.48° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9879 and 0.9361 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9657 / 1 / 557 
Goodness-of-fit on F2 1.093 
Final R indices [I>2sigma(I)] R1 = 0.0399, wR2 = 0.0945 
R indices (all data) R1 = 0.0405, wR2 = 0.0948 
Absolute structure parameter 0.017(12) 
Largest diff. peak and hole 0.558 and -0.500 e.Å-3 
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Figure 6-4: Crystal structure of 51 with ellipsoids drawn at the 50 % probability level. The structure 
contains a molecule of deuterated chloroform, which has been omitted for clarity. 
 
6.4 High Performance Liquid Chromatography 
Analytical HPLC was recorded using a reverse-phase C18 column with a water acetonitrile 
method: 0-40 min (0-100% acetonitrile), 40-50 min (100% acetonitrile), 50-60 min (O% 
acetonitrile) at 1 mL/min and was monitored at 210 nm. Chiral HPLC was conducted on AD 
or OD chiral columns using IPA/Hexane eluent with a flow rate of 1 mL/min. Three solutions 
were used to perform the chiral separations: Solvent system A: Hexane; Solvent system B: 
10% IPA in hexane, Solvent system C: 20% IPA in hexane. The enantiomeric excess of the 
compounds was calculated from the area of the peaks obtained. Any opposite enantiomers 
used in the determination of the ee via Chiral HPLC not reporte in the thesis were 
synthesised by Dr. H. Van Nguyen from Tucker group. 
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7 APPENDIX 
 
Figure 7-1: 
1H and 13C NMR of 47 in CDCl3. 
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Figure 7-2: 
1H and 13C NMR of 50 in CDCl3 
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Figure 7-3: 
1H and 13C NMR of 51 in CDCl3 
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Figure 7-4: 
1H and 13C NMR (UDEFT) of 53 in CDCl3 
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Figure 7-5: Chiral HPLC of 34 (10% IPA in Hexane at 1 mL/min, OD column) 
 
  
Figure 7-6: Chiral HPLC of the opposite enantiomer of 34 (10% IPA in Hexane at 1 mL/min, OD 
column) 
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Figure 7-7: Chiral HPLC of 34 and its enantiomer (10% IPA in Hexane at 1 mL/min, OD column) 
 
 
Figure 7-8: Chiral HPLC of 36 (10% IPA in Hexane at 1 mL/min, AD column) 
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Figure 7-9: Chiral HPLC of the opposite enantiomer of 36 (10% IPA in Hexane at 1 mL/min, AD 
column) 
 
Figure 7-10: Chiral HPLC of 36 and its enantiomer (10% IPA in Hexane at 1 mL/min, AD column) 
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Figure 7-11: Chiral HPLC of 39 (5% IPA in Hexane at 1 mL/min, AD column) 
 
 
Figure 7-12: Chiral HPLC of the opposite enantiomer of 39 (5% IPA in Hexane at 1 mL/min, AD 
column) 
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Figure 7-13: Chiral HPLC of 39 and its enantiomer (5% IPA in Hexane at 1 mL/min, AD column) 
 
 
 
Figure 7-14: Chiral HPLC of 40 (10% IPA in Hexane at 1 mL/min, AD column) 
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Figure 7-15: Chiral HPLC of the opposite enantiomer of 40 (10% IPA in Hexane at 1 mL/min, AD 
column) 
 
 
Figure 7-16: Chiral HPLC of 40 and its enantiomer (10% IPA in Hexane at 1 mL/min, AD column) 
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Figure 7-17: Chiral HPLC of 47 (2.5% IPA in Hexane at 1 mL/min, AD column) 
 
 
Figure 7-18: Chiral HPLC of the opposite enantiomer of 47 (2.5% IPA in Hexane at 1 mL/min, AD 
column) 
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Figure 7-19: Chiral HPLC of 47 and its enantiomer (2.5% IPA in Hexane at 1 mL/min, AD column) 
 
 
Figure 7-20: Chiral HPLC of 67 (1% IPA in Hexane at 1 mL/min, AD column) 
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Figure 7-21: Chiral HPLC of the opposite enantiomer of 67 (1% IPA in Hexane at 1 mL/min, AD 
column) 
 
 
 
Figure 7-22: Chiral HPLC of 67 and its enantiomer (1% IPA in Hexane at 1 mL/min, AD column) 
 
